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1 Curable sexually transmitted infections 
 
According to the World Health Organization (WHO), there exist over 30 different viruses, 
bacteria, and eukaryotic parasites that may be transmitted through sexual contact. Only 
eight of these pathogens comprise the greatest incidence of sexually transmitted disease 
(STD). Of these eight infections, five are currently curable: chlamydia, gonorrhea, syphilis 
and trichomoniasis, accounting for an estimated 357 million new sexually transmittible 
infections (STIs) in 2012 [1], and Hepatitis B virus (HBV).  With an estimated 257 million 
people living with HBV virus infection (defined as hepatitis B surface antigen positive). 
The other three are viral infections and are incurable: Herpes Simplex Virus (HSV), 
Human immunodeficiency virus (HIV), and Human papillomavirus (HPV), whereby the 
latter is the most common STI.  
1.1 Scope of the problem 
 
Sexually transmitted infections (STIs) have been encountered in every continent and 
climate and with no seasonal variability.  Every day over 1 million STIs are transmitted, 
STIs like herpes and syphilis can increase the risk of HIV acquisition three-fold or more 
[2]. Mother-to-child transmission of STIs can result in stillbirth, neonatal death, low-birth-
weight and prematurity, sepsis, pneumonia, neonatal conjunctivitis, and congenital 
deformities [3]. Over 900 000 pregnant women were infected with syphilis resulting in 
approximately 350 000 adverse birth outcomes including stillbirth in 2012 [4]. HPV 
infection causes 528 000 cases of cervical cancer and 266 000 cervical cancer deaths 
each year [5]. STIs such as chlamydia gonorrhoea and trichomoniasis are major causes 
of pelvic inflammatory disease (PID) and infertility in women [6]. Table 1.1 summarizes 
the burden of STIs in the various WHO regions in 2012.  
Although, there are several curable STIs, in this dissertation the term curable sexually 
transmitted infection is used exclusively to refer to chlamydia, gonorrhea, syphilis and 
trichomoniasis. This chapter provides a summary of various aspects of Trichomonas 
vaginalis. 
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 Table 1.1 Global and regional estimates of the prevalence (thousands) in 2012 of 
sexually transmitted infections (95% uncertainty interval). 
 
Reprinted from reference [1]. 
 
It is important to note that there is paucity of data to feed into models that provides 
estimates of incidence or prevalence of STIs such as the one use to generate Table 1.1. 
For instance no data points for trichomoniasis in men from the African region met the 
study inclusion criteria for during this analysis.  A study had to have met the following 
criteria; sample size of at least 100; specimens collected from 2005 through 2012; 
population could be considered representative of the general population and study used 
an internationally recognized diagnostic test with adequate performance characteristics 
on urine, urethral, or cervicovaginal specimens [1]. 
1.2 Trichomonas vaginalis 
 
Trichomonas vaginalis is a parasitic protozoan and the causative agent of trichomoniasis, 
the most prevalent curable STI worldwide [1]. The WHO estimated that in 2012, among 
adults aged 15–49 years, there were 143 (98–202) million new cases of trichomoniasis 
[1].  Although T. vaginalis can infect both men and women, women bear a 
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disproportionate amount of the burden of this infection. Newman et al. [1] estimated the 
global prevalence for trichomoniasis among women aged 15–49 years to be 5.0% (95% 
uncertainty intervals (UI): 4.0–6.4%) while that of men was estimated at 0.6% (0.4–0.8%). 
1.2.1 History 
 
Alfred Donné reported the first description of the protozoan T. vaginalis almost two 
centuries ago (1836) [7].  Donné cited Dujardin’s unpublished description of this 
organism. Dujardin considered it a composite combining the characteristics of both 
monas and tricodes groups, hence the original name Tricomonas vaginiae, which was 
later changed by Ehrenberg to Trichomonas vaginalis [8]. Although T. vaginalis is the 
scientific name, there are several names or short forms that are commonly used to refer 
to this pathogen; trich, ureitis, and TV. 
 
1.2.2 Taxonomic classification 
 
 Domain: Eukarya – larger, more complex cells with a nucleus. 
 Kingdom: Protista – unicellular eukaryotic organisms that are not an animal, plant 
or fungus are found here  
 Phylum: Metamonada – flagellated  
 Class: Parabasilia – have modified mitochondria, have one or more flagella, 
require host/partake in symbiosis 
 Order: Trichomonadida  – have undulating membrane, axostyle 
 Genus: Trichomonas – members of this genus infect or are commensal organisms 
of birds and mammals. 
 Species: Trichomonas vaginalis – this species infects only humans 
 
Other Trichomonas species have been identified in clinical studies in both human and 
nonhuman hosts summary of this Trichomonas spp is provided in Table 1.2. 
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Table 1.2. Overview of human and nonhuman Trichomonas spp. and their 
corresponding host.  
Ref. Trichomonas spp. Primary host  Site of isolation Clinical 
manifestation 
[9] Trichomonas foetus  Bovine UGT Vaginitis, 
endometritis, or a 
mummified fetus. 
[10] Trichomonas gallinae Birds GIT and RT Pulmonary infection 
[11] Trichomonas gallinarum Birds GIT and RT Pulmonary infections 
[12] Trichomonas muris Rodents GIT* NA 
[13] Trichomonas tenax Human  Bucal cavity Salivary 
trichomonosis, 
pulmonary infections 
[14] Pentatrichomonas hominis Human and 
Cats 
GIT chronic diarrhea in 
cats 
[15] Trichomonas brixi Cats and Dogs  Bucal cavity Salivary 
trichomonosis, 
pulmonary infections 
[16] Tritrichomonas musculis Rodents GIT* NA 
Legend: GIT; gastrointestinal tract, NA; not applicable, RT; respiratory tract, UGT; 
urogenital tract; *, symbiont 
1.2.3 Morphology  
 
T. vaginalis is a single-celled, pear-shaped eukaryote Figure 1.1 that varies in size and 
shape [17], with the average length and width being 10 and 7 μm, respectively [18]. The 
parasite takes on a more amoeboid appearance upon attaching to epithelial cells Figure 
1.1. T. vaginalis is a flagellated protozoan possessing four anterior and one posterior 
flagellum the parasite. An axial, rod-like structure, known as axostyle, bisects the 
protozoan longitudinally and sticks out beyond the posterior end of the parasite.
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The posterior flagellum is incorporated at the centre of the axostyle. This structure is 
thought to anchor the pathogen to epithelial cells, causing inflammation.  Half of the cell 
body also has an undulating membrane, which helps to sweep nutrients into the 
pathogens ‘mouth-like’ structure, called the cytosome. The nucleus in T. vaginalis is 
located at its anterior portion, and, as in other eukaryotes, it is surrounded by a porous 
nuclear envelope [18]. 
Figure 1.1 Morphology of Trichomonas vaginalis 
 
Figure 1.1 (A) T. vaginalis parasite as seen in broth culture. The axostyle, undulating membrane, 
and flagella are clearly visible. (B) T. vaginalis on the surface of a vaginal epithelial cell prior to 
amoeboid transformation. (C) Amoeboid morphology of T. vaginalis as seen in cell culture. Bars, 
5 μm. Reprinted from reference [4]. 
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1.2.4 Genome  
In 2007, Carlton et al. [19] published the first draft genome of T. vaginalis. Repeats and 
transposable elements comprise about two-thirds of the 160-megabase genome, which 
comprises of about 60,000 genes residing on six chromosomes [19]. Some strains of T. 
vaginalis harbour Trichomonas vaginalis viruses (TVVs) with some T. vaginalis strains 
concurrently harbouring up to four different TVV species [20].  Several typing attempts 
have been made done to shed lights of the strain diversity among T. vaginalis isolates 
Table 1.3 provides a summary of typing techniques and main findings.
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Still, of the several typing techniques highlighted in Table 1.3, only two have been widely 
used to perform typing on a large number of isolates covering a wide geographical area. 
The two techniques are that of Conrad et al. [29] which was used to type 211 isolates 
from Mexico, Chile, India, Australia, Papua New Guinea, Italy, South Africa and the United 
States. The other one is the typing proposed by Crucitti et al. [26] which was used to type 
151 isolates from Zambia and the Democratic Republic of Congo.  The two techniques 
differ on how they assign isolates to specific genotypes and are not comparable on that 
basis. 
The method used by Conrad et al. [29] groups T. vaginalis into two clusters ‘type 1’ and 
‘type 2’ and showed that the two types were present at nearly equal frequencies and are 
well distributed among all geographical locations, apart from two exceptions, i.e. isolates 
from South Africa and Mexico, which were significantly biased towards type 1 and type 2, 
respectively [29]. The same authors also noted a highly significant difference in the 
minimum lethal concentration (MLC) of metronidazole necessary to kill isolates, with type 
1 isolates at a mean MLC of 76.6 μg/ml of metronidazole as compared to type 2 isolates 
at a mean MLC of 228.4 μg/ml of metronidazole. They also found that carriage of TVV 
occurred significantly more frequently in type 1 isolates than in type 2.  
Alternative gel-based methods, such as the restriction fragment length polymorphism 
analysis (RFLP) of the actin gene, as proposed by Crucitti et al. [26], offer a more 
affordable alternative to the MLST scheme and can provide good resolution at short-
temporal scales [26]. However, the MLST approach is usually preferred because in gel-
based approaches, comparison of results between laboratories is often problematic and 
a high level of expertise is needed to interpret and to translate banding patterns. A good 
strain typing method should provide sufficient discriminatory power to distinguish between 
isolates from unlinked sources and be sufficiently reliable to cluster isolates from the 
same source [30]. Additionally, when performing T. vaginalis typing, it is important to 
factor in TVV as they appear to have a role in the pathogenesis of T. vaginalis. 
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1.2.5 Life cycle and transmission 
 
The life cycle of T. vaginalis has not been clearly described. The natural hosts are human 
beings, whereby the parasite lives in the female lower genital tract and the male urethra 
and prostate, where it replicates asexually by mitotic division and binary fission. No sexual 
reproduction of T. vaginalis has been documented. T. vaginalis is a facultative anaerobe 
which exists only in a trophozoite phase with no cystic phase [18]. 
Since T. vaginalis lacks a cyst, and the flagellate dies outside the human body unless 
protected against drying and extreme temperature, a moist environment is critical for 
transmission to occur. T. vaginalis may survive for at least an hour in urine [31] or for 
several hours on swimming pool water [32]. 
Sexual transmission is the main mode of transmission, although non-sexual transmission 
has been reported [33]. Newborn infants of mothers infected with T. vaginalis may 
become infected by T. vaginalis when the parasites are transferred into the neonate’s 
urinary or vaginal tract during passage through the infected birth canal [34]. Although 
neonatal infection with T. vaginalis is infrequently reported, it has been noted to cause 
urinary tract infections and vaginitis in infants as young as 14 weeks [34]. T. vaginalis has 
also been associated with upper respiratory distress among infants, where it has been 
isolated from nasopharyngeal secretions of infants presenting with significant respiratory 
distress [35]. 
T. vaginalis has been detected in the rectum of  individuals reporting anal sex [36]. 
However, these studies utilized nucleic acid amplification tests (NAATs) to detect T. 
vaginalis. Detection of rectal T. vaginalis using culture would be needed to demonstrate 
viability of T. vaginalis in the rectum  and shade light on plausibility of the rectum being a 
reservoir for T. vaginalis. However, given the low sensitivity culture 65% - 85% on female 
vaginal specimen where the organisim is know to thrive [37].  Using culture tests in rectal 
detection of T. vaginalis may lead to many cases going undetected. 
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Other possibilities of non-sexual transmission have been suggested to occur through 
contact with contaminated toilet seats, water, specula, sex toys, towels, underwear or 
linen. Whittington (1957) showed, by smearing vaginal material containing trichomonads 
on toilet seats, that the parasite remained viable for 45 minutes on bakelite and polished 
seats and for 30 minutes on an unpolished seat with an absorbent surface [38]. It is 
however highly unlikely that this can result into an actual infection in another woman, 
based on the low possibility of the vulva to come into contact with the toilet seat and the 
number of trichomonads required for an infection to occur, i.e., approximately 105 motile 
trichomonads per mL, based on the squirrel monkey T. vaginalis infection model [39]. 
 
1.2.6 Pathogenesis and clinical manifestations 
 
Many mechanisms are thought to be involved in T. vaginalis pathogenesis and these 
include cell-to-cell adhesion [40], hemolysis [41] and/or excretion of soluble factors [42] 
which all lead to epithelial cell damage and inflammation although the later varies from 
case to case [43].  
T. vaginalis is a free-living protozoan that can colonize mucosal epithelial surfaces. 
Infection with T. vaginalis in men generally persists between 2 weeks to 4 months [44], 
while untreated infection in women may persist for up to 5 years [45]. T. vaginalis has 
often been detected in individuals who are asymptomatic, a prospective multicenter study 
found that 72 % of male sex partners of women with trichomoniasis were also infected 
with T. vaginalis, and 77 % of these men were asymptomatic [46]. Whereas detection of 
T. vaginalis is often in asymptomatic individuals, among women, symptoms associated 
with trichomoniasis include; purulent vaginal discharge, abnormal vaginal odour, pruritus, 
dysuria, dyspareunia, lower abdominal pain, “colpitis macularis” “strawberry cervix” [47].  
Trichomoniasis has been associated with infertility [18] and adverse pregnancy 
outcomes, the most established association of adverse pregnancy outcomes are preterm 
delivery and low-birth-weight [48]. Women with trichomoniasis have been reported to be 
at a significantly higher risk of pelvic inflammatory disease than women without 
24 
Chapter One
trichomoniasis [6]. Vaginal infections including T. vaginalis were reported to be significant 
predictors of HIV vertical transmission in a study of HIV-infected pregnant women in 
Zimbabwe [49]. Some studies have suggested that infection with T. vaginalis increases 
the likelihood of HIV infection acquisition although the degree by which this is increases 
likelihood has not been computed. 
While it was once nearly ignored, T. vaginalis infection in men is now recognized as an 
important cause of non-gonococcal urethritis [50], is associated with prostatitis [51] and 
infertility among men [52]. 
 
1.2.7 Diagnosis and detection  
Diagnosis of T. vaginalis infection may be achieved by clinical syndromic diagnosis and/or 
by laboratory-based testing. Clinical diagnosis relies on the classical symptoms 
associated with T. vaginalis, which include a yellowish-green frothy vaginal discharge, 
vaginal odour, pruritus, dysuria, dyspareunia, and the “strawberry” cervix [18]. However, 
clinical manifestations may not be reliable diagnostic parameters as the clinical symptoms 
may be synonymous with those of other Sexually Transmitted Diseases (STDs). Thus 
laboratory investigations are warranted for the accurate diagnosis of trichomoniasis [37].  
There is a wide array of methods available and in development to detect and investigate 
T. vaginalis in both clinical and research settings. Below is a highlight of the main 
laboratory diagnostic techniques: 
A. Microscopy 
Laboratory detection of T. vaginalis has traditionally depended on wet smear microscopy. 
This technique was first described in 1836 [53].  A swab is used to collect material from 
the vaginal fornix and placed into a 0.5 to 1.0 mL of saline. A drop of the saline preparation 
is placed on a microscope glass slide and viewed with a microscope at a 400 x 
magnification. Motile trichomonads can be seen moving in the preparation with a 
distinctive jerky movement [54]. https://www.youtube.com/watch?v=9B1PFJXuJUs 
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Organisms lose motility ex vivo because of temperature shock, so to avoid false negative 
results slides should be prepared and read as soon as possible or within 2 hours if the 
sample is placed in phosphate buffered saline at room temperature otherwise T. vaginalis 
becomes significantly attenuated and no motility can be observed [37]. Correct 
reading/interpretation of wet smear microscopy depends on the inoculum size because 
as this test has a detection threshold of 104 organisms/mL, time and conditions under 
which the samples are kept and the experience of the one performing the microscopy 
[53]. Observation of motile trichomonads is highly specific and thus is very useful for 
determining a course of treatment. However, the sensitivity of this technique is generally 
low. Nevertheless, wet mount microscopy remains one of the best options for clinicians 
to quickly and specifically diagnose T. vaginalis in their clinical practice. But clinicians 
should be aware of the negative results may be false, missing approximately 50% or more 
infections, when dealing with a population at high-risk of T. vaginalis, more sensitive tests 
should be used. 
T. vaginalis may also be identified in smears after staining with acridine orange, Giemsa, 
Gram, Leishman, Diffquick, Fontana, periodic acid schiff or Papanicolaou (Pap) stain [54-
56], whereby the sensitivity of these stains have been shown to be slightly better or similar  
to that of a wet mount.  
B. Culture   
Biological amplification of T. vaginalis in culture increases the sensitivity when compared 
to direct microscopic observation 85% sensitivity versus 50% for direct microscopy when 
compared to newer techniques. The broth culture method has been the “gold standard” 
for the detection of T. vaginalis for half a century. It is easy to interpret and requires as 
few as 300 to 500 trichomonads/mL of inoculum to initiate growth [18]. 
The initial laboratory-based diagnostic culture test was on the Diamond medium.   
Diamond Trichomonas medium was developed by Diamond in 1957. The Center for 
Disease Control (CDC) modified the formulation in 1980 by substituting sheep serum with 
horse serum, increasing the concentration of maltose, cysteine, and ascorbic acid, and 
adding antibiotics to the medium to suppress the growth of bacteria and fungi. Culture 
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positivity is assessed by microscopy of a slide prepared from a drop of the culture 
medium, daily for up to 7 days [37]. However, there are inherent limitations to culture-
based diagnosis. An incubation period of 2 to 7 days is usually necessary to identify T. 
vaginalis by means of culture, during which time infected patients may continue to 
transmit the infection.  
An improvement in the culture technique was devised in the form of the InPouch TV test 
(Biomed Diagnostics, Santa Clara, CA). The InPouch TV is a self-contained culture pouch 
made of oxygen-resistant, optically clear plastic. It is a two-chambered pouch that allows 
one to perform an immediate wet-mount by microscopic examination through the bag, as 
well as a culture that can be microscopically examined directly during culture, eliminating 
the need to remove material from the culture for daily examination. InPouch TV can be 
stored at room temperature before use, and inoculated pouches can remain at room 
temperature up to 48 h before incubation at 37°C. Sood et al. [57] showed that the 
InPouch system sensitivity for the detection of T. vaginalis was twice that of wet mount. 
There have been no further evolutions in culture techniques mainly due to the laborious 
nature of culture but also viable organisms are not a requirement to make a diagnosis of 
infection with T. vaginalis. The main utility of culture moving forward will be to obtain viable 
organisms that may be important for antimicrobial susceptibility testing.  
C. Immunological techniques  
Several immunological techniques, including agglutination, complement fixation, enzyme-
linked immunosorbent assay, fluorescent antibody microscopy, gel diffusion, and indirect 
hemagglutination, have previously been used to demonstrate the presence of 
antitrichomonal antibodies [58-60]. The only commercially available antigen detection test 
include OSOM (Sekisui, Framingham, MA). The assay relies on a latex-tagged antibody 
to bind specifically to Trichomonas proteins and a secondary capture antibody to bind the 
complex to the lateral flow device [37]. 
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D. Nucleic acid amplification tests (NAATs) 
The advent of highly sensitive and specific NAATs has provided crucial new tools for 
diagnosis of infections with T. vaginalis. NAAT techniques help detect nonviable 
organisms and also have the ability to detect target sequences in clinical samples that 
have undergone fixation or partial degradation. NAATs are characterized by the 
amplification up to millions of copies from specific individual DNA or RNA target 
sequences. Thus, the analytical sensitivity of NAATs is fundamentally superior to that of 
microscopy, culture, antigen detection or nucleic acid probe assays, which detect existing 
organisms or their constituents.  
The high analytical specificity of NAATs stems from the use of nucleotide primer and 
probe sequences that are unique to the target organism. The type of urogenital 
specimens that can be used with NAATs includes non-invasive urine samples and 
minimally invasive self-collected vaginal swabs, in addition to clinician-collected vaginal, 
urethral and endocervical swabs and endocervical specimens collected for liquid-based 
Pap cytology. NAATs are now recognized as the gold standard for the screening and 
diagnosis of Chlamydia trachomatis and Neisseria gonorrhoeae [61]. 
Several nucleic acid amplification-based assays are now commercially available for 
detection of T. vaginalis. The following assays are both Food and Drug Administration 
agency (FDA) approved and have a CE marking (“Conformité Européene”/”European 
Conformity”): Aptima TV assay (Hologic, San Diego, CA).  Aptima TV has clinical 
sensitivity and specificity of 100% and 99.0% for vaginal swabs, 100% and 99.4% for 
endocervical swabs, 100% and 99.6% in ThinPrep samples, and 95.2% and 98.9% in 
urine specimens, respectively [62]. T. vaginalis Qx amplified DNA assay, which can be 
performed on the automated BD Viper system (BD, Sparks, MD) has sensitivity and 
specificity of 100% and 99.53% respectively when compared to culture [63]. AmpliVue 
Trichomonas assay (Quidel, San Diego, CA). Sensitivity for AmpliVue compared to 
Aptima was 90.7%, with 98.9% specificity [64]. Solana Trichomonas Assay (Quidel, San 
Diego, CA) Sensitivity and specificity compared to Aptima-TV, was 89.7% and 99.0% for 
swabs and 100% and 98.9% for urines respectively [65]. The recently FDA approved 
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NAATs is the Xpert TV assay (Cepheid, Sunnyvale, CA). When screening women 
specimens (urine samples, self-collected vaginal swabs, and endocervical swabs) it has 
a diagnostic sensitivity and specificity ranging from 99.5 to 100% and 99.4 to 99.9%, 
respectively. When tested on male urine samples, the diagnostic sensitivity and specificity 
are 97.2% and 99.9% [66].    
The main factor as to why NAATs are not routinely used in resource limited countries 
where the prevalence of STIs is high is the cost of testing using NAATs. The costs are 
high and can range from approximately 20 € to over 100 € per test. Several aspects 
determine cost of the test, this include; location, test volume, the price of the test kits, the 
number of tests per kit, size of the testing run, the number of controls required per testing 
run, and the type and amount of ancillary supplies [37]. Most NAATs kits do not contain 
nucleic acid extraction reagents, so additional equipment and reagents are necessary 
and can add approximately 3 € per test. Batch testing of samples may reduce the cost 
per test; however, often batching is not practical if the time to result is delayed beyond a 
period it would affect either clinical management or infection control practices.  
Another cost factor for NAATs is the cost of instrumentation which can be substantial per 
instrument, and higher volume laboratories may require multiple instruments. In the 
overall costing of tests, technical time is also factored in, this is also highly variable 
depending on the test complexity and run size. Finally, the costs for quality control, 
proficiency testing, and competency assessment all affect the overall cost per test. Apart 
from cost often NAATs involve multistep process which can make these assays laborious 
to set up and allow for the introduction of contamination at several steps. 
  A growing strength of NAATs is ability to multiplex enabling a single specimen to be 
interrogated for the presence of multiple pathogens associated with various clinical 
syndromes [37]. The Xpert TV assay (Cepheid, Sunnyvale, CA) is an example of a newly 
FDA approved T. vaginalis NAAT which is bridging the gap in terms of costs but also 
turnaround time. A number of specimens may be used [66], it has no requirement for 
separate nucleic acid extraction saving on time and costs, is equipped with internal quality 
controls. In addition GeneXpert platform may be used for other tests C. trachomatis,         
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N. gonorrhoeae, Mycobacterium tuberculosis, further sharing the instrumentation costs. 
The Xpert TV assay can provide on-demand results in 63 minutes or less, with early 
termination for positive results within 40 min [66]. This quicker turnaround time makes the 
GeneXpert platform ideal for use in high-risk settings where diagnosis and treatment 
could ideally take place in real time, catering for patients who may otherwise not return 
for treatment.   
1.2.8 Treatment 
T. vaginalis infection has been commonly treated using metronidazole, marketed under 
the trade name Flagyl. This is a 5-nitroimidazole drug derived from the Streptomyces 
antibiotic azomycin, which was found to be highly effective in the systemic treatment of 
trichomoniasis in 1959 [18]. Table 1.4 summarizes the currently recommended treatment 
regimens. Because T. vaginalis is mostly sexually transmitted, partner treatment is also 
recommended. 
Table 1.4 Current recommended regimens for treatment of Trichomonas vaginalis 
infection 
Regimen ASHA_2017 
[67] 
BASHH_2014 
[68] 
CDC_2015 
[69] 
WHO_2001 
[70]] 
Metronidazole 2 g  
orally single dose 
√ √ √ √ 
Metronidazole 500 mg  
orally twice daily for 7 days 
- HIV infected Alternative 
HIV infected 
_ 
Metronidazole 400-500 mg 
orally twice daily for 5-7 days 
Alternative √ - Alternative 
Tinidazole 2 g  
orally single dose 
√ Alternative √ √ 
Tinidazole 500 mg  
orally twice daily 5 days 
- - - Alternative 
 
Legend: ASHA: Australian Sexual Health Alliance, BASHH: British Association for Sexual Health and HIV, 
CDC: Centers for Disease Control and Prevention, WHO: World Health Organization, √: recommended by 
the guidelines, -: Not mentioned in the guidelines 
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A recent study found that 2 g single oral dose of metronidazole was not as effective as 
500 mg of metronidazole twice daily for 7 days among HIV-infected women [71]. In a 
recent meta-analysis comparing treatment failure between single versus multidose 
metronidazole for the treatment of T. vaginalis. The pooled risk ratio indicated higher 
treatment failure for single dose compared to multidose 1.87 (95% confidence interval, 
1.23-2.82; P < 0.01) [72].  
There have been several reports of metronidazole-resistant T. vaginalis [73], which can 
be categorized as either aerobic or anaerobic resistance. Resistance development is 
stepwise with aerobic resistance occurring first. Resistance occurs in clinical isolates from 
patients with treatment failure. Aerobic resistance is mostly the result of interference with 
intracellular oxygen through ferredoxin or oxygen-scavenging pathway [74]. Mechanisms 
involved in anaerobic resistance involve a decrease or cessation of activity of pyruvate 
ferredoxin oxidoreductase which in turn leads to low or no production of nitro radicals 
which are responsible for attacking T. vaginalis DNA [73, 75]. However, metronidazole 
resistant T. vaginalis is still not widely spread when compared to antibiotic resistance in 
other STI agents, such as N. gonorrhoeae.  
Before assessing T. vaginalis resistance, one must first consider other sources of 
treatment failure such as non-compliance, vomiting post oral administration of 
metronidazole, re-infection from an untreated partner, infection from a new partner, 
insufficient drug absorption, and inadequate transport of drug to site of infection. Most 
importantly is that there is no standardized technique for determining T. vaginalis 
resistance to metronidazole. 
The British association for sexual health and HIV (BASHH) guidelines recommend a 
treatment protocol for non-response to standard T. vaginalis therapy [68]. This involves a 
repeat course of 7-day standard therapy: Metronidazole 400-500 mg twice daily for 7 
days. For patients failing this second regimen: Higher dose course of nitroimidazole, i.e. 
metronidazole or tinidazole 2 g daily for 5-7 days or metronidazole 800 mg three times 
daily for 7 days [68].  
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For those failing this third regimen, resistance testing is suggested. In most cases the 
resistance testing is not possible as there is no standard protocol. The next option is a 
high dose tinidazole regimens may be considered: tinidazole 1 g twice or three times 
daily, or 2 g twice daily for 14 days +/- intravaginal tinidazole 500 mg twice daily for 14 
days [68]. 
Other treatments with some reported success include paromomycin intravaginally 250 
mg once or twice daily for 14 days or Furazolidone intravaginally 100 mg twice daily for 
12-14 days. Acetarsol pessaries 500 mg nocte for 2 weeks or 6% nonoxynol pessaries 
nightly for 2 weeks is also listed an option [68]. In a randomized dose-ranging pilot study 
conducted in two phases, whereby in the first phase, participants were randomized to the 
vaginal suppository (metronidazole 750 mg/miconazole nitrate 200 mg) twice a day for 7 
days versus oral metronidazole 2 g single dose, while in the second phase, participants 
randomized to suppository used it once a day for 7 days. There were no significant 
differences in cure rates between the vaginal suppositories and oral metronidazole in 
either phase. The overall efficacy across both follow-up visits was 80% versus 90% for 
the suppository (2×/d) versus oral medication arms in phase 1 (P = 1.00) and 78% versus 
70% for the suppository (1×/d) versus oral medication arms in phase 2 (P = 1.00) [76].  
1.2.9 Prevalence of T. vaginalis 
 
To generate a brief overview of the current prevalence of T. vaginalis infection in various 
countries, the PubMed database was searched, using the combination of all of the 
following search terms “Trichomonas vaginalis”, “T. vaginalis” or “trichomoniasis” with the 
following search term “prevalence”. The search was restricted to articles published 
between April and June 2018. The following data were extracted; authors, year of sample 
collection, study population, T. vaginalis detection method and the prevalence, as 
summarized in Table 1.5.  The prevalence of T. vaginalis from recently published studies 
varies widely, from 0% among men in the general population in the UK to 39.8% among 
women at a study recruiting women from a family planning in Jamaica. 
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Table 1.5 Current prevalence of Trichomonas vaginalis 
Ref. Authors  & 
Country 
Year of 
Sample 
collection 
Study population TV 
detection 
method 
Prevalence of 
T. vaginalis 
(%) 
[77] Daugherty et al. 
USA 
2013-2016 men 18-59 years NAAT 0.49 
[78] Ronda et al.USA 2015-2017 female adolescents 
and young adults, 
mean age 22.3 years 
NAAT 9.0 
[79] Teasdale et al. 
South Africa and 
Zimbabwe 
2003-2006 Pregnant, women 
aged 18-50 years 
NAAT 3.7 
[80] Shahesmaeili et 
al.  Iran 
2015 FSW 18-44 years NAAT 11.9 
[81] Garrett et al. 
South Africa 
2016-2017 Women attending 
the clinic for STI 
aged 18-40 years 
Immunologic
al rapid test 
3.0 
 
[82] Ijasan et al. 
Nigeria 
2016 HIV-positive 
pregnant women 
aged 15-49 years 
Direct 
microscopy 
10.0 
[83] Zia et al. Jamaica 2012-2014 Women at family 
planning clinics, 
Median age 25 years 
NAAT 39.8 
[84] Dionne-Odom et 
al. USA 
2015 HIV positive, median 
age 46.8 years 
NAAT 13.3 
[85] Davey et al. 
South Africa 
Not 
indicated 
HIV positive 
pregnant women, 
median age 30 years 
NAAT 10.0 
[86] Sarier et al. 
Turkey 
2016-2017 Renal transplant 
patients men & 
women, mean age 
45 years 
NAAT 1.3 
[87] Price et al.  
South Africa 
2016-2017 HIV positive 
pregnant women, 
mean age 30.1 years 
NAAT 20.0 
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Ref Authors  & 
Country 
Year of 
Sample 
collection 
Study population TV 
detection 
method 
Prevalence of 
T. vaginalis 
[88] Schwebke et al. 
USA 
2012-2013 Men & Women 
attending family 
planning/STD clinics, 
age range < 18 - >50 
years 
NAAT 6.1  Men, 11.3 
Women 
[89] Jacob et al. 
Germany 
2013-2015 
 
Women attending 
271 German 
gynecological clinics, 
age range < 20 - >60 
years 
Not 
mentioned 
0.2 
[90] Barnabas et al. 
South Africa 
2013-2015 HIV-seronegative 
adolescent females, 
16-22 years 
NAAT 5.0 
[91] Wynn et al. 
Botswana 
2015-2016 Pregnant women 
attending antenatal 
clinic, median age 30 
years 
NAAT 5.0 
[92] Field et al. UK 2010-2012 General population, 
aged 16-44 years 
NAAT 0.3 women, 
0% men 
Legend: NAAT; Nucleic Acid Amplification Test, TV; Trichomonas vaginalis. Studies are 
arranged starting from the most recently published.  
1.2.10 Factors associated with sexually transmitted infections 
 
Globally, the geographic distribution of STIs is unequal. Apart from the prevalence of 
syphilis [93], the prevalence of STIs seems to be generally decreasing or under control in 
high-income countries. However, high prevalences continue to be reported in low- and 
middle-income countries, particularly among sexually active risk groups such as 
commercial sex workers or men who have sex with men [94]. To better understand the 
disparities in the prevalence of STIs, some factors associated with STIs are highlighted. 
It is important to note that factors associated with STIs differ in various regions. 
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Individuals engaging in high-risk sexual behaviour are all at a higher risk of STIs. From a 
survey in Belgium, higher frequency of swinging was associated with an STI diagnosis (p 
= 0.036) [95]. It should be noted that swingers form a network through which STIs can 
easily spread. 
Among women, bacterial vaginosis (BV) is another factor that has been associated with 
increased susceptibility to STIs [96]. The burden of BV is highest in sub-Sahara Africa 
(sSA) [97] and in women of sSA descent living elsewhere [96].  Additionally, among 
women, vaginal douching has been shown to increase the risk of BV which would 
consequently increase the risk of STIs. In a longitudinal study, the relative risk for BV 
among those who practice regular vaginal douching as compared with no douching was 
1.21 (95% confidence interval: 1.08, 1.38) [98]. 
Individuals who abuse alcohol and other drugs have been also shown to be at a high-risk 
of STIs [95, 99]. Binge drinking, and using drugs like “club drugs” like ecstasy, and 
poppers can alter an individual’s judgment, lower inhibitions, and impair decisions about 
sex or other drug use including injection of drugs. Alcohol and drug abusers are more 
likely to have unplanned and unprotected sex, have a challenge in using a condom the 
right way every time they have sex. All these behaviours increase their risk of exposure 
to STIs including HIV. HIV on its own is associated with curable STIs, as the rate of 
curable STIs among HIV-infected individuals is generally higher compared to HIV-
negative individuals [84]. 
Socioeconomic status, which most of the time goes hand in hand with a lower level of 
education, has been associated with higher levels of STIs [100]. This is not surprising, 
since lower income is associated with less access to preventative information and 
healthcare, and increased used of sex for economic purposes and as a psychosocial 
coping mechanism [101]. In a study among female adolescents, ages 12-21 years, who 
leave on the streets in Kenya, the prevalence of chlamydia, gonorrhoea, HSV-2, HIV and 
trichomoniasis was 16%, 15%, 35%, 15%, 10% respectively, higher than what is seen in 
the general population [102].  
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In multi-racial countries and especially in the US, it has long been recognized that STI 
risk is strongly patterned by race/ethnicity, with the higher rates amongst African-
Americans [103]. This may stem from the fact that black men have higher-risk sexual 
behaviours than white men [104]. However, even within strata of sexual and substance-
use behaviour, there remain large differences in STI rates between race/ethnicities, 
particularly for black individuals [104]. It seems like there are unknown factors other than 
individual risk behaviours and covariates which appear to account for racial difference in 
STI prevalence and future studies may investigate this. 
Mobile populations have been identified to be at high risk of STI due to their propensity 
to engage in concurrent relationships and transactional sex. Mobile populations constitute 
a risk group for local and international STI-transmission. In a systematic review and meta-
analysis, examining the evidence regarding travel-related sexual risk-taking, the pooled 
prevalence of casual travel sex was 35% and prevalence of non-condom use was 17% 
[105]. Long distance truck drivers in sSA are particularly prone to acquiring STIs, with a 
previous study documenting prevalence rate of HIV of 15.4% in Mozambique [106], 26% 
South Africa [107] and 10% Nigeria [108]. 
Young age at first sexual intercourse has been associated with an increased risk of 
acquiring STIs [109], as young sexual debutants are more likely to have sexual risk 
behaviours at first sexual experience [110] and may be particularly prone to other risky 
behaviours later in life [111]. For example, in a study in Tanzania, women who had their 
first sexual intercourse at age 20+ 54 times less likely to have STIs, including HIV-1 and 
HSV-2, than women who had their first intercourse before their 18th birthday [109]. 
Some professions, such as military personnel, bar-maids/waiters, commercial sex 
workers, and fisherfolk, have also been associated with high prevalence of STIs. For 
instance, in Ugandan Lake Victorian fisherfolk communities, the HIV prevalence is 
estimated to be 22% [112], much higher than in the Ugandan general population, for 
whom HIV prevalence is estimated to be 7.3% [113].  Vulnerability to STI stems from 
complex, interacting factors that may include the mobility of many fisherfolk, the time 
fishermen spend away from home, their daily access to cash income in an overall context 
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of high poverty and vulnerability, their demographic profile, the ready availability of 
commercial sex in fishing ports and the subcultures of risk-taking. The subordinate 
economic and social position of women in many fishing communities in lowincome 
countries makes them even more vulnerable. The fisherfolk communities also have low 
access to STI care including HIV testing and health-care in general [114]. 
In conclusion, several factors may be associated with STIs and these factors will vary 
depending with the study population. Consequently it is essential for researchers, 
evaluating factors associated with STIs, to collect information on previous factors that 
have been associated with STIs. But additionally also collect information on other factors 
that they may consider to be important with regards to STIs, which may be unique to the 
population they are working with.
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2 Outline 
 
This Chapter provides an outline and the objectives of this dissertation. Sub-Saharan 
Africa (sSA) has the highest rates of curable Sexually Transmitted Infections (STI) 
worldwide, and more specifically of Trichomonas vaginalis (T. vaginalis), the most 
common non-viral STI. T. vaginalis affects both men and women but is more common in 
women. Chapter 3 covers the epidemiology of curable STIs among pregnant women in a 
rural county hospital in Kilifi, Kenya. Chapter 4 covers urogenital pathogen correlates of 
Trichomonas vaginalis among pregnant women in Kilifi, Kenya. Chapter 5 discusses 
Trichomonas vaginalis genotypes and their association with Trichomonas vaginalis 
viruses. Chapter 6 discusses the interaction of Trichomonas vaginalis and the vaginal 
microbiome. Chapter 7 discusses the interaction of Trichomonas vaginalis and HIV. 
Objective 1. In sSA, epidemiological data on curable STIs, including risk factors among 
pregnant women in rural areas, are very scarce, although they are necessary to design 
and implement curable STI prevention and treatment strategies. Therefore, the first 
objective of this dissertation was to assess the prevalence and risk factors associated 
with curable STIs among pregnant women at a rural county hospital in Kilifi, Kenya. This 
objective is addressed in Chapter 3. 
Objective 2. Classical screening of STIs is frequently only oriented towards the 
diagnosis of chlamydia, gonorrhea, syphilis and trichomoniasis, while pathogens, such as 
Mycoplasma genitalium among others, which demonstrate similar urogenital syndromes, 
remain undiagnosed and/or untreated. Determining pathogens associated with 
Trichomonas vaginalis, which is the most common curable STI may influence optimal 
patient management. Therefore, the second objective of this dissertation was to assess 
the urogenital pathogen correlates of Trichomonas vaginalis among pregnant women in 
Kilifi, Kenya. This objective is addressed in Chapter 4. 
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 Objective 3. At present, little is known regarding the degree of strain variability within 
the species T. vaginalis as no data exists about the genetic diversity of T. vaginalis in 
Kenya. Therefore, the third objective of this dissertation was to assess the genetic 
diversity of T. vaginalis isolates among pregnant women in Kilifi, Kenya. This objective is 
addressed in Chapter 5. 
Objective 4. Although the significance of the human vaginal microbiome for health and 
disease is increasingly acknowledged, differences in the composition of the vaginal 
microbiome upon infection with different sexually transmitted pathogens remains 
generally under explored.  Therefore, the fourth objective of this dissertation was to 
describe the vaginal microbiome of pregnant women in relation to Trichomonas vaginalis 
and Chlamydia trachomatis. This objective is addressed in Chapter 6. 
Objective 5. Individuals infected with T. vaginalis are thought to be at an increased risk 
of acquiring HIV and to have increased genital shedding of HIV compared to those 
individuals not infected with T. vaginalis. Therefore, the fifth objective of this dissertation 
was to assess to what extent T. vaginalis infection is: associated with HIV acquisition. 
This was achieved by means of systematic review and meta-analysis. This objective is 
addressed in Chapter 7. 
Finally, Chapters 8 and 9 summarize the objectives and main findings of this dissertation 
and provide future perspectives. 
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Abstract
Background
Women attending antenatal care (ANC) in resource-limited countries are frequently
screened for syphilis and HIV, but rarely for other sexually transmitted infections (STIs). We
assessed the prevalence of curable STIs, defined as infection with either Chlamydia tracho-
matis or Neisseria gonorrhoeae or Trichomonas vaginalis, from July to September 2015.
Methods
In a cross-sectional study, women attending ANC at the Kilifi County Hospital, Kenya, had a
urine sample tested forC. trachomatis/N. gonorrhoeae by GeneXpert and a vaginal swab
for T. vaginalis by culture. Bacterial vaginosis (BV) was defined as a Nugent score of 7–10
of the Gram stain of a vaginal smear in combination with self-reported vaginal discharge.
Genital ulcers were observed during collection of vaginal swabs. All women responded to
questions on socio-demographics and sexual health and clinical symptoms of STIs. Predic-
tors for curable STIs were assessed in multivariable logistic regression.
Results
A total of 42/202 (20.8%, 95% confidence interval (CI):15.4–27.0) women had a curable
STI. The prevalence was 14.9% forC. trachomatis (95% CI:10.2–20.5), 1.0% for N. gonor-
rhoeae (95% CI: 0.1–3.5), 7.4% for T. vaginalis (95% CI:4.2–12.0), 19.3% for BV (95% CI:
14.1–25.4) and 2.5% for genital ulcers (95% CI: 0.8–5.7). Predictors for infection with cur-
able STIs included women with a genital ulcer (adjusted odds ratio (AOR) = 35.0, 95% CI:
2.7–461.6) compared to women without a genital ulcer, women who used water for cleaning
after visiting the toilet compared to those who used toilet paper or other solid means (AOR =
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4.1, 95% CI:1.5–11.3), women who reported having sexual debut 17 years compared to
women having sexual debut18 years (AOR = 2.7, 95% CI:1.1–6.6), and BV-positive
women (AOR = 2.7, 95% CI:1.1–6.6) compared to BV-negative women.
Conclusion
One in five women attending ANC had a curable STI. These infections were associated with
genital ulcers, hygiene practices, early sexual debut and bacterial vaginosis.
Introduction
Sexually transmitted infections (STIs) are a major public health concern globally and especially
among women in resource-limited countries [1]. Common curable STIs among women in
sub-Saharan Africa (sSA) include Chlamydia trachomatis, Neisseria gonorrhoeae and Tricho-
monas vaginalis [2]. Additionally, bacterial vaginosis (BV), which has been associated with an
increased risk of incident infection with C. trachomatis and N. gonorrhoeae [3, 4], is highly
prevalent [5]. These curable STIs and BV have been associated with a number of adverse preg-
nancy outcomes such as spontaneous abortion, ectopic pregnancy, preterm delivery, low birth
weight, stillbirth, postpartum sepsis, and congenital infection [6]. Infants born of mothers with
genital C. trachomatis are at an increased risk of suffering from neonatal pneumonia and oph-
thalmia neonatorum [7]. At present the efficacy of neonatal ocular prophylaxis with erythro-
mycin for prevention of C. trachomatis ophthalmia is not clear [8]. These associated sequelae
of STIs hence necessitate prevention and management of curable STIs and BV, especially dur-
ing pregnancy.
Pregnant women attending antenatal care (ANC) in resource-limited countries are fre-
quently screened for syphilis [9] and HIV [10], but rarely for other curable STIs or BV. More-
over, curable STIs and BV are associated with increased acquisition and transmission of HIV
[11–13]. Among pregnant HIV positive women C. trachomatis is associated with increased
risk of HIV mother-to-child transmission [14]. Many resource-limited countries have adopted
the World Health Organization’s syndromic approach for the management of curable STI
[15]. This syndromic approach is deficient in both sensitivity and specificity because STIs may
be asymptomatic or have non-specific clinical signs and symptoms [16, 17].
There is a paucity of epidemiological and risk factor data on curable STIs among women
residing in rural areas, including among pregnant women in coastal Kenya. Most of the recent
information about the prevalence of curable STIs among women in Kenya has been from stud-
ies done among high-risk individuals [18], women residing in cities [19, 20] or from regions
with high incidence of HIV [13]. Consequently, we assessed the prevalence and predictors of
curable STIs in pregnant women attending ANC at a rural county hospital in Coastal Kenya.
Methods
This was a cross-sectional study conducted from July to September 2015, at the ANC clinic of
the Kilifi County Hospital (KCH), Kenya, a clinic attended to by approximately 4,000 women
annually [21]. We aimed to enroll a convenience sample of 350 consecutive pregnant women
to identify 20–25 women with T. vaginalis for detailed molecular studies of T. vaginalis and
assessment of the vaginal microbiome. Here, we report on a sub-study of 202 women who
were tested for curable STIs, i.e. C. trachomatis, N. gonorrhoeae, T. vaginalis, and for BV.
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Procedures
Recruitment: A nurse at the ANC clinic provided general information about the study to
women who had completed their ANC visit. Women interested to know more about the study
were invited to participate and up to nine consecutive women were enrolled per day.
Inclusion criteria: Women were eligible if they met the following criteria: age 18–45 years,
gestation 14 weeks, resident of the Kilifi Health and Demographic Surveillance area [22]
and willing to undergo free STI and BV screening procedures.
Study procedures: Consenting women underwent a short private interview with the nurse
at the ANC clinic using a structured questionnaire capturing symptoms of vaginal infections.
This was followed by a collection of vaginal swabs by the ANC nurse. During the collection of
vaginal swabs, the nurse observed for abnormal vaginal discharge and genital ulcers. Three
vaginal swabs were collected, by inserting one swab at a time approximately 2 inches into the
vaginal opening and gently turning around twice ensuring rubbing the swab against the vagi-
nal wall.
The first swab was used for BV diagnosis and vaginal smears were prepared by rolling the
swab onto a microscope glass slide. Slides were air-dried at the clinic before being transported
to the laboratory for heat fixation followed by Gram staining and microscopy using the scoring
system described by Nugent [23]. Women who self-reported discharge and had a Nugent
score of 7–10 were considered BV-positive, and were treated as recommended [8]. Women
with a Nugent score of 7–10 but without discharge were considered BV-negative.
The second swab was used to diagnose T. vaginalis using a commercially available T. vagi-
nalis InPouchTM system (BioMed Diagnostics, White City, Oregon, USA). The vaginal swab
was inoculated in the upper-chamber of the InPouch at the clinic. The inoculated InPouch was
transferred to the laboratory for direct microscopy of the upper chamber, after which the
upper chamber was merged with the lower chamber and incubated at 37˚C. Daily microscopy
was performed and samples with motile trichomonads within 5 days of culture were consid-
ered positive for T. vaginalis.
The third swab was placed in a sterile labeled 2 ml Eppendorf tube, the swab shaft was broken
by bending the shaft against the neck of the Eppendorf tube. The bottom portion of the swab with
the specimen was transported to the laboratory where it was immediately stored at -80˚C for
molecular studies of the vaginal microbiome. No transport or freezing medium was added.
Women provided fresh first catch urine for C. trachomatis and N. gonorrhoeae testing, that
was performed by the GeneXpert1 CT/NG Assay (Cepheid, Sunnyvale, California), according
to the manufacturer’s instructions.
Results for C. trachomatis, N. gonorrhoeae, for T. vaginalis direct microscopy and for BV
were reported on the same day of the visit, and STI and BV treatment was offered according to
Kenyan national guidelines [24], except for treatment of N. gonorrhoeae where ceftriaxone was
used in place of quinolones [25]. Women who were negative on T. vaginalis direct microscopy
but positive on culture were contacted to return to the ANC clinic for treatment immediately
after the culture turned positive. Treatment was also offered for the partners of the women
with curable STIs.
Syphilis and HIV test results were obtained from each participant’s ANC records. Syphilis
results were based on testing for treponemal antibodies only, done at the hospital laboratory
using a commercial test kit Advanced Quality One Step Anti-TP (InTec products INC, Xia-
men, China). Rapid HIV testing was done by the Alere Determine HIV-1/2 kit (Alere Medical
Co Ltd, Chiba, Japan), the First response HIV 1-2-0 kit (Premier Medical Corporation Lim-
ited, Daman, India) was used to confirm positive results, and the Uni-Gold kit (Trinity Bio-
tech, Wicklow, Ireland) was used to resolve any discordant test results.
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After clinical procedures were completed, all study participants were interviewed. The
interviews were conducted in Kiswahili by a trained female fieldworker. The questionnaire
covered sociodemographic, hygienic and sexual behavior questions. These included age, edu-
cation level, marital status, number of children, occupation, consumption of alcohol, con-
sumption of tobacco and other substances, age at first sex, number of sexual partners, history
of STIs, and hygiene and sanitary practices.
Ethical considerations
The study was approved by the KEMRI Scientific and Ethics Review Unit (#3022). All partici-
pants provided written informed consent for study participation. Permission to use hospital
records on syphilis and HIV status was obtained from Kilifi County Health department.
Data analysis
Data were entered in the REDCapTM electronic data capture tool, version 6.5.0 (Vanderbilt
University, Nashville, Tennessee). Prevalence of STIs was determined as the number of partici-
pants with either C. trachomatis, N. gonorrhoeae and/or T. vaginalis out of 202 women that
could be tested, expressed as a percentage. Exact 95% binomial confidence intervals (CIs) were
calculated for prevalence estimates. Bivariable logistic regression was used to determine associ-
ations of sociodemographic, hygienic, behavioral and clinical characteristics with curable STIs.
Variables significant at p 0.1 in bivariable analysis were entered into a multivariable model
to identify independent associations. Crude odds ratios (COR) and adjusted odds ratios
(AOR) were calculated. These statistical analyses were done using STATA version 13.1 (Stata-
Corp, College Station, Texas).
Results
From June to September 2015, a total of 373 women were invited to participate in the study.
Twenty-three (6.2%) women declined to participate citing no interest in research, lacking time or
having no permission from spouse/partner as the main reasons. Of the 350 women enrolled, 148
(42.3%) women did not have C. trachomatis andN. gonorrhoeae tests performed due the unavail-
ability of the tests at the beginning of the study. Therefore, a total of 202 women were tested for
C. trachomatis, N. gonorrhoeae, T. vaginalis and BV and were included in this sub-analysis (Fig 1).
Characteristics of the study population
The median age and gestation age including the interquartile range (IQR) for the participants
was 26 (22–31) years and 24 (20–28) weeks respectively. The majority of the participants were
married (93.6%) and Christian (72.3%). A quarter of the participants had secondary school
education and above. The median age and IQR of sexual debut was 18 (16–20) years, although
20.8% of the participants were not sure or did not respond to this question. Forty-two percent
of the participants had given birth before and the number of children ranged from 1–7. Sixty-
two percent of the participants had previously experienced signs/symptoms associated with
reproductive tract infection and one third had ever received syndromic treatment for genital
signs or symptoms of infection. The socio-demographic characteristics of the participants are
summarized in Table 1.
Prevalence of curable STIs, BV, HIV and syphilis
A total of 20.8% (42/202) (95% confidence interval (CI): 15.4–27.0) women had a curable STI
and 19.4% (39/202) (95% CI: 14.2–25.6) women had BV i.e. Nugent score of 7–10 and reported
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vaginal discharge. The prevalence was 14.9% for C. trachomatis (95% CI: 10.2–20.5), 1.0% for
N. gonorrhoeae (95% CI: 0.1–3.5) and 7.4% for T. vaginalis (95% CI: 4.2–12.0) (Fig 1). Five
(11.9%) women had more than one STI, while 13 (31%) out of the 42 women with a curable
STI also had BV. Only two women (1.0%) had asymptomatic BV and none of them had a cur-
able STI (data not shown).
Thirteen women were HIV-positive, a prevalence of 6.4% (95% CI: 3.4–10.8), including
four (2.0%; 95% CI: 0.5–5.0) women who were newly diagnosed. Of note, HIV prevalence in
82 women aged 18–24 vs. 120 women aged 25 years was 0% vs. 10.8% (p = 0.002). All nine
HIV positive women who knew their status were on anti-retroviral therapy. Among the 13
women with HIV, three women had curable STIs, i.e. a prevalence of 23.1% (95% CI: 5.0–
53.8). All women with HIV and a curable STI also had BV. The prevalence of curable STIs, or
BV in the 13 women with HIV was not statistically significantly different from that of the 189
women without HIV (data not shown).
Two women had treponemal antibodies, a prevalence of 1.0% (95% CI: 0.1–3.6). Prevalence
of HIV, treponemal antibodies and T. vaginalis for the 148 women who were not tested for C.
trachomatis and N. gonorrhoeae was not statistically significantly different than the prevalence
of HIV, syphilis, and T. vaginalis in the 202 tested for C. trachomatis and N. gonorrhoeae in the
sub-study.
Clinical signs and symptoms
The most commonly self-reported symptoms amongst all participants were vaginal discharge
(73.8%) and lower abdominal pain (46.5%). However, during collection of specimen by the
study nurse, only 17.3% of the participants had an abnormal discharge (defined as excess
Fig 1. Flow chart of women attending antenatal care clinic at Kilifi County Hospital invited to
participate in the study, June- September 2015
https://doi.org/10.1371/journal.pone.0175166.g001
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Table 1. Socio-demographic, hygienic, and behavioral characteristics of 202 women attending ante-
natal care and tested for sexually transmitted infections and bacterial vaginosis in Kilifi County Hos-
pital, Kenya, July-September 2015.
Total
n = 202
Positive for curable STIs n = 42
(%)
Demographic characteristics
Age group (Years)
18–24 82 24 (29.3)
 25 120 18 (15.0)
Religion
Christian 146 28(19.2)
Muslim 28 7 (25.0)
Other/None 28 7 (25.0)
Education
None 35 7 (20.0)
Primary 118 26 (22.0)
Secondary/Tertiary 49 9 (18.4)
Marital status
Single 13 5 (38.5)
Married 189 37 (19.6)
Residency
Living with partner 138 27 (19.6)
Not living with the partner 64 15 (23.4)
Employment status
Employed/self-employed 115 20 (17.4)
Unemployed 87 22 (25.3)
Parity
0 58 15 (25.9)
1–2 69 17 (24.6)
3+ 75 10 (13.3)
Gestational age (weeks)**
14–25 114 24 (21.1)
 26 87 18 (20.7)
Hygiene characteristics
Toilet type
Flushing toilet 75 15 (20.0)
Pit latrine 105 22 (21.0)
Bush/Other 22 5 (22.7)
Mode of cleaning after visiting the toilet
Tissue paper/other solid materials 64 7 (10.9)
Water 138 35 (25.4)
Vaginal washing when bathing ‡
External 32 6 (18.8)
Internal 166 35 (21.1)
Behavioral characteristics
Sexual debut age (years)
 17 64 21 (32.8)
 18 96 14 (14.6)
Don’t know/no response 42 7 (16.7)
Number of lifetime sex partners
1 96 16 (16.7)
(Continued )
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Table 1. (Continued)
Total
n = 202
Positive for curable STIs n = 42
(%)
2+ 106 26 (24.5)
Partner had other sexual partners in the last 6
months
No 182 38 (20.9)
Yes 20 4 (20.0)
Alcohol consumption ever
No 160 35 (21.9)
Yes 42 7 (16.7)
Tobacco smoking/chewing ever
No 191 41 (21.5)
Yes 11 1 (9.1)
Drugs/substance use ever
No 194 39 (20.1)
Yes 8 3 (37.5)
Sexually transmitted infections/ reproductive tract
infection
HIV
Negative 189 39 (20.6)
Positive 13 3 (23.1)
Syphilis
Negative 198 42 (21.2)
Positive 2 0 (0.0)
Bacterial vaginosis*
Negative 162 29 (17.9)
Positive 39 13 (33.3)
Clinical signs and symptoms of STI¥
Previous history of vaginal discharge
No 75 13 (17.3)
Yes 127 29 (22.8)
Previous syndromic treatment of genital infection
No 136 28 (20.6)
Yes 66 14 (21.2)
Current vaginal discharge (self-reported)
No 52 10 (19.2)
Yes 149 32 (21.5)
Abnormal vaginal discharge foul smell/color
(observed)
No 165 32 (19.4)
Yes 36 10 (27.8)
Dysuria
No 159 32 (20.1)
Yes 42 10 (23.8)
Dyspareunia
No 150 29 (19.3)
Yes 51 13 (25.5)
Vaginal itching
No 146 31 (21.2)
Yes 55 11 (20.0)
(Continued)
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discharge/foul smelling discharge/colored discharge) upon examination. Five (2.5%) women
had genital ulcers upon examination, of which 4 (9.6%) of the 42 women with a curable STI vs.
1 (0.6%) of the 159 women without a curable STI (p = 0.001). None of the women with genital
ulcers had HIV or treponemal antibodies. Other self-reported clinical signs or symptoms were
not associated with curable STIs.
Based on symptoms routinely used in syndromic management of STIs (i.e. genital ulcer,
lower abdominal pain or abnormal vaginal discharge), 45.2% of the 42 women with curable
STIs were asymptomatic.
Risk factors/predictors
In bivariable analysis, curable STIs were more common among participants who were24
years, had less than 3 children, had a sexual debut17 years, used water to clean themselves
after visiting the toilet, had a genital ulcer or were BV positive (Table 2).
In multivariable analysis, independent predictors associated with curable STIs included
women with a genital ulcer (AOR = 35.0, 95% CI: 2.7–461.6) compared to women without a
genital ulcer, women who used water for cleaning after visiting the toilet compared to those
who used toilet paper or other solid materials (AOR = 4.1, 95% CI: 1.5–11.3), women who
reported having sexual debut17 years compared to women having sexual debut18 years
(AOR = 2.7, 95% CI: 1.1–6.6), and BV-positive women (AOR = 2.7, 95% CI: 1.1–6.6) com-
pared to BV-negative women (Table 2).
Discussion
We found that one in five out of 202 pregnant women attending the ANC at the Kilifi County
Hospital, Kenya, during the period July to September 2015 had at least one curable STI. The
Table 1. (Continued)
Total
n = 202
Positive for curable STIs n = 42
(%)
Lower abdominal pain
No 107 24 (22.4)
Yes 94 18 (19.1)
Genital warts
No 196 40 (20.4)
Yes 5 2(40.0)
Genital ulcer (observed)
No 196 38 (19.4)
Yes 5 4 (80.0)
Vaginitis
No 195 40 (20.5)
Yes 6 2 (33.3)
Curable STIs = Infection with any of the following sexually transmitted infectious agents: Chlamydia
trachomatis, Neisseria gonorrheae and/or Trichomonas vaginalis
‡ Four participants did not respond to this question
*Bacterial vaginosis result for one participant was not available
**Gestational age for one participant was missing
*** Syphilis hospital records for two participants were unavailable.
¥Clinical signs and symptoms of STI records for one participant were missing.
https://doi.org/10.1371/journal.pone.0175166.t001
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Table 2. Bivariable andmultivariable analysis of socio-demographic, hygienic, behavioral, and clinical characteristics of pregnant womenwith
curable sexually transmitted infections attending antenatal clinic at Kilifi County Hospital, July—September 2015 (n = 202).
CurableSTIs n(%) Bivariable analysis Multivariable analysis
Demographic characteristics COR (95% C.I) P-
value
AOR (95% C.I) P-value
Age group (Years)
18–24 24 (29.3) 2.3 (1.2–4.7) 0.016 1.8 (0.7–4.4) 0.226
 25 18 (15.0) Ref
Religion
Christian 28 (19.2) Ref
Muslim 7 (25.0) 1.4 (0.5–3.6) 0.483 - -
Other/None 7 (25.0) 1.4 (0.5–3.6) 0.483 - -
Education
None 7 (20.0) Ref
Primary 26 (22.0) 1.1 (0.4–2.9) 0.797 - -
Secondary/Tertiary 9 (18.4) 0.9 (0.3–2.7) 0.851 - -
Marital status
Single 5 (38.5) Ref
Married 37 (19.6) 0.4 (0.1–1.3) 0.115 - -
Residency
Living with partner 27 (19.6) Ref
Not living with partner 15 (23.4) 1.3 (0.6–2.6) 0.529 - -
Employment status
Employed/self-employed 20 (17.4) Ref
Unemployed 22 (25.3) 1.6 (0.8–3.2) 0.173 - -
Parity
0 15 (25.9) 2.3 (0.9–5.5) 0.071 2.7 (0.8–8.9) 0.111
1–2 17 (24.6) 2.1 (0.9–5.0) 0.087 1.9 (0.7–5.2) 0.237
3+ 10 (13.3) Ref
Gestational age (weeks)
14–25 23 (20.5) Ref
 26 18 (20.7) 1.0 (0.5–2.0) 0.979 - -
Hygiene characteristics
Toilet type
Flushing toilet 15 (20.0) Ref
Pit latrine 22 (21.0) 1.1 (0.5–2.2) 0.876 - -
Bush/Other 5 (22.7) 1.2 (0.4–3.7) 0.781 - -
Mode of cleaning after visiting the toilet
Tissue paper/other solid material 7 (10.9) Ref
Water 35 (25.4) 2.8 (1.2–6.6) 0.022 4.1 (1.5–11.3) 0.007
Vaginal washing when bathing*
External 6 (18.8) Ref
Internal 35 (21.1) 1.2 (0.4–3.0) 0.766 - -
Behavioral characteristics
Sexual debut age (years)
 17 21 (32.8) 2.9 (1.3–6.2) 0.007 2.7 (1.1–6.6) 0.026
 18 14 (14.6) Ref
Don’t know/no response 7 (16.7) 1.2 (0.4–3.2) 0.754 - -
Number of lifetime sex partners
1 16 (16.7) Ref
(Continued )
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Table 2. (Continued)
CurableSTIs n(%) Bivariable analysis Multivariable analysis
Demographic characteristics COR (95% C.I) P-
value
AOR (95% C.I) P-value
2 26 (24.5) 1.6 (0.8–3.3) 0.171 - -
Partner has had other sexual partner(s) in the last 6 months
No 38 (20.9) 1.1 (0.3–3.3) 0.927 - -
Yes 4 (20.0) Ref
Alcohol consumption ever
No 35 (21.9) 1.4 (0.6–3.4) 0.461 - -
Yes 7 (16.7) Ref
Tobacco smoking/chewing ever
No 41 (21.5) 2.7 (0.3–22.0) 0.344 - -
Yes 1 (9.1) Ref
Drugs/Substance use ever
No 39 (20.1) 0.4 (0.1–1.8) 0.248 - -
Yes 3 (37.5) Ref
Clinical characteristics
HIV status
Negative 39 (20.6) Ref
Positive 3 (23.1) 1.2 (0.3–4.4) 0.834 - -
Bacterial vaginosis
Negative 29 (17.9) Ref
Positive 13 (33.3) 2.3 (1.1–5.0) 0.036 2.7 (1.1–6.6) 0.031
Clinical signs and symptoms of STI
Previous history of vaginal discharge
No 13 (17.3) Ref
Yes 29 (22.8) 1.4(0.7–2.9) 0.353 - -
Previous syndromic treatment of genital infection
No 28 (20.5) Ref
Yes 14 (21.2) 1.0 (0.5–2.1) 0.918 - -
Current vaginal discharge (self-reported)
No 10 (19.2) Ref
Yes 32 (21.5) 1.1 (0.5–2.5) 0.732 - -
Abnormal vaginal discharge (observed)
No 32 (19.4) Ref
Yes 10 (27.8) 1.6 (0.7–3.6) 0.265 - -
Dysuria
No 32 (20.1) Ref
Yes 10 (23.8) 1.2 (0.6–2.8) 0.602 - -
Dyspareunia
No 29 (19.3) Ref
Yes 13 (25.5) 1.4 (0.7–3.0) 0.352 - -
Vaginal itching
No 31 (21.2) Ref
Yes 11 (20.0) 0.9 (0.4–2.0) 0.848 - -
Lower abdominal pain
No 24 (22.4) Ref
Yes 18 (19.1) 0.8 (0.4–1.6) 0.568 - -
Genital warts
No 40 (20.4) Ref
Yes 2 (40.0) 2.6 (0.4–16.1) 0.304 - -
(Continued)
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high burden of curable STIs was mostly due to cases of C. trachomatis (14.9% of women) and
T. vaginalis (7.4% of women). We also found approximately 19.4% of the women to have BV,
defined as the presence of vaginal discharge in combination with a Nugent score7. Four out
of the 5 women with genital ulcers also had a curable STI. Our study documented that having
genital ulcers, cleaning with water as opposed to use of toilet paper after visiting the toilet,
early sexual debut, and BV were strongly associated with the presence of curable STIs.
The high prevalence (14.9%) of C. trachomatis found in this study is comparable to a preva-
lence of 13% (95% CI: 8.6–16.8) among women seeking family planning services in Nairobi,
Kenya [20] and 9.9% (95% CI: 7.2–13.2) among women in a multi-country (Kenya, Rwanda
and South Africa) cross-sectional study [26]. Two other recent studies reported lower preva-
lence rates of C. trachomatis: 5.6% (95% CI: 4.4–7.0) among 1300 HIV-seronegative ANC-
attending women at two district hospitals in rural western Kenya [13], and 6.0% (95% CI: 3.6–
9.3) in another study among 300 women attending outpatient clinics in Nairobi [27]. Since the
high prevalence of C. trachomatis among pregnant women may likely reflect ongoing trans-
mission of C. trachomatis among the general rural population in Kilifi, further studies con-
firming the high prevalence and ongoing C. trachomatis transmission among this population
would be helpful. Chlamydia infection has been found to be an independent predictor of HIV-
1 acquisition in a recent study from western Kenya, with also syphilis, yeast infection/colonisa-
tion and BV showing strong associations with incident HIV-1 infection [13].
We documented a prevalence of T. vaginalis (7.4%) comparable to 6.0% among HIV-sero-
negative ANC-attending women in rural western Kenya [13], and 7.7% among women attend-
ing a child-health clinic in Mombasa, Kenya [28]. In vitro evidence suggests that T. vaginalis
may alter the vaginal microbiome towards BV [29]. T. vaginalis has also been associated with
increased viral shedding and increased acquisition of HIV [30, 31], potentially contributing to
a significant number of additional HIV infections globally [31].
The prevalence of HIV-1 (6.4%) in this study was substantial, with all known and newly diag-
nosed cases occurring amongst the 120 women25 years. In Coastal Kenya, HIV-1 prevalence
estimates in women aged 15–24 years decreased from 5.7% in 2007 to 2.0% in 2012 (p = 0.026)
[32]. Our results suggest a further decline in HIV-1 prevalence, among women 24 years.
Table 2. (Continued)
CurableSTIs n(%) Bivariable analysis Multivariable analysis
Demographic characteristics COR (95% C.I) P-
value
AOR (95% C.I) P-value
Genital ulcer (observed)
No 38 (19.4) Ref
Yes 4 (80.0) 16.6 (1.8–153.1) 0.013 35.0 (2.7–461.6) 0.031
Vaginitis
No 40 (20.5) Ref
Yes 2 (33.3) 1.9 (0.3–11.0) 0.454 - -
Curable STI = Infection with any of the following sexually transmitted infectious agents: Chlamydia trachomatis, Neisseria gonorrheae, Trichomonas
vaginalis
AOR: Adjusted Odds Ratio
CI: Conﬁdence interval
COR: Crude Odds Ratio
*One participant did not respond to this question
https://doi.org/10.1371/journal.pone.0175166.t002
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A relatively low prevalence of N. gonorrhoeae (1%) and treponemal antibodies (1%) were
found in our study. The prevalence of treponemal antibodies was similar to the study among
HIV-seronegative ANC-attending women in rural western Kenya, [13] while the N. gonor-
rhoeae prevalence in the latter study was 3.0%.
BV diagnosis in our study was based on an a priori self-report of vaginal discharge in combi-
nation with a Nugent score of7 (while only 2 (1%) women had asymptomatic BV). Women
with BV had an almost 3-fold higher risk of infection with a curable STIs than women without
BV, comparable to other studies [4, 33]. It might be advisable to better document the presence
of BV. However, general screening for BV among all women attending ANC, using the Nugent
score [23] or Amsel’s criteria [34], would require significant commitment of resources and staff.
Using simple point of care testing, Madhivanan et al. [35] demonstrated that a vaginal pH>4.5
and a positive whiff test had a sensitivity of 83% but a specificity of only 47% for diagnosing BV.
Although, not specific this approach may be adopted for BV screening in resource poor settings.
Alternatively, presumptive treatment with intravaginal metronidazole (750 mg) plus micona-
zole (200 mg) for five consecutive nights each month for 12 months was shown to be effective
to improve vaginal health and to decrease susceptibility to bacterial STIs, in a recent trial among
non-pregnant women [36], but the frequency of treatment would make it challenging to upscale
this intervention.
Our findings reinforce the need to integrate STI services at ANC. Screening for T. vaginalis
can be achieved at a relatively affordable cost (US $ 5), making screening for T. vaginalis po-
tentially feasible. Recent acquisition by the Kenyan government of over 120 GeneXpert IV
machines for county and sub-county hospitals for tuberculosis testing [37], has potentially
expanded the diagnostic capacity for curable STIs using the same testing platform at larger
hospitals. However, the cost of the C. trachomatis and N. gonorrhoeae test kits are currently
high. Without assay costs becoming considerably less expensive, it seems unlikely that ANC-
attending women will be routinely tested for C. trachomatis and N. gonorrhoeae. Cost-effective
studies have played an important role of informing policy on the gains of syphilis screening in
pregnancy while minimizing on the expenditure [38]. Such cost-effectiveness studies of ANC
screening and treatment of C. trachomatis, N. gonorrhoeae, and T. vaginalis should be con-
ducted in resource poor settings.
Treatment of STIs in both infected persons and their partner is pivotal for STI management,
ensuring reduction in cases of reinfection or non-resolving infections and prevention of adverse
outcomes [8]. In our study a presumptive patient delivered partner treatment approach was
adopted. Despite the fact that we did not collect information on the number of partners who
were treated, this approach has been shown to be acceptable and feasible among pregnant
women in Kenya [39].
Early sexual debut was strongly associated with curable STIs in our study population, simi-
lar to findings in other studies [40, 41]. Kilifi county is one of the poorest counties in Kenya,
characterized by low literacy levels mostly among women, young age at marriage of women,
and high fertility rates [42]. Structural changes focusing on the economic empowerment of
communities, including improved access to education, and legislation protecting women from
early marriage will be necessary to reduce the high burden of curable STIs among pregnant
women.
A salient predictor of curable STIs in our study population was the use of water to clean after
visiting the toilet as compared to those women who reported to use toilet paper or other solid
materials. Unfortunately, our hygiene question did not distinguish urinating from defecating,
or inquired whether the cleaning mode included both anus and vagina. It is possible that such
cleaning transported bacteria from the perianal area to the vagina, as pathogens causing curable
STIs may be found in paragenital areas [43]. Moreover, there is a strong correspondence in
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bacterial species and loads between the vagina and rectum of pregnant women [44]. McClelland
et.al [31] showed that vaginal washing increased risk of HIV-1 acquisition among African
women. Although, we did not assess whether water used by our study participants was shared,
sharing of water may potentially lead to contamination of the vagina [45]. Pereira-Neves and
Benchimol [46] showed in vitro that T. vaginalis remained viable and infective in swimming
pool water samples for several hours. Further research is required to investigate the potential
role that sanitary and hygiene practices may play in women with high prevalence of curable
STIs and BV.
Observed genital ulcers had the strongest association with curable STIs, and were found in
2.5% of study participants. Presumptively treating curable STIs on the basis of observed genital
ulcers in pregnant women would have treated ~10% of the curable STIs in our study. Studies
examining microbial aetiology of genital ulcer disease, have shown that genital ulcers can be
attributed to several sexually transmitted pathogens with most cases being attributed to Herpes
Simplex virus type 2 [47, 48]. Genital ulcers were also identified as the strongest predictor of
acute HIV acquisition in attendees of STD clinics who initially had HIV-seronegative or dis-
cordant rapid test results [49]. While in our study no women with genital ulcers had HIV,
observing genital ulcers in women may help initiate risk reduction during ANC counselling
and targeted acute HIV screening [50].
Our study had some limitations. First, our study only included a relatively small sample of
pregnant women limiting the precision of our prevalence estimates. Second, we only included
adult women and were not able to enroll pregnant women who were minors. Minors are
potentially more vulnerable and may have presented with different STIs. Third, we included
only women residing within the Kilifi Health and Demographic Surveillance Area [22], and
therefore will have excluded women from outside the surveillance area who may have different
health characteristics. Fourth, our hygiene and sanitary questions were few, and limited [51].
Finally, this was a cross-sectional study, only allowing for an assessment of associations and
we did not collect data on pregnancy outcomes.
Despite these limitations, we showed that there is high prevalence of curable STIs among
pregnant women attending an antenatal clinic at Kilifi County Hospital, Kenya. Curable STIs
were associated with genital ulcers, hygienic practices, early sexual debut and BV. We recom-
mend that antenatal care programs consider strengthening their diagnostic screening for cur-
able STIs and BV.
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Chapter Four
4.1 Abstract 
 
BACKGROUND: Screening of curable sexually transmitted infections is frequently 
oriented towards the diagnosis of chlamydia, gonorrhea, syphilis and trichomoniasis, 
whereas other pathogens, sometimes associated with similar urogenital syndromes, 
remain undiagnosed and/or untreated. Some of these pathogens are associated with 
adverse pregnancy outcomes. 
METHODS: In a nested case-control approach, vaginal swabs from 79 pregnant women, 
i.e., 28 T. vaginalis-positive (cases) and 51 T. vaginalis-negative (controls), were 
screened by quantitative PCR for Adenovirus 1 and 2, Cytomegalovirus, Herpes Simplex 
Virus 1 and 2, Chlamydia trachomatis, Escherichia coli, Haemophilus ducreyi, 
Mycoplasma genitalium, M. hominis, candidatus M. girerdii, Neisseria gonorrhoeae, 
Streptococcus agalactiae, Treponema pallidum, Ureaplasma parvum, U. urealyticum, 
and Candida albicans. Additionally, we determined whether women with pathogens highly 
associated with T. vaginalis had distinct clinical signs and symptoms compared to women 
with T. vaginalis mono-infection. 
RESULTS: M. hominis was independently associated with T. vaginalis (adjusted odds 
ratio = 6.8, 95% CI: 2.3–19.8). Moreover, M. genitalium and Ca M. girerdii were 
exclusively detected in women with T. vaginalis (P = 0.002 and P = 0.001), respectively. 
Four of the six women co-infected with T. vaginalis and Ca M. girerdii complained of 
vaginal itching, compared to only 4 out of the 22 women infected with T. vaginalis without 
Ca M. girerdii (P = 0.020).  
CONCLUSION: We confirm M. hominis as a correlate of T. vaginalis in our population, 
and the exclusive association of both M. genitalium and Ca. M. girerdii with T. vaginalis. 
Screening and treatment of this pathogens should be considered. 
Key words: 
Trichomonas vaginalis, Mycoplasma hominis, M. genitalium, Candidatus Mycoplasma 
girerdii, pregnant, screening, sexually transmitted infections, Kenya  
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Chapter Four
4.2 Introduction 
 
Sexually transmitted infections (STIs) are among the most common acute infections 
globally [1]. The most common curable STIs include Chlamydia trachomatis, Neisseria 
gonorrhoeae, Treponema pallidum subspecies pallidum (syphilis), Trichomonas vaginalis 
and Hepatitis B virus. These five infections cause acute conditions such as cervicitis-
endometritis, vaginal/urethral discharge, urethritis and genital/anorectal/oral ulceration. 
They can also lead to severe complications and long term sequelae, including pelvic 
inflammatory disease, oophoritis, salpingitis, ectopic pregnancy, infertility, neurological 
disease, neonatal death, premature delivery and blindness [2]. Another public health 
concern is the association of STIs with the increased risk of HIV acquisition and 
transmission [3].  
Of the four common curable STIs, T. vaginalis is globally the most prevalent pathogen 
[1], with a prevalence of up to 11.5% among women in sub-Sahara Africa [1]. Although 
there is a wealth of data regarding the clinical presentation and global burden of T. 
vaginalis [4], studies assessing associations of T. vaginalis with other genital pathogens 
are scarce, although it has been suggested that T. vaginalis has a unique symbiotic 
relationship with Mycoplasma hominis (M. hominis) [5]. T. vaginalis is also associated 
with an increase in vaginal pH [6] which may influence the composition of the associated 
vaginal microbial community and is strongly associated with bacterial vaginosis (BV) [6]. 
Less appreciated pathogens like M. hominis, M. genitalium, Ureaplasma parvum and U. 
urealyticum are increasingly being associated with adverse pregnancy outcomes as well 
as respiratory infections in neonates [7]. 
Sexually transmitted infection (STI) screening programs and STI research mostly focus 
on the four most common curable STIs, whereas other pathogens, associated with similar 
urogenital syndromes, remain undiagnosed and/or untreated. Detection of urogenital 
pathogens that may be associated with T. vaginalis may be important as it might have an 
effect on the clinical presentation and management and the long-term outcome of those 
infections. Here, we assess the occurrence of specific urogenital species in T. vaginalis-
positive (cases) and T. vaginalis-negative (controls) among pregnant women in Kilifi, 
Kenya.   
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4.3 Materials and methods 
 
Study setting 
Kenya is divided administratively into 47 counties. Kilifi County, which lies along the Indian 
Ocean Coast, is one of the poorest and is typical of a rural equatorial African setting.  
Among pregnant women in Kilifi the HIV prevalence is estimated to be 6.4 %, for 
chlamydia 14.9 %, for gonorrhea 1.0 % and 7.4 % for trichomoniasis [8]. 
From July till September 2015, we carried out a cross-sectional study (curable STI study) 
at the antenatal care clinic of Kilifi County Hospital, Kenya. The main aim of the curable 
STI study was to describe the prevalence and predictors of curable sexually transmitted 
infections (STIs) among 350 pregnant women attending the antenatal care clinic [8]. 
Women were eligible if they met the following criteria: age 18-45 years, gestation ≥ 14 
weeks, being residents of the Kilifi Health and Demographic Surveillance area, 
willingness to undergo free STI and bacterial vaginosis (BV) screening procedures and 
willing to give written informed consent. This study presents a secondary objective of the 
above-mentioned study, namely to describe urogenital pathogen correlates of T. vaginalis 
among pregnant women in Kilifi, Kenya. 
For the above-described curable STI study, a nurse collected vaginal secretions from the 
vaginal introitus using two sterile cotton swabs. The first vaginal swab was inoculated at 
the clinic in the upper-chamber of an InPouch system (BioMed Diagnostics, White City, 
Oregon, USA), a highly specific and sensitive device containing a fluid medium supporting 
the growth of T. vaginalis and allowing microscopic observation of T. vaginalis. The 
inoculated InPouch was transferred to the laboratory within 15 minutes for direct 
microscopy of the upper chamber, after which it was merged with the lower chamber and 
incubated at 37 °C ± 1 °C. Daily microscopic observation (at both ×10 and ×40 
magnification, for six fields) of the InPouch system was performed by qualified 
technicians. Samples with motile trichomonads within 5 days of culture were considered 
positive for T. vaginalis.  
Women found to be positive for T. vaginalis by means of direct microscopy were treated 
on the same day. Women who were negative for T. vaginalis direct microscopy but 
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positive on culture were contacted to return to the clinic for treatment immediately after 
the culture turned positive. Secnidazole 2 g statim was administered as treatment, and 
participants were also asked to refer their sexual partner(s) to the clinic for treatment or 
were given the same medication to take to their sexual partner(s). 
The second swab was placed in a sterile labeled 2 ml Eppendorf tube, the swab shaft 
was broken by bending the shaft against the neck of the Eppendorf tube, and the tube 
containing the swab tip was closed and transported to the laboratory where it was 
immediately stored at -80 °C for molecular studies of the vaginal microbiome. No transport 
or freezing medium was added. 
Specimens for this case-control study are derived from the stored swabs from the curable 
STI study, published previously [7]. Because of financial and logistic constraints we could 
process only a subset of the 350 vaginal swabs from the main study. Vaginal swabs from 
79 pregnant women were divided in two groups for analysis, i.e., those from women 
positive for T. vaginalis (cases) and those from women negative for T. vaginalis (controls) 
as determined by PCR. Controls were age-matched (+/- 5 years) and all were bacterial 
vaginosis (BV) negative by Nugent score, largely matching the cases because only 4 out 
of the 28 T. vaginalis positive cases were BV+. Selection of controls was guided by being 
T. vaginalis negative. The statistical power of a study can be increased by enrolling more 
controls than cases. However, the additional power that is achieved diminishes as the 
ratio of controls to cases increases, and ratios greater than 4:1 have little additional impact 
on power. Nevertheless, if the data on controls is easily obtained, there is no reason to 
limit the number of controls. For financial reasons we had to settled for 2:1 ratio which is 
acceptable. The swabs of 51 women selected as controls were not significantly different 
from the swabs of the other 270 women not selected as controls (Supplementary Table 
4.1). 
DNA extraction 
Before DNA extraction, was performed in Kilifi, the frozen swabs were thawed at room 
temperature for 30 minutes. Extraction was performed using the QIAamp DNA Mini Kit 
(Qiagen, Hilden, Germany) according to manufacturer’s instructions and 160 μL of eluted 
DNA was transferred to Eppendorf tubes and frozen at -80 °C until shipment to the 
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Laboratory of Bacteriology Research (LBR, Ghent University, Belgium), using shipping 
boxes filled with dry ice (-78.5°C). Once at the LBR the Eppendorf tubes with DNA-
extracts were transferred back to -80 °C until molecular analysis was performed. No 
thawing and freezing occurred after freezing the DNA extract until the point of molecular 
testing in the laboratory in Belgium. 
TaqMan® Array Card  
This assay has multiple genetic targets per pathogen in order to maximize both specificity 
and sensitivity [9]. Samples were determined to be positive for a specific species on the 
TaqMan® Array Card (TAC), only in case the assay was positive for two independent 
PCR targets of that species. Sample quality was assessed by amplification of human 
DNA, to evaluate the quantity of epithelial cells recovered by the swab. Most quantitative 
PCRs were performed using this highly sensitive and specific TaqMan® Array Card 
(TAC), developed at AZ Sint-Jan Brugge-Oostende, Belgium. The array card was used 
for detecting Chlamydia trachomatis (including Lymphogranuloma venereum (LGV) or C. 
trachomatis serovars L1-L2-L3), Haemophilus ducreyi, Neisseria gonorrhoeae, 
Mycoplasma genitalium (including M. genitalium macrolide resistance-mediating 
mutations A2058G, A2059G, A2058T, A2058C in region V of the 23S rRNA gene), M. 
hominis, Ureaplasma parvum, U. urealyticum, Treponema pallidum, Herpes Simplex 
virus-1/-2 (HSV 1/2), adenoviruses, Cytomegalovirus (CMV), and T. vaginalis 
qPCRs 
Further individual qPCRs were performed at the LBR for Candida albicans [10], 
Escherichia coli [11] and Streptococcus agalactiae [11,12]. The amplification, detection 
and quantification were carried out using the LightCycler 480 platform and the LightCycler 
1480 Software Version 1.5 (Roche). Each qPCR was performed in a final volume of 10 μl 
of which 2 μl of DNA extract or 2 μl of HPLC water as negative template control or 2 μl of 
a positive control. All the specific primers and probes were synthesized by Eurogentec, 
Liège, Belgium. Specific qPCR details are provided in Supplementary Table 2. 
For the construction of qPCR standard curves, the procedures as described by Cools et 
al. [10] were adopted. Briefly, DNA was extracted from overnight cultures of C. albicans 
ATCC 90028 grown on Sabouraud agar (Becton Dickinson, Erembodegem, Belgium) and 
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of E. coli ATCC 25922 or S. agalactiae LMG 14694T grown on TSA + 5% sheep blood 
(Becton Dickinson). All growth was harvested from the plate and re-suspended in 1 ml of 
saline. DNA of this suspension was extracted using the High Pure PCR Template 
Preparation Kit (Roche Applied Science, Basel, Switzerland), according to the 
manufacturer’s instructions. DNA-concentration was determined by means of Nanodrop 
and the number of genomes was calculated. A tenfold dilution series in HPLC-grade water 
was made to establish for each dilution the number of colonies needed to pass the 
detection threshold. Using these data, a regression curve was constructed. 
PCR for T. vaginalis and for Candidatus Mycoplasma girerdii (Ca. M. girerdii) 
PCRs for T. vaginalis targeting the actin gene, using outer primers, previously used in a 
nested PCR [13] and yielding a fragment of 1100 bp and for Ca. M. girerdii, yielding a 
fragment of 594 bp [14], were carried out on the ABI Veriti thermocycler platform 
(ThermoFisher Scientific, Waltham, Massachusetts). The primers were synthesized by 
Eurogentec, Liège, Belgium. Amplified fragments were visualized under UV light after 
agarose gel electrophoresis and EtBr staining.  
Details of these species-specific PCRs are summarized in Suppl. Table 4.2. 
Sequencing 
Sequencing of PCR amplicons of Ca. M. girerdii was carried out by GATC Biotech 
(Constance, Germany) to confirm specificity of the PCR products. Sequencing was done 
using the forward PCR primers (Suppl. Table 2). Sequences were cleaned using 
Chromas Lite version 2.1 (Technelysium, Brisbane, Australia). BLAST was performed on 
the sequences to confirm the identity. 
Data analysis 
Epidemiological data were analyzed using StataCorp. 2013. Stata Statistical Software: 
Release 13 (College Station, TX: StataCorp LP). Prevalence of urogenital pathogens 
were computed with 95% confidence intervals (CIs). Associations between T. vaginalis 
positivity and socio-demographic, hygienic and behavioral characteristics were calculated 
using the χ2 test. To build a multivariate model of urogenital species associated with T. 
vaginalis, we first carried out univariate regression analysis. For computation of odds 
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ratios (ORs), we replaced all zero values in cells by the value ‘0.5’, as suggested by Deeks 
& Higgins [13]. 
Species that were significantly associated with T. vaginalis in univariate regression 
analysis P-value ≤ 0.1 were selected for multivariate logistic regression analysis. 
Associations in the final multivariate model were expressed as adjusted odds ratios 
(AORs) with p-values ≤ 0.05 considered significant. We further assessed whether 
pathogens, significantly associated with T. vaginalis infection, had an implication on the 
clinical presentation. 
Ethical considerations 
We obtained ethical approval from the Kenya Medical Research Institute Scientific and 
Ethics Review Unit (#3022). Written informed consent was obtained from all the 
participants. 
4.4 Results 
 
A total of 23 out of 350 samples (6.5%) were positive by InPouch culture for Trichomonas 
vaginalis, of which eight (34.8%) were initially positive on direct microscopy. The T. 
vaginalis-specific PCR [13] detected one additional case of T. vaginalis from a sample 
that was negative by InPouch culture but positive by the TAC assay, which found four 
more positive samples. In summary, sensitivity of direct microscopy, of T. vaginalis 
InPouch culture and of T. vaginalis-specific PCR were respectively 28.6%, 82.1% and 
85.7%, when compared to the TAC assay. For this study cases of T. vaginalis was based 
on the TAC assay results. 
Distribution of age, religion, education level, marital status, parity, gestational age and 
number of lifetime sex partners were similar among cases and controls (Table 4.1). HIV 
and BV status was different between the two groups by our case-control study design 
(Table 4.2), but the resulting overall difference was minimal, i.e. 0 HIV and 0 BV cases in 
the control group compared to 3 HIV-positives (10.7 %) and 4 BV-positives (14.3 %) in 
the Trichomonas positive group. Moreover, we could show that these differences had no 
influence on the species associated with T. vaginalis (Supplementary Table 4.3 and 4.4). 
Additionally, occupation was also significantly different (Table 4.2). 
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Prevalence of urogenital species  
The prevalence of the co-infecting urogenital species is indicated in Table 4.2. 
Adenovirus, Haemophilus ducreyi, Neisseria gonorrhoeae and Treponema pallidum were 
not detected and are not reported in Table 4.2. Ureaplasma parvum was the most 
prevalent at 74.7% (95% Confidence interval (CI): 63.6-83.8), followed by U. urealyticum 
at 48.1% (CI: 36.7-59.6).  
Univariate and multivariate association analysis 
Although, M. genitalium and Ca. M. girerdii, had generally a low prevalence of 
respectively 6.3% and 7.6%, the two were exclusively detected in women with T. vaginalis 
(Chi-square test: χ2 = 9.7, df = 1, P < 0.002 and χ2 = 11.8, df = 1, P < 0.001, respectively). 
Both M. genitalium and Ca. M. girerdii were significantly associated with T. vaginalis on 
univariate analysis but not on multivariable analysis (Table 4.2) as they were not included 
in the multivariable analysis. None of the samples for which M. genitalium could be 
detected showed macrolide resistance-associated mutations. In a univariate regression 
analysis, M. hominis and U. urealyticum were significantly associated with T. vaginalis 
(crude odds ratio (COR) = 7.3; 95% CI: 2.6–20.5 and COR = 2.2; 95% CI: 0.9–5.7, 
respectively). We detected M. hominis from the vaginal DNA extracts of approximately 
70% of women with T. vaginalis. M. hominis was also independently associated with T. 
vaginalis in a multivariate regression analysis (adjusted odds ratio (AOR) = 6.8; 95% CI: 
2.3–19.8).  
Tables 4.3- 4.5 compare clinical signs and symptoms among T. vaginalis-infected women 
co-infected or not with M. hominis (Table 4.3), or with Ca M. girerdii (Table 4.4) or with M. 
genitalium (Table 4.5). 
Women co-infected with T. vaginalis and Ca. M. girerdii were more likely to report vaginal 
itching compared to T. vaginalis-positive women not co-infected with Ca. M. girerdii 
(66.8% vs. 18.2% (p = 0.020)). There was no difference in clinical presentation of T. 
vaginalis-infected pregnant women co-infected with M. hominis or with M. genitalium, 
compared to those not co-infected with these species. 
Of the five participants that had M. genitalium and the six that had Ca M. girerdii, only one 
participant had a co-infection with M. genitalium and Ca M. girerdii. However, M. hominis 
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was always present in vaginal samples from which M. genitalium and Ca M. girerdii were 
detected. Due to the detection of CMV, HSV 1/ 2, M. genitalium and Ca. M. girerdii 
exclusively in cases or controls, the species were excluded from the regression model. 
 
4.5 Discussion 
 
Our results indicate that women with Trichomonas vaginalis (n = 28) have a high rate 
(71.4%) of co-infection with Mycoplasma hominis compared to only 25.5% of 51 women 
not infected with T. vaginalis. Comparable rates of co-infection have been reported by 
Becker et al. [15], i.e., 56.7% in Brazil and by Xiao et al. [16], i.e., 50.0% in China. Rappelli 
et al. [18] reported much higher rates (94.3%) of co-infection among Italian, Mozambican, 
and Angolan women. M. hominis has been shown to have a symbiotic relationship with 
T. vaginalis. Owing to its small genome, this bacterial species is strongly dependent on 
host cell metabolism. M. hominis has the ability to enter trichomonad cells by endocytosis 
and to multiply in coordination with the protozoan [5]. We could not establish differences 
in clinical presentation of women co-infected with both T. vaginalis and M. hominis as 
compared to those infected with only T. vaginalis, in agreement with previous data [19]. 
As such, at present, co-infection of T. vaginalis with M. hominis seems to be of limited 
clinical relevance, also because antibiotic treatment of the former will probably 
consecutively diminish the presence of the latter. 
The pathogenic potential of M. genitalium among pregnant women in Kenya has not been 
extensively investigated probably because its prevalence is overshadowed by a higher 
prevalence of other STIs, as was the case in this study. Our results indicate that in our 
population M. genitalium was strongly associated with T. vaginalis (p = 0.002). Given the 
presence of M. genitalium exclusively in women with T. vaginalis infection, screening and 
treatment of women for T. vaginalis might also at once reduce the prevalence of M. 
genitalium. Although macrolide resistance associated mutations among M. genitalium 
strains are on the rise, as was recently shown among female sex workers in Belgium [20], 
macrolide resistance-associated mutations could not be detected in any of the five 
samples positive for M. genitalium and therefore our results, although based on a very 
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small sample, suggest that macrolides can still be used for treatment of M. genitalium in 
this population in Kilifi, Kenya.  
To our knowledge, this is the first report of Ca. M. girerdii in Africa. In agreement with the 
two initial reports on the prevalence of Ca. M. girerdii [15, 21], we found it to be strongly 
associated with T. vaginalis (p = 0.001). Fettweis et al. [15], using a pyrosequencing 
approach, were the first to detect Ca. M. girerdii DNA in the vaginal swabs of a few women 
not infected with T. vaginalis, as assessed with qPCR, although in our study, Ca. M. 
girerdii was found only in T. vaginalis positive women. A recent report by Costello et al. 
[22] is in support of the close association of Ca. M. girerdii and T. vaginalis as they 
recovered Ca. M. girerdii and T. vaginalis genomes from the saliva of a premature infant.  
Our data suggest that T. vaginalis-positive women, co-infected with Ca. M. girerdii, were 
more likely to report vaginal itching compared to T. vaginalis mono-infected women. 
Future studies should elucidate the nature of the interaction of these two pathogens and 
the effect that co-infection may have on clinical presentation. 
U. parvum and U. urealyticum are commonly isolated from the vaginal microbiome of 
asymptomatic pregnant women [23], as was the case in our study. Although detection of 
U. parvum has been associated with preterm birth [24], opinions differ with regard to the 
need to screen and treat Ureaplasma spp. infection during pregnancy, since its presence 
often represents colonization rather than infection [25]. Our data did not show any 
association between T. vaginalis and either U. parvum or U. urealyticum.  
C. trachomatis was highly prevalent (13.9%) in our study. All isolates were non-LGV 
strains, and were not associated with T. vaginalis infection. Our results on urogenital 
carriage of Candida, E. coli, and GBS indicate that the three were not associated with T. 
vaginalis infection, either. While the prevalence of Candida in our study was higher than 
that reported in a cross-sectional study by Cools et al. [11] among women in Kenya, 
Rwanda and South-Africa, our prevalence for E. coli and GBS is comparable to what they 
reported. 
Our study had some limitations. First, it only included a relatively small sample size of 
pregnant women limiting the precision of our prevalence estimates. Furthermore, only BV 
negative samples were included in the control arm, which may represent a bias on the 
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interpretation of the results. Among the 28 T. vaginalis-positive women, only four were 
positive for BV and excluding them in the analysis does not affect the results (Suppl. Table 
3). It should be noted that our T. vaginalis/BV co-infection rate of 14 % was comparable 
to that observed in a recent study, i.e. 17.5% among HIV + women [26]. Finally, no internal 
control was added during the DNA extraction process, so inefficient genome extraction or 
(partial) PCR inhibition could not be documented. However, sample adequacy was 
evaluated by detecting a minimal level of human DNA present in the sample, which was 
the case for all samples, moreover none of the samples that were culture-positive for T. 
vaginalis were missed by PCR. 
In conclusion, we observed notable prevalence of urogenital micro-organisms, pathogens 
and colonizing germs among pregnant women which emphasizes the need for laboratory 
testing and treatment to avoid unfavorable pregnancy outcomes. We confirm M. hominis 
as a correlate of T. vaginalis in our population, but the most salient finding was the 
exclusive association of both M. genitalium and Ca. M. girerdii with T. vaginalis. The latter 
finding ought to be further addressed using a larger sample size. 
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Table 4.1. Study participant characteristics 
Socio-demographic and behavioral characteristics of Trichomonas vaginalis qPCR 
positive women (cases) and T. vaginalis qPCR negative women (controls), attending 
antenatal care at Kilifi County Hospital, Kenya.  
Characteristic Cases (%) 
N = 28 
Controls (%) 
N = 51  
χ2  
P-value 
Age group (Years)  
18-24 42.9 31.4 0.307 
 ≥ 25 57.1 68.6  
Religion  
Christian   64.3 68.6 0.383 
Muslim 10.7 17.7  
Other/None 25.0 13.7  
Education  
None 21.4 23.5 0.946 
Primary   60.7 56.9  
Secondary/Tertiary    17.9 19.6  
Employment status   
 Employed/self-employed 50.0 72.6 0.045 
 Unemployed 50.0 27.5  
Parity  
    0 25.0 35.3 0.234 
    1-2 46.4 25.4  
    3+ 28.6 37.3  
Gestational age  
   14-27 57.1 58.8 0.885 
    ≥ 28 42.9 41.2  
Number of lifetime sex  
     1 82.1 90.2 0.303 
     3+ 21.7 9.8  
 
Legend 
In bold: significantly associated, i.e., P ≤ 0.05
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Table 4.3 Comparison of women co-infected with Trichomonas vaginalis and M. hominis 
with those infected with T. vaginalis only 
Comparison of clinical signs and symptoms among women co-infected with Trichomonas 
vaginalis and Mycoplasma hominis with those infected with T. vaginalis only 
 
 
Legend:  
MH: Mycoplasma hominis; TV: Trichomonas vaginalis  
Clinical sign or symptom TV with MH  
N = 20 (%) 
TV without MH  
N = 8 (%) 
χ2 
P-value 
Dyspareunia 40.0 37.5 0.903 
Dysuria 30.0 37.5 0.701 
Foul smelling vaginal discharge 30.0 12.5 0.334 
Genital ulcers 15.0 12.5 0.864 
Genital warts 10.0 0.0 0.353 
Lower abdominal pain 40.0 25.0 0.454 
Vaginal discharge 75.0 62.5 0.508 
Vaginal itching 30.0 25.0 0.791 
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Table 4.4 Comparison of women co-infected with Trichomonas vaginalis and Ca 
Mycoplasma girerdii with those infected with T. vaginalis only 
Comparison of clinical signs and symptoms among women co-infected with Trichomonas 
vaginalis and Ca Mycoplasma girerdii and those infected with T. vaginalis only 
 
 
Legend: 
Ca MG: Candidatus Mycoplasma girerdii; TV: Trichomonas vaginalis; in bold: significantly 
associated. 
  
Clinical sign or symptom TV with Ca MG  
N = 6 (%) 
TV without Ca 
MG  
N = 22 (%) 
χ2 
P-value 
Dyspareunia 50.0 36.4 0.544 
Dysuria 50.0 27.3 0.291 
Foul smelling vaginal discharge 33.3 22.7 0.595 
Genital ulcers 16.7 13.6 0.851 
Genital warts 0.0 9.1 0.443 
Lower abdominal pain 50.0 32.8 0.410 
Vaginal discharge 100.0 63.6 0.081 
Vaginal itching 66.7 18.2 0.020 
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Table 4.5 Comparison of women co-infected with Trichomonas vaginalis and M. 
genitalium with those infected with T. vaginalis only 
Comparison of clinical signs and symptoms among women co-infected with Trichomonas 
vaginalis and Mycoplasma genitalium compared to those infected with T. vaginalis only 
Clinical sign or symptom TV with MG 
N = 5 (%) 
TV without MG 
N = 23 (%) 
(χ2).P-value 
Dyspareunia 20.0 43.5 0.330 
Dysuria 20.0 34.8 0.521 
Foul smelling vaginal discharge 40.0 21.7 0.393 
Genital ulcers 0.0 17.4 0.314 
Genital warts 0.0 8.7 0.494 
Lower abdominal pain 40.0 34.8 0.825 
Vaginal discharge 80.0 69.6 0.640 
Vaginal itching 0.0 34.8 0.119 
 
Legend: 
MG: Mycoplasma genitalium; TV: Trichomonas vaginalis. 
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Chapter Four
Supplementary Table 4.1. Socio-demographic and behavioral characteristics of women 
selected as controls and women not selected as controls, attending antenatal care at 
Kilifi County Hospital, Kenya.  
Characteristic Not selected as controls 
(%)N = 270* 
Selected as controls 
(%) N = 51 
χ2  
P-value 
Age group (Years)  
18-24 38.5 31.4 0.333 
 ≥ 25 61.5 68.6  
Religion  
Christian   72.2 68.6 0.872 
Muslim 15.6 17.7  
Other/None 12.2 13.7  
Education  
None 16.7 23.5 0.387 
Primary   57.0 56.9  
Secondary/Tertiary    26.3 19.6  
Employment status   
 Employed/self-employed 55.2 72.6 0.021 
 Unemployed 44.8 27.5  
Parity  
    0 25.6 35.3 0.207 
    1-2 39.3 25.4  
    3+ 35.2 37.3  
Gestational age  
   14-27 63.7 58.8 0.511 
    ≥ 28 36.3 41.2  
Number of lifetime sex  
     1 88.9 90.2 0.784 
     3+ 11.1 9.8  
 
Legend 
In bold: significantly associated, i.e., P ≤ 0.05 
* Socio-demographic and behavioral characteristics for one participant were missing and thus 
270 and not 271. 
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Supplementary Table 4.2. Specific PCR details;  
 
 
Legend: 
* Candidatus Mycoplasma girerdii and Trichomonas vaginalis PCRs were carried out in a total 
volume of 20 μl. 2 μL of DNA extract was used for each PCR 
 
Target 
organism 
[reference] 
Composition and primer reference (final volumes: 10 μl)* Thermocycler 
conditions 
Candida 
albicans  
[9] 
LightCycler 4801SYBR Green I Master (Roche): 5 μl 
Forward primer: 0.3 μM, , 0.13 μl CA_FW:  
CAACGAACTGAACTGGCAGA 
Reverse primer: 0.3 μM, , 0.13 μl  CA_RV:  
CATTACGCTGCGATGGAT 
50 °C for 2 min  
95 °C for 10 min 
40 x (95 °C for 15 s 
and 60 °C for 1 
min) 
Escherichia  
coli 
[10] 
LightCycler 4801 SYBR Green I Master (Roche): 5 μl  
Forward primer: 0.3 μM, 0.1 μl Ecoli_FW:  
CAACGAACTGAACTGGCAGA 
Reverse primer: 0.3 μM, 0.1 μl Ecoli_RV:  
CATTACGCTGCGATGGAT 
Probe: 0.3 μM, 0.1 μl TATCCCGCCGGGAATGGTGA 
50 °C for 2 min  
95 °C for 10 min 
40 x (95 °C for 15 s 
and 60 °C for 1 
min) 
Streptococcus 
agalactiae  
[11] 
LightCycler 4801SYBR Green I Master (Roche): 5 μl  
Forward primer: 0.5 μM, 0.25 μl  Sip1:  
ATCCTGAGACAACACTGACA 
Reverse primer: 0.5 μM, 0.25 μl  Sip2  
TTGCTGGTGTTTCTATTTTCA 
Probe: 0.3 μM, 0.10 μl   
6-FAM–ATCAG AAGAGTCATACTGCCACTTC–
TAMRA 
95 °C for 5 min 
40 x (95 °C for 10 
s, 58 °C for 15 s 
and 72 °C for 20 s) 
Trichomonas 
vaginalis 
[13] 
Faststart PCR master (Roche): 10 μl  
Forward primer: 0.2 μM , 0.2 μl Tv8S  
TCT GGA ATG GCT GAA GAA GAC G 
Reverse primer: 0.2 μM, 0.2 μl Tv9R  
CAG GGT ACA TCG TAT TGG TC  
95 °C for 5 min 
40 x (95 °C for 30 
s, 58 °C for 30 s 
and 72 °C for 3min) 
72°C for 7 min 
Candidatus 
Mycoplasma 
girerdii 
 
[14] 
Faststart PCR master (Roche): 10 μl  
Forward primer: 0.2 μM, 0.2 μl  M1_Contig1-3_F:  
TGCATATCCATCTAATGCAACC 
Reverse primer: 0.2, 0.2 μl μM M1_Contig1-3_R:  
AGGGACTGTATTTTATCGCAATGG 
95 °C for 5 min,  
40 x (95 °C for 30 
s, 50 °C for 30 s 
and 72 °C for 45 s)  
72°C for 7 min 
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Molecular typing of Trichomonas vaginalis
isolates by actin gene sequence analysis
and carriage of T. vaginalis viruses
Simon C. Masha1,2,3*, Piet Cools2, Tania Crucitti4, Eduard J. Sanders1 and Mario Vaneechoutte2
Abstract
Background: The protozoan parasite Trichomonas vaginalis is the most common non-viral, sexually transmitted
pathogen. Although T. vaginalis is highly prevalent among women in Kenya, there is lack of data regarding
genetic diversity of isolates currently in circulation in Kenya.
Methods: Typing was performed on 22 clinical isolates of T. vaginalis collected from women attending the antenatal
care clinic at Kilifi County Hospital, Kenya, in 2015. Genotyping followed a previously proposed restriction fragment
length polymorphism (RFLP) scheme, which involved in silico cleavage of the amplified actin gene by HindII, MseI and
RsaI restriction enzymes. Phylogenetic analysis of all the sequences was performed to confirm the results obtained by
RFLP-analysis and to assess the diversity within the RFLP genotypes. Additionally, we determined carriage of the four
different types of Trichomonas vaginalis viruses (TVVs) by polymerase chain reaction.
Results: In silico RFLP-analysis revealed five actin genotypes; 50.0% of the isolates were of actin genotype E, 27.3%
of actin genotype N, 13.6% of actin genotype G and 4.5% of actin genotypes I and P. Phylogenetic analysis was in
agreement with the RFLP-analysis, with the different actin genotypes clustering together. Prevalence of TVVs was
43.5% (95% confidence interval, CI: 23.2–65.5). TVV1 was the most prevalent, present in 39.1% of the strains and
90% of the T. vaginalis isolates which harbored TVVs had more than one type of TVV. None of the isolates of actin
genotype E harbored any TVV.
Conclusion: The presence of five actin genotypes in our study suggests notable diversity among T. vaginalis
isolates occurring among pregnant women in Kilifi, Kenya. Isolates of the most prevalent actin genotype E
lacked TVVs. We found no association between T. vaginalis genotype, carriage of TVVs and symptoms. Further
studies with higher number of strains should be conducted in order to corroborate these results.
Keywords: Trichomonas vaginalis, Trichomonas vaginalis viruses, actin gene, Typing, Kilifi, Kenya
Background
Trichomonas vaginalis is a flagellated protozoan parasite
that infects the human urogenital tract, causing the most
common non-viral, sexually transmitted infectious
disease worldwide [1]. The prevalence of T. vaginalis
among women in sub-Saharan Africa is 11.5% [1]. In
about half of the infected women, T. vaginalis causes a
malodorous vaginal discharge, vulval irritation and
inflammation, and a ‘strawberry cervix’ characterized by
punctate hemorrhagic lesions [2]. Men typically remain
asymptomatic, but can suffer from urethral discharge,
dysuria, urethritis, epididymitis and prostatitis [2, 3].
Trichomonas vaginalis has been associated with adverse
pregnancy outcomes, such as preterm birth and prema-
ture rupture of membranes [4–6], increased shedding
and acquisition of the human immunodeficiency virus
(HIV) [7, 8], hence contributing to the HIV pandemic.
The global prevalence of T. vaginalis and the health
sequelae associated with it have necessitated the need to
understand its genetic make-up. Trichomonas vaginalis is a
complex pathogen, with a genome size of ~160 megabases,
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two-thirds of which is composed of repeats and transpos-
able elements [9]. Some strains of T. vaginalis can harbor
up to four types of Trichomonas vaginalis viruses (TVVs)
[10]. TVVs are members of the family Totiviridae under
the distinct genus Trichomonasvirus [11]. Carriage of TVVs
has been suggested to upregulate pro-inflammatory host
responses [12] and T. vaginalis immunogenic protein P270
[13] and is also associated with differential qualitative and
quantitative expression of cysteine proteinases [14]. Thus,
since TVVs induce various phenotypic changes that may
impact T. vaginalis virulence [14], determining carriage of
TVVs seems to be essential in the characterization of T.
vaginalis infection. However, no method has been adapted
as a standard clinical diagnostic test for TVVs [15].
Better understanding the diversity of T. vaginalis and
geographical distribution of various genotypes may
improve our knowledge regarding the epidemiology of this
infectious agent and contribute to vaccine development
efforts. At present, none of the described techniques have
been recognized as the “gold standard” for genotyping of
T. vaginalis isolates [16–23].
In this study, we opted to sequence the T. vaginalis
actin gene to better understand the genetic diversity of
T. vaginalis. Actin is a ubiquitous well conserved struc-
tural protein in all eukaryotic cells [24] and has been
used to clarify the molecular phylogeny of protists,
plants, animals and fungi [25].
The data produced by sequencing are unambiguous,
reproducible and portable, thus offering the advantage that
public databases can be constructed. In Kenya, screening
for T. vaginalis is not routinely done. However, recent stud-
ies have indicated that there is high prevalence of T.
vaginalis among different groups in Kenya [26–29]. Despite
this, no typing has been carried out. In this study, we
genotyped T. vaginalis isolated from pregnant women
attending ANC in Kilifi, Kenya.
Methods
Study design, population and specimens processing
From July through to September 2015, we conducted a
cross-sectional study at the antenatal care clinic of Kilifi
County Hospital, Kenya. The main aim of that study was
to describe the prevalence and predictors of curable sexu-
ally transmitted infections (STIs) among pregnant women
attending to the antenatal care clinic [29]. Women were
eligible if they met the following criteria: age 18–45 years,
gestation ≥ 14 weeks, resident of the Kilifi Health and
Demographic Surveillance area, willingness to undergo
free STI and bacterial vaginosis screening procedures, and
able and willing to give written informed consent [29].
The current study presents a secondary objective of the
above-mentioned study, namely to perform typing of T.
vaginalis clinical isolates from this study population.
A total of 349 pregnant women were included in the
study. A nurse collected vaginal secretions from the
vaginal introitus using a sterile cotton swab. The vaginal
swab was inoculated at the clinic in the upper-chamber
of an InPouch system (BioMed Diagnostics, White City,
Oregon, USA). The inoculated InPouch was transferred
to the laboratory within 15 min for direct microscopy of
the upper chamber, after which it was merged with the
lower chamber and incubated at 37 ± 1 °C under aerobic
conditions. Daily microscopic observation of the
InPouch system was performed and media with motile
trichomonads within 5 days of culture were considered
positive for T. vaginalis. Two ml of the contents of each
InPouch system positive for T. vaginalis were transferred
into a 2.0 ml Eppendorf tube and stored at -80 °C until
shipment to the Laboratory of Bacteriology Research
(Ghent University, Belgium) using shipping boxes filled
with dry ice (-78.5 °C). The samples were stored at -80 °C
until molecular analysis was performed.
Women found to be positive for T. vaginalis using
direct microscopy, i.e. microscopy of the upper chamber,
were treated on the same day, while women who were
negative for T. vaginalis using direct microscopy but
positive on culture were contacted to return to the clinic
for treatment immediately after the culture turned positive.
Partners of women treated for T. vaginalis infection re-
ceived presumptive treatment.
Nucleic acid extraction
Frozen cultures were first thawed at room temperature
for 30 min, after which the tubes were vortexed for 30 s
to ensure that a homogeneous mix was achieved before
starting the nucleic acid extraction. Total nucleic acid ex-
traction was performed using the NucliSENS® easyMAG®
(bioMérieux, Marcy l’Etoile, France) according to the
manufacturer’s instructions (generic protocol 2.0.1).
Actin gene PCR
The actin gene was amplified using the outer primers
previously used in a nested polymerase chain reaction
(PCR), i.e. primers Tv8S (5′-TCT GGA ATG GCT
GAA GAA GAC G-3′) and Tv9R (5′-CAG GGT
ACA TCG TAT TGG TC-3′) [20], with the following
thermocycling conditions: 5 min at 95 °C, 40 cycles
of 30 s at 95 °C, 30 s at 55 °C and 3 min at 72 °C,
followed by 7 min at 72 °C. This was performed on
the ABI Veriti thermocycler platform (ThermoFisher
Scientific, Waltham, Massachusetts, USA).
Gel electrophoresis
PCR amplification products were visualized under UV light
after electrophoresis on 1% agarose gels in Tris-acetate-
EDTA buffer pH 8.5 (30 min at 10 V/cm) and staining with
ethidium bromide (0.5 mg⁄ l; Sigma, Bornem, Belgium). The
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size of the amplified products was assessed by compari-
son with a commercial weight marker, Smart Ladder
(Eurogentec, Liege, Belgium).
Sequencing
Amplicons (20 μl) were sent for sequencing to GATC
Biotech (Constance, Germany), using the Sanger sequen-
cing technique. Sequencing was performed bi-directionally
using the same primers used in PCR amplification of the
actin gene.
Genotyping of T. vaginalis
Trichomonas vaginalis actin sequences were edited using
Chromas Lite 2.01 (http://technelysium.com.au/wp/). Fur-
thermore, we identified the T. vaginalis actin genotypes
amongst our isolates by means of in silico RFLP-analysis
Webcutter version 2.0; http://rna.lundberg.gu.se/cutter2/
with the three restriction enzymes (HindII, MseI and RsaI)
used by Crucitti et al. [20]. The in silico analysis was done
on our clinical isolates and on retrieved sequences repre-
senting the genotypes that have been proposed. To identify
if there were additional T. vaginalis actin genotypes not
captured by the previous proposed scheme, in silico
RFLP was performed on actin sequences retrieved
from the GenBank whose actin genotype is yet to be
documented. The sequences were of at least 1100 bp
in length (Additional file 1: Table S1).
To compare results obtained in the RFLP analysis, and
to determine the genetic variation among the identified
genotypes, we performed phylogenetic analysis of the se-
quences. Sequences obtained in our study were aligned
using MEGA software and compared with analogous se-
quences representative of known T. vaginalis actin ge-
notypes identified in from our isolates.
Evolutionary distances were calculated by Kimura’s
two-parameter model (Kimura, 1980) and a phylogenetic
tree was generated using the Maximum Likelihood
method using the MEGA software (version 7.0) [30]. Fi-
nally, confidence levels were estimated using bootstrap
resampling on 1000 randomly selected pseudoreplicates.
Detection of Trichomonas vaginalis viruses
Synthesis of cDNA was performed on the nucleic acid
extract using the RevertAid First Strand cDNA Synthesis
Kit (ThermoFisher Scientific, Gent, Belgium). The cDNA
was used to amplify the four known TVVs by means of
previously described type specific primers: TVV1F2875 (5′-
ATT AGC GGT GTT TGT GAT GCA-3′) and
TVV1R3443 (5′-CTA TCT TGC CAT CCT GAC TC-3′),
TVV2F1401 (5′-ATT AGC GGT GTT TGT GAT GCA-
3′) and TVV2R1953b (5′-GGT TCG TGG AAG CGG
TTG ATG A-3′), TVV3F1474 (5′-CTA CCA AGA AGG
AGG CTT GA-3′) and TVV3R2025b (5′-GGT TCG TGG
AAG CGG TTG ATG A-3′), and TVV4F1338 (5′-ATG
CCA GTT GCT TTC CG-3′) and TVV4R1834 (5′-TTC
CCC AATAGT TAT CAG-3′) [10]. The amplification con-
ditions were: 5 min at 95 °C, 40 cycles of 30 s at 95 °C, 30 s
at 50 °C and 45 s at 72 °C, followed by 7 min at 72 °C. The
PCR products were visualized by electrophoresis as de-
scribed above.
Statistical analysis
The socio-demographic and clinical data of the partici-
pants were entered in the REDCapTM electronic data
capture tool, version 6.5.0 (Vanderbilt University, Nashville,
Tennessee). Prevalence of T. vaginalis was expressed as a
percentage with exact 95% binomial confidence intervals
(CIs). Univariable logistic regression was used to de-
termine associations of T. vaginalis presence with
socio-demographic data, hygienic data, sexual behav-
ior, and vaginal signs & symptoms. Variables signifi-
cant at P ≤ 0.1 in bivariable analysis were entered
into a multivariable model to identify independent as-
sociations. Crude odds ratios (COR) and adjusted
odds ratios (AOR) were calculated. These statistical
analyses were done using STATA, version 13.1
(Stata-Corp, College Station, Texas).
Results
Characteristics of the study population
The median age and gestation age including the inter-
quartile range (IQR) for the participants was 27 (22–31)
years and 25 (20–30) weeks, respectively. The majority
of the participants were married (93.6%) and Christian
(72.3%). Approximately a quarter of the participants had
received secondary school education and above. The
median age and IQR of sexual debut was 18.6 (16–20)
years, although 17.4% of the participants were not sure
or did not respond to this question. Seventy-three
percent of the participants had given birth before and
the number of children ranged between 1 and 10. Sixty-
five percent of the participants had previously experi-
enced signs/symptoms associated with reproductive tract
infection and about one third had ever received syndromic
treatment for genital signs or symptoms of infection. The
socio-demographic characteristics of the participants are
summarized in Table 1.
Prevalence, clinical signs and symptoms
A total of 23/349 (6.6%, 95% CI: 4.2–9.7) women
were culture-positive for T. vaginalis, and 34.8% of
these cases were positive by direct microscopy prior
to further incubation. Based on symptoms routinely
used in syndromic management of STIs (i.e. genital
ulcer, lower abdominal pain or abnormal vaginal discharge),
43.5% of the 23 women with T. vaginalis infection were
asymptomatic. The most commonly self-reported symp-
toms amongst all participants included vaginal discharge
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Table 1 Univariable and multivariable analysis of characteristics
of pregnant women with T. vaginalis attending antenatal care
clinic at Kilifi County Hospital, Kenya
Variable N = 349 Percentage with
T. vaginalis
Crude OR
(95% CI)
P-value
Demographic characteristics
Age group (years)
18–24 132 6.8 1.1 (0.4–2.5) 0.894
≥ 25 217 6.5
Religion
Christian 248 5.7
Muslim 54 5.7 1.0 (0.3–3.5) 0.979
Other/None 47 12.8 2.4 (0.9–6.7) 0.083a
Education
None 63 7.9
Primary 200 7.0 0.9 (0.3–2.5) 0.802
Secondary/Tertiary 86 4.7 0.6 (0.1–2.1) 0.411
Marital status
Single 25 4.0
Married 224 6.8 1.7 (0.2–13.5) 0.593
Residency
Living with partner 255 5.5
Not living with a
partner
94 9.6 1.8 (0.8–4.4) 0.178
Employment status
Employed/self-
employed
199 5.0
Unemployed 150 8.7 1.8 (0.8–4.2) 0.180
Parity
0 94 6.4 1.1 (0.3–3.5) 0.843
1–2 133 7.5 1.3 (0.5–3.6) 0.570
3+ 122 5.7
Gestational age (weeks)c
14–25 183 5.5
≥ 26 165 7.9 1.5 (0.6–3.4) 0.382
Hygiene characteristics
Toilet type
Flushing toilet 117 7.7
Pit latrine 197 5.1 0.6 (0.3–1.6) 0.350
Bush/Other 35 11.4 1.5 (0.4–5.4) 0.491
Mode of cleaning after visiting the toilet
Tissue paper/Other
solid materials
106 2.8
Water 243 8.2 3.1 (0.9–10.5) 0.074a
Behavioral characteristics
Sexual debut age (years)
≤ 17 106 8.5 1.8 (0.7–4.7) 0.231
≥ 18 183 4.9
Do not know/No
response
60 6.7 1.5 (0.4–5.0) 0.523
Table 1 Univariable and multivariable analysis of characteristics
of pregnant women with T. vaginalis attending antenatal care
clinic at Kilifi County Hospital, Kenya (Continued)
Variable N = 349 Percentage with
T. vaginalis
Crude OR
(95% CI)
P-value
Number of lifetime sex partnersc
1 158 3.8
2+ 189 9.0 2.5 (1.0–6.5) 0.060a
Polygamous partner
No 303 6.9 1.6 (0.4–7.2) 0.515
Yes 46 4.4
Alcohol consumption ever
No 262 6.5 0.9 (0.4–2.5) 0.894
Yes 87 6.9
Tobacco use
No 332 6.6 1.1 (0.1–8.9) 0.904
Yes 17 5.9
Other drugs/substance use ever
No 332 6.6 1.1 (0.1–8.9) 0.904
Yes 17 5.9
Sexually transmitted infections/reproductive tract infections
HIV
Negative 324 6.2
Positive 25 12.0 2.1 (0.6–7.5) 0.268
Bacterial vaginosisd
Negative 293 6.5
Positive 53 7.6 1.1 (0.4–3.6) 0.775
Clinical signs and symptoms of STI
Previous history of vaginal discharge
No 122 5.6
Yes 227 7.1 1.2 (0.5–3.1) 0.638
Previous syndromic treatment of genital infection
No 229 6.6
Yes 120 6.7 1.0 (0.4–2.5) 0.967
Current vaginal discharge (self-reported)c
No 96 3.1
Yes 252 7.9 2.7 (0.8–9.2) 0.119
Abnormal vaginal discharge foul smell/color (observed)c
No 271 5.9
Yes 77 9.1 1.6 (0.6–4.0) 0.324
Dysuriac
No 263 6.1
Yes 85 8.2 1.4 (0.5–3.5) 0.489
Dyspareuniac
No 245 4.9
Yes 103 10.7 2.3 (1.0–5.4) 0.053
Vaginal itchingc
No 231 6.5
Yes 117 6.8 1.1 (0.4–2.6) 0.903
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(72.4%). However, during collection of specimens by the
study nurse, only 22.1% of the participants had an abnormal
discharge (defined as excess discharge/foul smelling dis-
charge/colored discharge) upon examination. A total of
51.4% of the women reported having lower abdominal pain,
genital ulcers were observed in 2.9% of the women. Dyspar-
eunia, genital warts and genital ulcers were the only clinical
signs or symptoms significantly associated with T. vaginalis
infection (Chi-square test: χ2 = 3.93, df = 1, P < 0.048;
χ2 = 5.58, df = 1, P < 0.018; and χ2 = 18.60, df = 1, P < 0.05,
respectively).
Predictors of T. vaginalis infection
Univariable analysis indicated that T. vaginalis infection
was more common among participants who were
traditionalist or reported having no religion compared to
participants who were Christians or Muslims, used water
to clean themselves after visiting the toilet compared to
those who used tissue paper or other solid materials, re-
ported having ≥ 2 lifetime sexual partners, reported
dyspareunia, had genital warts, and/or had a genital
ulcer (Table 1). In multivariable analysis, the only inde-
pendent predictor associated with T. vaginalis was hav-
ing a genital ulcer (AOR = 7.6, 95% CI: 1.4–42.3).
Genotyping analysis
The actin gene target could be amplified from 21 of the
23 T. vaginalis isolates. All 21 amplicons had the ex-
pected length of approximately 1100 bp. The two
remaining isolates could only be amplified by a higher
primer concentration of 0.5 μM, instead of 0.3 μM.
However, one of these clinical isolates did not yield an
interpretable sequence and thus only sequences from 22
clinical isolates were utilized in the typing. Five different
actin types (E, G, I, N and P) were identified according
to the position and the number of cleavage sites, follow-
ing the scheme proposed by Crucitti et al. [20] (Table 2).
The most prevalent actin genotype was E, representing
50.0% of the isolates. The other genotypes were, in order
of descending frequency, N (27.3%), G (13.6%) and I and
P (each 4.5%).
Multiple sequence analysis to compare polymorphic sites
found on our actin sequences, and those retrieved from the
GenBank, revealed a total of 33 single nucleotide differ-
ences in the open reading frame of the actin gene. Three of
these single nucleotide polymorphisms were exclusively
found in actin sequences from our study (Additional file 2).
The nucleotide sequences obtained of the actin gene for all
the 22 isolates were submitted in GenBank under accession
numbers: (MF350322–MF350343). The phylogenetic ana-
lysis (Fig. 1) showed that actin genotype E clustered with a
bootstrap value of 99. Lower bootstrap values were ob-
served for actin genotypes N, G, I and P.
Prevalence of T. vaginalis viruses
TVVs were present in 43.5% (95% CI: 23.2–65.5) (10/23)
of T. vaginalis isolates. Trichomonas vaginalis virus type
1 (TVV1) was the most prevalent (39.1%), followed by
Table 1 Univariable and multivariable analysis of characteristics
of pregnant women with T. vaginalis attending antenatal care
clinic at Kilifi County Hospital, Kenya (Continued)
Variable N = 349 Percentage with
T. vaginalis
Crude OR
(95% CI)
P-value
Lower abdominal painc
No 169 8.3
Yes 179 5.0 0.6 (0.2–1.4) 0.226
Genital wartsc
No 341 6.2
Yes 7 28.6 6.1 (1.1–33.3) 0.037a
Genital ulcer (observed)c
No 338 5.6
Yes 10 40.0 11.2 (2.9–43.1) < 0.001b
Vaginitisc
No 334 6.6
Yes 14 7.1 1.1 (0.1–8.7) 0.935
Symptomaticc
No 145 6.9
Yes 203 6.4 0.9 (0.4–2.2) 0.855
aSignificant in univariable analysis
bSignificant on multivariable association; symptomatic (any or a
combination of the three symptoms, i.e. genital ulcer, lower abdominal
pain or abnormal vaginal discharge)
cMissing data/some participants did not respond to this question(s)
dBacterial vaginosis results for three participants were not available due to
poor slides
Table 2 Number and position of restriction sites using HindII, MseI and RsaI restriction enzymes
Genotype No. of
isolates
HindII MseI RsaI
213 273 699 185 314 518 103 190 426 878 994
E 11 × × × × × × × ×
G 3 × × × × × × ×
I 1 × × × × × × × ×
N 6 × × × × × × × × ×
P 1 × × × × × × × × ×
× indicates the presence of a restriction cut site
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TVV2 (26.1%), TVV3 (17.4%) and TVV4 (13.0%). Nine
out of 10 T. vaginalis isolates with TVVs harbored more
than one type of TVV (Table 3). TVV1 was present in
all virus-positive T. vaginalis isolates but one (TV207).
All 11 genotype E isolates were virus-negative.
Finally, the distribution of symptomatic and asymptom-
atic cases was not linked to any particular T. vaginalis actin
genotype. Similarly, presence or absence of TVVs did not
appear to have an influence as to whether a patient was
symptomatic or asymptomatic.
Discussion
To our knowledge, this is the first study determining T.
vaginalis genotypes and co-occurrence of T. vaginalis vi-
ruses in Kenya. We sequenced the actin gene for 22 isolates
and identified five types of T. vaginalis by in silico RFLP-
analysis of the amplified actin gene. We found notable gen-
etic diversity by full actin gene sequence analysis among T.
vaginalis isolates in Kilifi, as well as those retrieved from
GenBank. Prevalence of T. vaginalis in this study (6.6% in
349 pregnant women) was high but, however, fell short of
the prevalence of T. vaginalis among women aged 15–
49 years in the World Health Organization Africa region in
2012, which was estimated to be 11.5% (95% CI: 9.0–14.6)
[1]. This is suggestive of lower rates of T. vaginalis among
the general population of women in Kilifi, Kenya compared
to other African countries [31].
Although T. vaginalis does not traditionally present with
genital ulcers [32], multivariable analysis showed that
genital ulcers were the only predictor of an infection with
T. vaginalis in our study. Ulcers could not be due to
syphilis, which was not diagnosed in any of the women
with T. vaginalis, but we did not test for the Herpes
simplex virus, which is also associated with genital ulcers.
The association of genital ulcer with T. vaginalis is not
unique to our study as it has been reported amongst female
sex workers in China [33].
Nucleotide sequence analysis of actin sequences showed
33 polymorphic sites, three of which caused amino acid
substitution. Two of these amino acid substitutions have
been previously reported to occur in genotypes G, N, I and
P, in which nucleotide 371 substituted alanine for valine,
and nucleotide 904 substituted lysine for glutamine [20,
34]. A unique polymorphism leading to an amino acid
Fig. 1 Phylogenetic tree for actin gene nuclotide sequences of T. vaginalis. The tree was generated using Maximum Likelihood method.
Bootstrap test for 1000 replicates. Sequences from Kilifi isolates (n = 22) have accession numbers with the prefix “MF”, all other sequences were
retreived from GenBank and are representative of the five actin genotypes. Scale-bar: 0.001 (1 substitution per 1000 nucleotides)
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substitution, in which nucleotide 892 substituted
threonine for serine, was observed to be exclusively
present on a GenBank sequence (accession number
XM_001301892). As such, in silico genotyping of
isolates provides an opportunity to distinguish closely
related isolates based on these polymorphic sites and
to further identify such polymorphic sites.
Our phylogenetic analysis confirms RFLP as a good
typing method, as the results from this method were in
agreement with phylogenetic analysis. Phylogenetic ana-
lysis and detection of carriage of TVVs, revealed that
none of the isolates of the most prevalent actin genotype
E harbored a TVV. Furthermore, phylogenetic analysis
indicated that genotype E formed a distinct phylogenetic
lineage, suggesting clonal stability of this genotype [35].
The high prevalence (43.5%) of TVVs found in this
study is comparable to a prevalence of 55% (95% CI:
38.4–70.7) among Cuban isolates [36]. Two recent
studies have reported lower carriage of TVV, 18.7% (95%
CI: 11.5–28.0) in the Philippines [37] and 17.3% (95%
CI: 7.8–31.4) among Iranian isolates [38], although the
latter study only determined the presence of TVV1.
However, higher prevalence rates of TVV have been re-
ported as well, 81.9% (95% CI: 71.1–90.0) in South
Africa [39], and 75.0% (95% CI: 55.1–89.3) in Baltimore
City, Maryland [40]. The presence of TVV, in addition
to metronidazole susceptibility, has been found to differ
significantly between T. vaginalis isolates genotyped by a
panel of 21 microsatellites and six single-copy genes of
T. vaginalis, which classifies T. vaginalis into two types:
type 1 and type 2 [23]. Type 2 is characteristically free of
TVV and resistant to metronidazole [23]. Metronidazole
susceptibility in relation to actin genotypes is yet to be
determined.
Fifty-seven percent of isolates in our study did not
harbor TVV, suggesting that they might be of type 2.
Our study might have been biased towards type 2;
63.6% were recovered from patients who were diag-
nosed by culture, after direct microscopy had been
determined to be negative, suggesting that the para-
site load in the patient was low. Conrad et al. [23]
observed that type 1 parasites are often diagnosed by
direct microscopy and suggested that this may be in-
dicative of higher parasite load in type 1 which har-
bor TVVs. Additional studies, sampling a more
diverse population and other regions in Kenya, are
needed to confirm the population type and distribu-
tion of T. vaginalis in the country.
A total of 22 TVVs were identified in 10 T. vaginalis
cultures, with multiple TVVs detected in nine cultures
(Table 2). The higher prevalence of T. vaginalis cultures
with either TVV1 or TVV2 than with TVV3 or TVV4 is
consistent with previous reports [10, 37]. In these publi-
cations, concurrent TVV infection, with at least two or
3 TVVs, was recorded in six and three T. vaginalis sam-
ple cultures, respectively. Although we identified single
actin genotypes in all T. vaginalis cultures, which is indi-
cative for the presence of only 1 T. vaginalis strain per
culture, we cannot rule out that the presence of the mul-
tiple TVVs may be the result of a mixture of T. vaginalis
strains, each infected with a different TVV. Therefore,
our data does not necessarily indicate concurrent infec-
tion of TVVs in a single TV strain. The lytic cycle of
TVVs is yet to be described, and attempts to infect
uninfected isolates have been unsuccessful [41]. There-
fore, it is plausible that the virus may solely be acquired
through vertical transmission, making its presence an
important genetic marker [42].
Fifty-six percent of women with T. vaginalis infection in
our study were symptomatic and the symptoms occurred
independently of the presence of TVV in the protozoon.
In vitro studies have shown that TVVs are sensed by the
Table 3 Genotypes of Trichomonas vaginalis and carriage of T.
vaginalis viruses, in relation to symptoms among 23 T. vaginalis
isolates in Kilifi, Kenya
Sample ID TVV1 TVV2 TVV3 TVV4 Genotype Symptomatica
TV279 + – + – * +
TV022 – – – – E +
TV042 – – – – E +
TV050 – – – – E –
TV066 – – – – E +
TV075 – – – – E +
TV176 – – – – E –
TV188 – – – – E –
TV203 – – – – E +
TV224 – – – – E –
TV299 – – – – E +
TV323 – – – – E –
TV185 + – + + G –
TV207 – + – – G +
TV238 + + + – G +
TV307 + + – – I –
TV116 + + – – N –
TV131 + + – – N +
TV156 + – – + N –
TV190 + + + – N +
TV210 – – – – N +
TV234 + – – + N –
TV140 – – – – P +
Abbreviations: TVV1 Trichomonas vaginalis virus type 1, TVV2 T. vaginalis virus
type 2, TVV3 T. vaginalis virus type 3, TVV4 T. vaginalis virus type 4
Code: *Not typed; + present; − absent
aSymptomatic: any or a combination of the three symptoms, i.e. genital ulcer,
lower abdominal pain and/or abnormal vaginal discharge
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human epithelial cells via Toll-like receptor 3, triggering
Interferon Regulating Factor − 3, interferon type I and
pro-inflammatory cascades previously implicated in
preterm birth and HIV-1 susceptibility [12]. While
treatment with metronidazole generally eliminates T.
vaginalis, this may aggravate T. vaginalis-associated
inflammation caused by the release of TVV by stressed
or dying parasites [12]. Additionally, TVVs upregulate
levels of phenotypically variable immunogen mRNA
P270 of T. vaginalis [13], while also playing a role in
T. vaginalis protein composition and its growth
kinetics [14].
Conclusion
Our study was limited by the small number of isolates,
which rendered it difficult to investigate the implication
of TVV carriage on clinical signs and symptoms. Despite
the low number of T. vaginalis isolates, the presence of
all four types of TVVs in our isolates, in addition to the
five actin genotypes, demonstrates there is notable
genetic diversity of T. vaginalis isolated from pregnant
women in Kilifi, Kenya. Isolates of the most prevalent
actin genotype E lacked TVVs; further studies with
higher number of strains should be conducted in order
to corroborate these results. The actin gene should be
considered as a potential genetic marker for molecular
epidemiology and genotypic traits of T. vaginalis.
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6.1 Abstract 
Background: Although the significance of the human vaginal microbiome for health and 
disease is increasingly acknowledged, differences in the composition of the vaginal 
microbiome upon infection with different sexually transmitted pathogens remain generally 
under explored.  
Method: The vaginal bacterial composition of women with Trichomonas vaginalis (T. 
vaginalis, N = 18) was compared to that of women with Chlamydia trachomatis (C. 
trachomatis, N = 14), and controls (N = 21) (women negative for both T. vaginalis and C. 
trachomatis). The vaginal bacterial composition was determined using high throughput 
sequencing with the Ion 16S metagenomics kit of the variable regions 2, 4 and 8 of the 
bacterial 16S ribosomal RNA gene from the vaginal swab DNA extract of the women. 
QIIME and R package “Phyloseq” were used to assess the α- and β-diversity and absolute 
abundance of the 16S rRNA gene per location in the three groups. Differences in taxa at 
various levels were determined using the independent T-test. 
Results: A total of 545 operational taxonomic units (OTUs) were identified in all the three 
groups of which 488 occurred in all three groups (core OTUs).  Bacterial α-diversity, by 
both Simpson’s and Shannon’s indices, was significantly higher, (p = 0.056) and (p = 
0.001) respectively, among women with either T. vaginalis or C. trachomatis than among 
controls (mean α-diversity T. vaginalis-infected > C. trachomatis-infected > Controls). At 
the genus level, women infected with TV had significantly (p < 0.01) higher abundance of 
Parvimonas and Prevotella species compared to both controls and C. trachomatis-
infected women, whereas women infected with C. trachomatis had significantly (p < 0.05) 
higher abundance of Anaerococcus, Collinsella, Corynebacterium and Dialister.  
Conclusion: The vaginal microbiomes of T. vaginalis and C. trachomatis-infected women 
were markedly different from each other and from women without T. vaginalis and C. 
trachomatis. Future studies should determine whether the altered microbiomes are 
merely markers of disease, or whether they actively contribute to the pathology of the two 
genital infections. 
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Key words: Chlamydia trachomatis, pregnancy, Kenya, Trichomonas vaginalis, vaginal 
microbiome,  
6.2 Introduction 
The human body hosts approximately 4 * 1013 bacterial cells, roughly equaling the number 
of human cells [1]. Bacteria represent the major part of microbiomes on the human body 
and have been shown to play a significant role in human health, affecting development of 
the immune system, nutrition and weight, among other physiological aspects [2]. Instead 
of distinct microbial species being either beneficial or harmful to human health, changes 
in the global balance of the microbiome might play a more crucial function [3]. Therefore, 
it is important to understand how the bacterial communities may vary under different 
circumstances. 
Genital infections with either Trichomonas vaginalis (T. vaginalis) or Chlamydia 
trachomatis (C. trachomatis) were estimated to affect over a quarter of a billion women 
worldwide in 2012 [4]. These two pathogens invade the vaginal microbiome despite it 
having various protective mechanisms, including low pH [5, 6].  A vaginal microbiome 
associated with vaginal health is typically characterized by the predominance of one or 
few species of lactobacilli [7]. Lactobacillus crispatus and L. iners are the most prevalent 
vaginal lactobacilli in women of reproductive age, [7-9] and L. crispatus plays a major role 
in maintaining the vaginal environment in equilibrium, whereas L. iners has been 
associated with both eubiotic vaginal microbiomes as well as dysbiotic vaginal 
microbiomes associated with bacterial vaginosis (BV) or sexually transmitted infections 
(STIs) [9]. 
T. vaginalis has been associated with a vaginal pH ≥ 4.5 [10].  The increased vaginal pH 
associated with T. vaginalis would potentially lead to invasion of other pathogenic 
organisms as well as overgrowth of the aciduric lactobacilli by many different species. 
Martin et al. [11] suggested that T. vaginalis infection was associated with Mycoplasma 
hominis and Candidatus Mycoplasma girerdii a species almost exclusively found in 
women infected with T. vaginalis. Vaginal dysbiosis has been associated with an 
increased risk of STIs, including C. trachomatis [12]. 
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Imbalances in the vaginal microbiome during pregnancy are associated with an increased 
risk of post-abortion infection [13], both early and late miscarriage [14,15], preterm 
premature rupture of membranes [16], and preterm birth [17]. Preterm birth complications 
are of unique importance as they are estimated to be responsible for 14 % of the world’s 
annual neonatal deaths [18]. Here, we determined the vaginal microbiome profiles of 
three groups of pregnant women (T. vaginalis-infected, C. trachomatis-infected, and 
controls, i.e. women with none of the two infections) attending antenatal care at Kilifi, 
County Hospital, Kenya, and compare our results with previous findings.  
 
6.3 Materials and methods 
This report utilized repository samples from a study of 350 pregnant Kenyan women, as 
previously described [19]. Briefly, from July until September 2015, women attending the 
antenatal care clinic of Kilifi County Hospital, Kenya, were recruited into a cross-sectional 
study. The main aim of that study was to describe the prevalence and the predictors of 
curable STIs among pregnant women [19]. Women were eligible if they met the following 
criteria: age 18-45 years, gestation ≥ 14 weeks, being residents of the Kilifi Health and 
Demographic Surveillance area, willingness to undergo free STI and BV screening 
procedures and willing to give written informed consent.  
For the above-described study, a nurse collected vaginal secretions from the vaginal 
introitus using three sterile cotton swabs. The first vaginal swab was inoculated at the 
clinic in the upper-chamber of an InPouch system (BioMed Diagnostics, White City, 
Oregon), a highly specific and sensitive device containing a fluid medium supporting the 
growth of T. vaginalis and allowing microscopic observation of T. vaginalis. The 
inoculated InPouch was transferred to the laboratory within 15 minutes for direct 
microscopy of the upper chamber, after which it was merged with the lower chamber and 
incubated at 37 °C ± 1 °C. Daily microscopic observation (at both ×10 and ×40 
magnification, for six fields) of the InPouch system was performed by qualified 
technicians. Samples with motile trichomonads within 5 days of culture were considered 
positive for T. vaginalis.  
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The second swab was used for BV diagnosis using the scoring system described by 
Nugent [20].  
The third swab was placed in a sterile labelled 2 ml Eppendorf tube and the swab shaft 
was broken by bending the shaft against the neck of the Eppendorf tube. The bottom 
portion of the swab with the specimen was transported to the laboratory where it was 
immediately stored dry at -80 °C for molecular studies of the vaginal microbiome. No 
transport or freezing medium was added. C. trachomatis and N. gonorrhoeae detection 
was performed on fresh first catch urine, using the GeneXpert® CT/NG Assay (Cepheid, 
Sunnyvale, California), according to the manufacturer’s instructions. 
Specimens for this study are derived from the stored swabs. Due to financial and logistic 
constraints, we could process only a subset of the 350 vaginal swabs from the main study. 
Vaginal swabs from 53 pregnant women were divided into three groups: 18 vaginal swabs 
from women culture-positive for T. vaginalis, 14 vaginal swabs from women PCR-positive 
for C. trachomatis in urine and 21 vaginal swabs from women culture-negative for T. 
vaginalis and PCR-negative for C. trachomatis in urine (controls). Additional specific 
criteria for controls included BV-negativity by Nugent score and HIV-negativity by rapid 
HIV 1/2 antibody test. 
 
DNA extraction 
Before DNA extraction the frozen swabs were thawed at room temperature for 30 
minutes. Extraction was performed using the QIAamp DNA Mini Kit (Qiagen, Hilden, 
Germany) according to manufacturer’s instructions and 160 μl of eluted DNA was 
transferred to Eppendorf tubes and frozen at -80 °C until molecular analysis was 
performed. 
 
Bacterial 16S ribosomal RNA (rRNA) gene PCR and sequencing 
The Ion 16S MetagenomicsTM Kit (ThermoFisher Scientific, Waltham, MA) primer set V2-
4-8 was used to amplify the hypervariable regions of the 16S rRNA gene from bacteria 
for all the samples and from a positive control (DNA from Microbial Mock Community A 
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(HM-278D – BEI)), according to the kit instructions. The amplicons were then purified 
using the AMPure magnetic bead-based purification system (Beckman Coulter, 
Porterville, CA) and quantified using the Qubit® 2.0 Fluorometer and the Qubit dsDNA 
HS Assay kit (ThermoFisher Scientific). 
Sequencing libraries were synthesized using the Ion Plus™ Fragment Library Kit 
(ThermoFisher Scientific) to ligate barcoded adapters to the amplicons.  For quality 
control, each barcoded library was assessed in order to determine proper ligation of the 
adapters by checking the size distribution and concentration of libraries.  The Agilent 
Bioanalyzer (Agilent, Santa Clara, CA) was used for size distribution, while the library 
concentration was determined using the Ion Library TaqMan® Quantitation Kit 
(ThermoFisher Scientific) according to the kit instructions.  The barcoded libraries were 
pooled in equimolar amounts with 25 libraries and one positive control (Microbial Mock 
Community A) pooled into one batch.  Templating of the pooled library was done using 
the Ion PGM™ Hi-Q™ OT2 Kit on the OneTouch2™ system according to the 
manufacturer’s recommendations (ThermoFisher Scientific). The templated library was 
then enriched for template-positive Ion Sphere particles on the ion one touch ES system 
followed by 400-bp sequencing on the Ion Torrent PGM (ThermoFisher Scientific) using 
the Ion PGM™ Hi-Q™ Sequencing Kit and a 318 v2 chip (ThermoFisher Scientific). 
 
Data processing and statistical analysis 
Identification of bacterial taxa in vaginal samples 
After sequencing, the individual sequence reads were filtered by the Personal Genome 
Machine (PGM) software to remove low quality and polyclonal sequences. This was an 
automated process performed using the Ion software. Reads that are removed are those 
that are of mixed DNA templates on an Ion sphere particle in a given well. Sequences 
matching the PGM 3′ adaptor were automatically trimmed. All PGM quality-approved, 
trimmed and filtered data were exported as sff files and further visualized and trimmed on 
quality in CLC Genomics Workbench version 9.5.3.  Quality trimmed reads were exported 
as fasta files and processed using QIIME version 1.9.1 [21]. Sequences with a length 
between 200 and 250 bp, mean sequence quality score > 25 were retained.  
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Presence of homopolymers of > 6 bp, and sequences with mismatched primers were 
omitted.  In order to calculate downstream diversity measures (α- and β-diversity indices, 
Unifrac analysis), 16S rRNA Operational taxonomic units (OTUs) were defined at ≥ 97% 
sequence homology using the open reference picking pipeline and taxonomy assignment 
workflow of QIIME and the Greengenes version 13.8 reference dataset [22].   
The alpha diversity (diversity within samples) was evaluated using Simpson’s and 
Shannon indices. Samples were clustered into three groups, i.e. C. trachomatis-infected, 
T. vaginalis-infected, and controls, and median diversity indices per group were compared 
using Analysis of variance (ANOVA). The beta diversity (diversity between samples) was 
evaluated using Bray Curtis and illustrated using Principal coordinate Analysis (PCoA). 
 
The 16S rRNA gene sequences reported in this study have been submitted to the 
European nucleotide archive (ENA) under accession number PRJEB25935. Low 
abundant OTUs were excluded from subsequent analysis, i.e. only those OTUs were 
included that had a relative abundance of > 0.01 (assigned reads/total number of reads) 
in at least one sample.  
Data-mining and statistical analysis was done in Calypso version 8.54, available at 
(http://bioinfo.qimr.edu.au/calypso/), including visualization of the taxonomic information 
[23]. Chi-square was used to compare the socio-demographic and behavioral 
characteristics when comparing the groups of women on STATA version 13.1 (Stata 
Corp, College Station, Texas). 
 
6.4 Results  
Two of the women with a T. vaginalis infection were co-infected with HIV but both were 
not on HIV therapy at the time of sample collection as HIV had just been diagnosed 
(Supplementary Table 6.1). There were no significant differences in the socio-
demographic  and behavioral characteristics of women with T. vaginalis and the controls 
(Supplementary Table 6.2). However, women with C. trachomatis compared to the 
controls differed significantly with reference to age and number of lifetime sexual partners 
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(Supplementary Table 6.3). No difference was observed when comparing of socio-
demographic and behavioral characteristics of women with T. vaginalis and those of 
women with CT (Supplementary Table 6.4). Finally, the swabs of 21 women selected as 
controls were not significantly different from the swabs of the other 251 women not 
selected as controls (Supplementary Table 6.5). 
To quantify the community composition of the three study groups of pregnant women 
(Controls, TV-infected and CT-infected women), amplicons were clustered in operational 
taxonomic units (OTUs) using UCLUST [16] with a sequence similarity threshold of 97%. 
After quality filtering and chimeric checking, a total of 7232969 reads were assigned to 
545 OTUs. Four hundred and eighty eight OTUs were considered as the core OTUs since 
they occurred in all three groups. Controls and TV-infected women had 4 unique OTUs 
each, while CT-infected women had 5 unique OTUs (Figure 6.1)  
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Figure 6.1 Venn diagram of OTU’s for each group. 
 
The circles represent C. trachomatis-infected, T. vaginalis-infected and healthy controls 
with numbers within circles or overlapping areas indicating the number of OTU’s in 
common. 
 
Bacterial α-diversity was significantly higher among women with either T. vaginalis or C. 
trachomatis compared to controls, with the mean α-diversity of T. vaginalis-infected 
women being higher than that of C. trachomatis-infected and the mean α-diversity of the 
CT-infected women being higher than that of controls (Figure 6.2).These findings suggest 
that the diversity of bacteria may be affected by the nature of concomitant genital 
infections. 
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Figure 6. 2 Bacterial α-diversity among the different groups of women 
 
Figure shows that bacterial α-diversity analysis reveals significant difference in the vaginal 
bacteria of pregnant women in Kilifi, Kenya infected with T. vaginalis (n = 18), C. trachomatis (n 
= 14) and controls (n = 21). Dot plot (A) Shannon index and (B) Simpson index. Statistical analysis 
was performed using ANOVA. Lines inside dot plot represent mean ± standard error. 
 
β-diversity analysis was used to evaluate whether there was dissimilarity in variation 
between the three groups of women. Analysis of dissimilarity between groups was 
performed by Bray-Curtis (non-phylogeny based method that only takes the relative 
abundance of OTUs into account) and visualized through principal coordinates analysis 
(PCoA). The analysis of similarity (Anosim) test showed that the vaginal microbiome 
diversity within each group was not significantly different between the groups.  
Non-metric multidimensional scaling (NMDS) analysis was applied to the dataset. PCoA 
was used to model the variation between samples based on the three groups. The 
centroids, or average center, were not significantly different for the three groups (Figure 
6.3).     
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Figure 6.3 β-diversity of vaginal microbiomes among the different groups of 
women 
 
β-diversity of vaginal microbiomes among pregnant women with T. vaginalis (n = 18), C. 
trachomatis (n = 14) and a control group (n = 21). (A) Non-metric multidimensional scaling 
(NMDS) plot of the vaginal bacteria of the three groups. Points represent the vaginal microbiomes 
of individual women at all taxonomic levels; colors indicate the infection status. (B) Principle 
coordinates analysis (PCoA) based on Bray Curtis metric on Operational Taxonomic Units 
(OTUs). 
Taxonomic similarities between each of the three groups were assessed by comparing 
the bacterial abundance in the three groups at various taxonomic levels. At the genus 
level, women infected with TV had significantly (p < 0.01) higher abundance of 
Parvimonas and Prevotella compared to controls and to CT-infected women. Women 
infected with CT had in addition to abundant Chlamydia, significantly (p < 0.05) higher 
abundance of Anaerococcus, Collinsella, Corynebacterium and Dialister (Figure 6.4). 
At family level, abundance by Lactobacillaceae was evident across the three groups and 
not significantly different between groups (Supplementary Figure 6.1).  
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Figure 6.4 Bar graphs showing relative abundance of genera 
 
 
Lege 
The bar graphs are of genera that were significantly different among women with T. vaginalis (n 
= 18), C. trachomatis (n = 14) and controls (n = 21). Pair-wise comparisons are done by t-test and 
annotated as *; p < 0.05, **; p < 0.01.Standard error is depicted by error bars.  
We further performed analysis based on Nugent scores irrespective of genital infection 
status. We compared women with a normal Nugent score (0-3) (n = 42) with those with 
an intermediate Nugent score (4-6) (n = 11).  Bacterial α-diversity was higher among 
women with intermediate Nugent scores as compared to those with normal Nugent scores 
(Supplementary Figure 2). At family level, the abundance of Aerococcaceae, 
Alcaligenaceae, Clostridiaceae, Coriobacteriaceae, Fusobacteriaceae, Gemellaceae, 
Lachnospiraceae, Lactobacillaceae, Leptotrichiaceae, Prevotellaceae and 
Tissierellaceae was significantly different between the two groups (Supplementary Figure 
6.3). 
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6.5 Discussion 
This molecular epidemiological study, using high-throughput sequencing of the 16S rRNA 
gene of vaginal microbiomes intended to decipher whether vaginal microbiomes differ 
among pregnant women with genital infections with Chlamydia trachomatis (C. 
trachomatis), Trichomonas vaginalis (T. vaginalis) and women without C. trachomatis and 
T. vaginalis infection. We demonstrated increased α-diversity during infection with both 
T. vaginalis and C. trachomatis as compared to women not infected with either or both 
infectious agents. Both indices used to determine the α-diversity take into account the 
abundance and evenness of the OTUs present. Thus this suggests that infection with 
either T. vaginalis or C. trachomatis is associated with an increase in species diversity. 
In a previous study [24], TV infection was associated with vaginal microbiota consisting 
of low proportions of lactobacilli and high proportions of Mycoplasma, Parvimonas, 
Sneathia and other anaerobes. Martin et al. [11] similarly identified Parvimonas and 
Prevotella as significantly associated with T. vaginalis infection. Also in our study, women 
infected with T. vaginalis had significantly (p < 0.01) higher abundance of Parvimonas 
and Prevotella (Figure 6.4) as compared to controls and to C. trachomatis-infected 
women. Parvimonas is mostly associated with acute and chronic dental root canal 
infections [25], whereas the proportion of Prevotella has been shown to be elevated in 
women with BV [26]. Whether Parvimonas and Prevotella play an active role in the 
pathology of T. vaginalis or are markers of infection with T. vaginalis is not clear. 
High throughput sequencing confirmed that women infected with C. trachomatis had a 
significantly higher vaginal abundance of Chlamydia as compared to those with T. 
vaginalis or controls, whereas C. trachomatis detection assay had been performed on 
urine samples. Other genera that were more abundant among samples of women with C. 
trachomatis included Anaerococcus, Collinsella, Corynebacterium and Dialister (Figure 
6.4). Tamarelle et al. [27], reported that infection with C. trachomatis was associated with 
vaginal microbiomes dominated by Lactobacillus iners and largely lacking other 
Lactobacillus species respectively with a wide array of strict and facultative anaerobes. 
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The clinical relevance of genera associated with C. trachomatis in our study varies. 
Anaerococcus has been isolated in cases of urinary tract infections [28]. Bacteria of the 
genus Collinsella, although statistically significant, are probably not as meaningful not 
really known to be associated with vaginal dysbiosis. They are mainly found in the gut 
and their abundance in the gut of patients with rheumatoid arthritis correlates strongly 
with increased production of the proinflammatory cytokine IL-17A [29]. Bacteria of the 
genus Corynebacterium are increasingly being recognized as causing opportunistic 
infections in patients who are immunocompromised, have prosthetic devices, or have 
been in hospitals/nursing homes for long-term periods of time [30]. While Dialister species 
have been implicated in oral diseases, the importance of Dialister species in human 
clinical samples remains unknown [31]. 
In general, the genus Lactobacillus was most abundant in all three groups, without 
significant differences. Our sequencing depth could not allow for identification of all 
species in the samples, to check whether individuals with T. vaginalis or C. trachomatis 
were colonized by different Lactobacillus species as compared to the controls, although 
e.g. L. iners and L. crispatus may play very different roles [9] whereby L. crispatus is more 
protective against urogenital infections. 
Our study had a few limitations; first, we did not perform a biochemical analysis to check 
if the participants were on antibiotics. Antibiotics used for various treatments might also 
interfere with a healthy bacterial equilibrium in the vaginal microbiome, specifically 
causing a decrease in the prevalence of commensal Lactobacillus spp. However, we 
collected data using a questionnaire on antibiotic use and none of the participants 
declared to be on antibiotics. Second, no internal control was added during the DNA 
extraction process, so inefficient genome extraction may have occurred, although a 
genomic DNA from Microbial Mock Community A (HM-278D – BEI) was used as a positive 
control during amplification. Third, other STIs were not analyzed and they may have had 
an effect on the microbiome, or other unknown confounding factors. Finally, our sample 
was limited due to financial constraints and was obtained using a cross-sectional survey 
a longitudinal survey would have provided additional info on the dynamics of the change 
in microbiome.  
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 6.6 Conclusion 
Colinsella, Dialister and Prevotella were significantly increased in C. trachomatis- and T. 
vaginalis -infected women compared to controls, Anaerococcus and Corynebacterium 
were most abundant in C. trachomatis-infected women and significantly more abundant 
when compared to T. vaginalis-infected women, and finally Parvimonas was most 
abundant in T. vaginalis-infected women and significantly increased compared to 
controls. Future research should focus on the functional importance of the various vaginal 
bacteria, including specific Lactobacillus species, associated with either T. vaginalis or C. 
trachomatis. Longitudinal studies of vaginal microbiome and STIs are critical in order to 
determine causality, including its direction, and temporality.   
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Supplementary Table 6.1. Clinical characteristics of pregnant women attending antenatal 
care at Kilifi County Hospital, Kenya (N=53).  
 
Characteristic TV-infected  
N = 18 
CT-infected  
N = 14 
*Controls  
N = 21 
HIV  
Positive 2 0 0 
Negative 0 0 0 
Neisseria gonorrhea    
Positive 0 1 0 
Negative 0 0 0 
Nugent scores    
Normal (0-3) 10 12 20 
Intermediate (4-6) 8 2 1 
 
Legend:  
TV; Trichomonas vaginalis, CT; Chlamydia trachomatis, *Controls were not infected with T. vaginalis, C. 
trachomatis, BV or HIV. 
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Supplementary Table 6.2. Socio-demographic and behavioral characteristics of 
Trichomonas vaginalis qPCR positive women (cases) and T. vaginalis qPCR negative 
women (controls), attending antenatal care at Kilifi County Hospital, Kenya.  
Characteristic Cases (%) 
N = 18 
Controls (%) 
N = 21  
χ2  
P-value 
Age group (Years)  
18-24 38.9 28.6  
 ≥ 25 61.1 71.4 0.496 
Religion  
Christian   72.2 66.7  
Muslim 11.1 9.5  
Other/None 16.7 23.8 0.857 
Education  
None 22.2 19.1  
Primary   61.1 61.9  
Secondary/Tertiary    16.7 19.1 0.961 
Parity  
    0 27.8 19.2  
    1-2 44.4 42.7  
    3+ 27.8 38.1 0.728 
Gestational age  
   14-27 55.6 66.7  
    ≥ 28 44.4 33.3 0.477 
Number of lifetime  
     ≤ 2 77.8 95.2  
     ≥3 22.2 4.8 0.104 
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 Supplementary Table 6.3. Socio-demographic and behavioral characteristics of 
Chlamydia trachomatis qPCR positive women (cases) and C. trachomatis qPCR negative 
women (controls), attending antenatal care at Kilifi County Hospital, Kenya.  
Characteristic Cases (%) 
N = 14 
Controls (%) 
N = 21  
χ2  
P-value 
Age group (Years)  
18-24 64.3 28.6  
 ≥ 25 35.7 71.4 0.036 
Religion  
Christian   78.6 66.7  
Muslim 21.4 9.5  
Other/None 0.0 23.8 0.115 
Education  
None 21.4 19.1  
Primary   57.2 61.9  
Secondary/Tertiary    21.4 19.0 0.961 
Parity  
    0 21.4 19.1  
    1-2 57.1 42.9  
    3+ 21.5 38.0 0.571 
Gestational age  
   14-27 53.9 66.7  
    ≥ 28 46.1 33.3 0.455 
Number of lifetime  
     ≤ 2 64.3 95.2  
     ≥3 35.7 4.8 0.017 
 
Legend 
In bold: significantly differed, i.e., P ≤ 0.05
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Supplementary Table 6.4. Socio-demographic and behavioral characteristics of 
Trichomonas vaginalis qPCR positive women and Chlamydia trachomatis qPCR negative 
women, attending antenatal care at Kilifi County Hospital, Kenya.  
Characteristic T. vaginalis (%) 
N = 18 
C. trachomatis (%) 
N = 14  
χ2  
P-value 
Age group (Years)  
18-24 38.9 64.3  
 ≥ 25 61.1 35.7 0.154 
Religion  
Christian   72.2 78.6  
Muslim 11.1 21.4  
Other/None 16.7 0.0 0.233 
Education  
None 22.2 21.5  
Primary   61.1 57.1  
Secondary/Tertiary    16.7 21.4 0.943 
Parity  
    0 27.8 21.5  
    1-2 44.4 57.1  
    3+ 27.8 21.4 0.776 
Gestational age  
   14-27 55.6 53.9  
    ≥ 28 44.4 46.1 0.952 
Number of lifetime  
     ≤ 2 77.8 64.3  
     ≥3 22.2 35.7 0.400 
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Supplementary Table 6.5. Socio-demographic and behavioral characteristics of women 
selected as controls and women not selected as controls, attending antenatal care at Kilifi 
County Hospital, Kenya.  
Characteristic Selected as controls (%) 
N = 21 
Not selected as controls (%) 
  N = 251  
χ2  
P-value 
Age group (Years)  
18-24 28.6 36.4  
 ≥ 25 71.4 63.6 0.474 
Religion  
Christian   66.7 72.3  
Muslim 9.5 15.8  
Other/None 23.8 11.9 0.251 
Education  
None 19.1 17.0  
Primary   61.9 57.7  
Secondary/Tertiary   19.0 25.3 0.814 
Parity  
    0 19.1 26.4  
    1-2 42.9 36.8  
    3+ 38.1 36.8 0.753 
Gestational age  
   14-27 66.7 60.3  
    ≥ 28 33.3 39.6 0.567 
Number of lifetime  
     ≤ 2 95.2 88.8  
     ≥3 4.8 11.2 0.362 
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Supplementary Figure 6.1. Bar graph showing relative abundance at family level based on 
genital infection 
 
 
Legend. Bar graphs are of taxa that are significantly different with a p-value < 1 are shown. A 
Pair-wise comparisons is performed by t-test and annotated as *: p<0.05, **: p<0.01, ***: p<0.001 
for women with T. vaginalis (n = 18), C. trachomatis (n = 14) and controls (n = 21).  
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Supplementary Figure 6.2. Bacterial α-diversity using Simpson and Shannon indices of 
women based on Nugent scores. 
 
 
 
Legend. Intermediate Nugent score; 4-6 (n = 11), Normal Nugent score; (0-3) (n=42).  
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7.1 Abstract 
BACKGROUND 
Trichomoniasis is the most prevalent curable sexually transmitted infection (STI) globally, 
with the highest incidence and prevalence in sub-Saharan Africa (sSA). STIs have largely 
been associated with an increase in HIV acquisition. We assessed the existing literature 
regarding the association of Trichomoniasis and HIV acquisition. 
METHODS 
The review protocol was registered at the International Prospective Register of 
Systematic Reviews (PROSPERO) as/under number CRD42018082702. We searched 
MEDLINE, EMBASE and SCOPUS databases to collect articles measuring the 
association of Trichomonas vaginalis infection and HIV acquisition and performed a meta-
analysis and qualitative synthesis of the literature. 
RESULTS 
We identified 1806 unduplicated citations, of which 18 papers and one conference 
abstract were eligible for inclusion in the review after applying our inclusion and exclusion 
criteria. All the studies included in the systematic review had been carried out in sSA. The 
articles reported various measures of effects, namely: hazard ratios (HR), rate ratios, risk 
ratios, and odds ratios. In a meta-analysis restricted to 11 studies reporting HR, 
individuals infected with T. vaginalis were 1.5 times more likely to acquire HIV compared 
to individuals not infected with T. vaginalis (95% Confidence Interval, 1.3 –1.7; p < 0.001). 
CONCLUSIONS 
T. vaginalis is an important factor in HIV acquisition especially in sSA where the 
prevalence of T. vaginalis is high. This systematic review and meta-analysis firms up the 
evidence that infection with T. vaginalis augments HIV acquisition with 50%. Diagnosis 
and treatment of T. vaginalis infection in both high-risk and low-risk individuals may be a 
potential tool to reduce new HIV infections. 
 
KEYWORDS: HIV acquisition; sub-Saharan Africa; Trichomonas vaginalis 
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7.2 Introduction 
The protozoan Trichomonas vaginalis is responsible for trichomoniasis, the most common 
curable sexually transmitted infection [1].  T. vaginalis infects both men and women, 
although this unicellular parasite is more prevalent in women than men. Among people 
aged 15–49 years, it was estimated that in 2012 the global prevalence of T. vaginalis 
infection among women was 5.0%, vs. 0.6% among men. These figures correspond to 
an estimated 143 million infected individuals [1]. Similar to HIV, T. vaginalis is more 
prevalent in sub-Saharan Africa (sSA), as the cumulative prevalence was estimated to be 
11.5 % among women aged between 15-49 years in sSA in 2012 [1]. 
According to The Joint United Nations Programme on HIV and AIDS [2], about 5000 new 
HIV infections occurred daily in 2016, with a huge proportion, i.e., 64%, of new infections 
occurring in (sSA). Already two decades ago, reports suggested that individuals infected 
with T. vaginalis were at an increased risk of HIV acquisition [3]. Some studies have also 
indicated that T. vaginalis and HIV co-infection increases genital shedding of HIV [4], but 
opinions differ, especially in the context of antiretroviral therapy (ART) [5]. In summary, 
there is growing evidence that there is a need for special treatment considerations for T. 
vaginalis among women with HIV co-infection [6]. 
Better understanding of the association T. vaginalis and HIV may provide insights on HIV 
infections that may be attributed to T. vaginalis. In addition it may enhance understanding 
on how control of T. vaginalis may impact HIV transmission as a potentially cost-effective 
strategy for reducing HIV transmission, particularly in regions where T. vaginalis is 
common. The objective of this systematic review and meta-analysis was to clarify the 
extent to which T. vaginalis infection is associated with HIV infection and acquisition.  
7.3 Methods 
Protocol and registration: We followed the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) guidelines [7] for carrying out and reporting this 
systematic review and meta-analysis, using an a priori defined protocol. The protocol for 
this systematic review and meta-analysis was registered at the International Prospective 
Register of Systematic Reviews (PROSPERO)(https://www.crd.york.ac.uk/PROSPERO/) 
under registration number CRD42018082702.  
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Eligibility criteria We included studies that reported both T. vaginalis infection status 
and HIV status. We only included studies written in English, and that documented odds 
ratio (OR), or risk ratio (RR), or hazard ratios (HR), or provided the absolute numbers for 
these parameters to be calculated. There were no restrictions in terms of study design 
and there was no lower bound date of publication. We included papers that were 
published up to 11th March 2018.  
Reviews, narrative only conference abstracts, comments, guidelines, case reports or 
case series, unpublished articles, multiple reports of the same data and in vitro and animal 
studies were not considered for inclusion. Infection with T. vaginalis was defined as the 
presence of the pathogen as assessed by culture, wet mount or molecular methods. 
While HIV status was defined by the presence of HIV antibodies, HIV proteins, HIV RNA 
or DNA.  
Search strategy We searched EMBASE, MEDLINE (through PubMed) and Scopus. We 
used the combination of all of the following search terms (Trichomonas vaginalis, T. 
vaginalis, trichomoniasis) with all of the following search terms (AIDS, acquired 
immunodeficiency syndrome, human immunodeficiency virus, HIV, HIV-1, HIV-2). The 
bibliographic references of the studies that were considered eligible were also hand 
searched. 
Study selection Studies were selected in a two-stage process (Figure 7.1). First, all 
bibliographic references were screened to identify studies for full-text evaluation by one 
reviewer Simon Chengo Masha (SCM), on the basis of only the information present in the 
title and abstract. Subsequently, the full texts of those articles not excluded in the 
screening process were assessed for eligibility, using the aforementioned criteria, by two 
authors independently SCM and Piet Cools (PC). Reasons for exclusion were recorded 
and categorized, and disagreements were resolved by consensus. 
Using all search terms, searches were conducted for relevant papers in the pre-identified 
databases (EMBASE, PubMed, and Scopus) and from this we identified 3398 papers. 
Once the search was completed, all of the retrieved articles were imported into EndNote 
X7.8 for removal of duplicates.  
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Data collection process  
A predefined data extraction form was pilot-tested and used for data extraction. From the 
19 studies included in the systematic review and meta-analysis. The following information 
was collected; authors, year of publication, journal, country where the study had been 
carried out, study design, sample collection period, study population, mean/median age 
of the participants, total number of study participants, total number of samples included 
in the analysis, T. vaginalis detection method, assessment of HIV status, relevant 
measures of effects or absolute numbers, statistics. This procedure was performed 
independently by two authors (SCM and PC) and disagreements were resolved by 
discussion between both authors. 
Risk of bias in individual studies  
To assess the quality and risk of bias of the included studies, we developed a quality 
appraisal tool (Supplementary Table 7.2), based on the Newcastle-Ottawa Scale [8]. We 
adapted this tool to the content of our meta-analysis. Stars were assigned by SCM for 
three broad criteria (representativeness of the study groups, comparability of the study 
groups, and quality of the outcome assessment) in order to provide a measure of their 
quality.  
Studies that scored none or one, two, or three stars for representativeness were classified 
as having respectively a high, medium or low risk of bias for this criterion. Studies 
assigned none, one, or two stars for comparability or outcome were considered to have 
respectively a high, medium or low risk of bias for comparability and outcome. 
Data analysis.  
The meta-analyses was performed using STATA version 13.1 (Stata- Corp, College 
Station, Texas). We reported the results of the meta-analyses obtained after pooling 
individual study estimates with random effects model as HRs with 95% confidence 
interval (CI). The degree of heterogeneity between the studies was assessed using the I2 
index, with percentages 25%, 50%, and 75% being indicative of low, moderate, and high 
heterogeneity, respectively [9]. 
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7.4 Results 
Manuscript and study selection; a total of 1806 unduplicated citations were identified, we 
selected 164 abstracts for full text evaluation and (Figure 7.1). There were 19 studies 
which met our inclusion criteria to be included in our systematic review. 
Figure 7.1 Identification and selection of studies for the systematic-review 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching 
PubMed n = 801 
Embase n = 1028 
Scopus n = 1569  
Sc
re
en
in
g 
In
cl
ud
ed
 
El
ig
ib
ili
ty
 
Id
en
tif
ic
at
io
n 
Records after duplicates removed 
n = 1806  
Screened by title and /or abstract 
n = 1806  
Records excluded 
n = 1642 
Full-text articles assessed 
n = 164 Exclusions n = 145 
 
Not reporting predefined 
outcome/exposure n = 64 
TV and HIV transmission n = 7 
TV and HIV co-infection n = 53 
TV and HIV shedding n = 14 
Treatment of TV during HIV  
co-infection n = 7 
Qualitative synthesis n = 19 
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Description of selected studies 
All studies were conducted in sSA, namely Burkina Faso (n = 1), Democratic Republic of 
Congo (n = 2), Ivory Coast (n = 1), Kenya (n = 5), Malawi (n = 1), South Africa (n = 4), 
Uganda (n = 4), Zambia (n = 1), and Zimbabwe (n = 3). Some of the studies were 
conducted in more than once country. Of the included the 19 studies, 17 were cohorts, 
and 2 were nested case-control studies. Generally, all these studies involved a baseline 
T. vaginalis test and additional testing performed at varying intervals depending on the 
study, with treatment for participants testing positive for T. vaginalis. Thirteen of the 
studies found a significant positive association between T. vaginalis infection and HIV 
acquisition.  
Eleven studies reported hazard ratios (HR) of HIV acquisition in relation to T. vaginalis 
infection, three reported rate ratios (RR*) of HIV acquisition in relation to T. vaginalis, two 
studies reported risk ratios (RR) of HIV acquisition in relation to T. vaginalis and  three  
reported odds ratios (OR) of HIV acquisition in relation to T. vaginalis (Table 7.1).  
Most studies (63%) had been carried out amongst high-risk individuals, i.e. female sex 
workers, and serodiscordant couples. The rest of the studies (37%) had been carried out 
amongst low-risk populations, including women attending pre- or postnatal clinics and 
family planning clinics and individuals from the general population. Direct microscopy was 
the most common method used for detection of T. vaginalis (73%) in the studies. 
Detection of HIV antibodies was the most common method used to determine HIV status 
(84%) in the studies (Table 7.1). 
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Risk of bias within studies 
The results of the critical appraisals of the included studies are shown in (Figure 7.2). 
Fourteen studies were assessed as having a high risk of bias for representativeness, 
three as having a medium risk of bias for representativeness and two studies as having 
a low risk of bias for representativeness. For the risk of bias for outcome assessment it 
was high for one study, medium for 16 studies and low for two studies. Eight out of the 
nineteen studies were assessed as having a medium risk of bias for comparability while 
11 studies had a low risk of bias for comparability. Individual study appraisals are captured 
in (Supplementary Table 3). 
 
Figure 7.2 Quality assessment using an adapted Newcastle-Ottawa Scale for risk 
of bias.  
 
 
Legend: The absolute numbers of studies are shown in the boxes.  
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Association of T. vaginalis and HIV acquisition 
 
Eleven of the studies that were reporting HR, provided data for the meta-analysis. The 
point estimate for the HR ranged from 0.71 to 4.79 (Table 7.1). Bearing in mind that ORs 
and RRs measure only the number of events and take not into account when they occur, 
these two measures are appropriate for measuring dichotomous outcomes, but less 
appropriate for analyzing time-to-event outcomes which is important when relating T. 
vaginalis infection and HIV acquisition. The meta-analysis indicated that individuals 
infected with T. vaginalis were 1.5 times more likely to acquire HIV as compared to 
individuals not infected with T. vaginalis (HR: 1.5; 95% Confidence Interval (CI), 1.3–1.7; 
p < 0.001). There was low heterogeneity of studies included in the meta-analysis as 
shown by the I2 = 0.0%, P = 0.510 (Figure 7.3). 
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Figure 7.3 Forest plot of estimates of association between trichomoniasis and HIV 
acquisition 
 
 
Studies are plotted starting with the one with the least weight. Each study is represented 
by a black circle and a horizontal line, which correspond to the HR and 95% CI, 
respectively.  The area of the gray box around each study reflects the weight of the study 
(determined by random effects analysis) in the meta-analysis. The vertical line in the 
middle corresponds to a HR of 1.0. The diamond represent the overall HR with the 95% 
CI given by its width.  The arrow indicates the study with the highest confidence interval. 
 
7.5 Discussion 
In this systematic review and meta-analysis, we assessed the extent to which T. vaginalis 
infection is associated with HIV acquisition. There has been a global decline in deaths 
from HIV/AIDS-related causes, from a peak of 1.9 million in 2005 to 1.0 million in 2016 
[2]. Despite this AIDS-related illnesses remain the leading cause of death among women 
of reproductive age (15–49 years) globally [2] and the second leading cause of death for 
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young women aged 15–24 years in sSA [2]. The prevalence of T. vaginalis was estimated 
to be approximately 11 % in 2012 among women in sSA [1].   
Studies included in our meta-analysis had no heterogeneity and thus appropriate to be 
combined in a meta-analysis where we demonstrate that individuals infected with T. 
vaginalis are at a higher risk of HIV acquisition. T. vaginalis augments the likelihood of 
HIV acquisition by 50% (HR, 1.5; 95% CI, 1.3–1.7), the amount of HIV acquisition 
attributable to this pathogen (attributable risk) and its contribution to the HIV pandemic 
may be substantial due to the high prevalence of T. vaginalis infection, especially in sSA. 
In a study where they included both high-risk individuals and low-risk individuals, the 
adjusted hazard ratio for HIV acquisition for women with T. vaginalis were higher in the 
low-risk individuals, suggesting that for women with less risk from sexual networks, 
infection with T. vaginalis infection is a very important risk factor for HIV acquisition [10]. 
Even though most studies included in this systematic review utilized direct microscopy for 
detection of T. vaginalis a diagnostic technique which has been shown to have a low 
sensitivity [11]. In a study using both direct microscopy and NAAT, both sets of results 
were associated with a higher HIV acquisition although fewer cases were detected by 
direct microscopy [10].  
Several T. vaginalis pathogenic mechanisms of T. vaginalis may help to explain why 
individuals infected with T. vaginalis may be at a higher risk of HIV acquisition. First, T. 
vaginalis may damage the epithelial membrane [12] which acts as a barrier to HIV through 
several pathogenic mechanisms; its cell-to-cell adhesion [13], hemolysis [14] and/or 
excretion of soluble factors [15]. Second, T. vaginalis has been shown to elicit an 
inflammatory response among infected individuals this may lead to an increase in the 
appearance of HIV target cells [16, 17]. Third, infection with T. vaginalis has been 
associated with bacterial vaginosis [18], which, in turn, can increase the risk of HIV 
acquisition [19]. All these consequences may facilitate HIV in T. vaginalis infected 
individuals.  
In cases of HIV and T. vaginalis co-infection, T. vaginalis has been associated with 
increased genital shedding of HIV [20]. A previous study showed high prevalence of T. 
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vaginalis among HIV serodiscordant African couples [21]. T. vaginalis may be an 
important factor for HIV transmission in HIV discordant couples more so if both are 
infected with T. vaginalis as there is potential for synergistic effect leading to an even 
higher likely hood of HIV acquisition. That is by increased genital HIV shedding and 
pathogenic mechanisms of T. vaginalis making the HIV uninfected partner more 
susceptible to HIV acquisition.  
Both T. vaginalis and HIV are associated with high-risk behavior and one may argue that 
the HIV acquisition is as a result of the high-risk behavior and not necessarily due to 
pathophysiological mechanisms of T. vaginalis. However, from the studies that reported 
odds ratios, the results suggest that exposure to T. vaginalis was associated with a higher 
chance of HIV infection acquisition. For instance women attending family planning who 
were determined to be T. vaginalis positive at previous visit were more likely to 
seroconvert than women without T. vaginalis in a study in Uganda and Zimbabwe AOR 
3.3 (95% CI, 1.36–7.85) [10]. Therefore, T. vaginalis infection seems to be a good marker 
for predicting those who are at high risk of HIV infection acquisition. 
When interpreting the results of the meta-analysis, the following ought to be taken into 
consideration. First, most studies included in the review were conducted amongst high-
risk individuals, i.e. female sex workers, and serodiscordant couples. Thus, our result may 
not reflect the situation in the general population. Second, only a couple of studies 
included in the review had male participants and thus our results are biased towards high-
risk females.  Third, most of the studies in the review utilized direct microscopy to detect 
T. vaginalis infection, whereby direct microscopy is characterized by low sensitivity and 
samples detected through this technique usually have high parasitemia. Although, the 
few studies that utilized culture or NAATs for T. vaginalis detection also reported positive 
association of T. vaginalis infection and increased likelihood of HIV acquisition, they also 
signal the need for further longitudinal research on this area. Four, we only included 
studies reported in English and this may in itself constitute a bias.  Finally, all studies 
included in the review were done in sSA and thus our results may only apply to the sSA 
population. 
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7.6 Conclusion  
T. vaginalis may be used as a biological marker for enhanced risk for HIV acquisition for 
both in high-risk and low-risk individuals. T. vaginalis may be an important factor in HIV 
acquisition especially in sSA where the prevalence of both T. vaginalis and HIV is high 
and this systematic review and meta-analysis provides consolidated evidence that 
infection with T. vaginalis augments HIV acquisition. Diagnosis and treatment of T. 
vaginalis in both individuals at high-risk and low-risk for HIV may perhaps be a potential 
tool to reduce new HIV infections. 
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Glossary 
Hazard ratio: This can be defined as the ratio of [risk of outcome in one group]/[risk of 
outcome in another group], occurring at a given interval of time. 
Odds ratio: This can be defined as a measure of association between an exposure and 
an outcome. The odds ratio represents the odds that an outcome will occur given a 
particular exposure, compared to the odds of the outcome occurring in the absence of 
that exposure.  
Rate ratio: This can be defined as a measure of association that compares the incidence 
of events happening at different times.  
Relative risk or risk ratio: This can be defined as the ratio of the probability of an event 
occurring in an exposed group to the probability of the event occurring in a comparison, 
non-exposed group exposed.  
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Supplementary Table 7.1. TOOL FOR EVALUATION OF RISK OF BIAS IN 
INDIVIDUAL STUDIES 
SELECTION 
 
1. Representativeness of the group tested for Trichomonas vaginalis & HIV 
 
a) Truly representative of people in the community *** 
b) Somewhat representative of the community  ** 
c) Selected group people * 
d) No description 
COMPARABILITY 
 
2. The subjects in different comparison groups are comparable, based on 
the study design or analysis 
a) Controlling for confounding factors (logistic regression or propensity 
scoring) ** 
b) Subjects in different groups are comparable * 
c) No reporting on comparability between comparison groups and no control 
for confounding 
 
OUTCOME 
 
3. Ascertainment of infection with either Trichomonas vaginalis or HIV 
 
a) Both ascertained by validated, highly specific and sensitive assays 
performed for the study *** 
b) Either T. vaginalis or HIV ascertained by validated moderate specific and 
sensitive assays performed for the study while the other is through 
medical records** 
c) Both ascertained through medical records * 
d) Self-reported without further documentation/ assay not stated 
 
  
RISK OF BIAS 
Selection: 3 stars, low risk of bias; 2 stars, medium risk of bias; 0 or 1 star(s), high risk 
of bias 
Comparability: 2 stars, low risk of bias; 1 star, medium risk of bias; 0 stars, high risk of 
bias 
Outcome: 3 stars, low risk of bias; 2 or1 star(s), medium risk of bias; 0 stars, high risk of 
bias 
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Supplementary Table 7.2: Individual study summary of risk of bias assessment  
Author & Year Selection 
Interpretation 
Comparability 
Interpretation 
Outcome 
Interpretation 
Delany-Moretlwe et al. (2011) high medium high 
Ghys et al. (2001) high low medium 
Hester et al. (2003) High medium medium 
Kinuthia et al. (2015) High medium medium 
Kleinschmidt et al. (2007) medium low medium 
Laga et al. (1993) High medium medium 
Laga et al. (1994) High low medium 
Martin et al. (1998) High medium medium 
Masese et al. (2015) High low medium 
Mavedzenge et al. (2010) Low low low 
McClelland et al. (2005) High medium medium 
McClelland et al. (2007) High low medium 
Myer et al. (2006) Low medium medium 
Nagot et al. (2005) High medium medium 
Quinn et al. (2000) High low medium 
Taha et al. (1998) medium low medium 
van de Wijgert et al. (2009)  medium low medium 
Van Der Pol et al. (2008) High low low 
Vandepitte et al. (2013) High low medium 
 
Legend: Studies are arranged alphabetically according to the first authors name and year. 
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The first objective of this doctoral dissertation was to assess the prevalence and risk 
factors associated with curable sexually transmitted infections (STIs) among pregnant 
women, attending antenatal care at a rural county hospital in Kilifi, Kenya, for routine 
screening of HIV and syphilis.  
More details with regard to the assessment of the prevalence and risk factors are outlined 
in detail in Chapter 3. In brief, from July to September 2015, we performed a cross-
sectional study, whereby the women had a urine sample tested for Chlamydia 
trachomatis/Neisseria gonorrhoeae by GeneXpert® and a vaginal swab for Trichomonas 
vaginalis by culture and microscopy. Bacterial vaginosis (BV) was defined as a Nugent 
score of 7-10 of the Gram stain of a vaginal smear in combination with self-reported 
vaginal discharge. Genital ulcers were screened during collection of vaginal swabs. All 
women answered questions with regard to socio-demographics and sexual health and 
clinical symptoms of STIs. Predictors for curable STIs were assessed in multivariable 
logistic regression. 
The main why reason Trichomonas vaginalis was detected by culture was cost and 
availability of the testing technique. Furthermore, culture enabled provision of initial same 
day results via direct microscopy which was applied on the same test kit (Tv Inpouch). 
Moreover, the funding to perform C. trachomatis and N. gonorrhoeae detection was 
obtained separately. In addition, culture provides with strains (i.e. full genomes) of T. 
vaginalis from which nucleic acids could be extracted for further studies such as the 
determination of the actin gene type or the presence of T. vaginalis viruses (TVVs). 
Of 202 women included, a total of 20.8% (95% confidence interval (CI):15.4-27.0), i.e. 
one in five, had a curable STI. The prevalence was 14.9% for C. trachomatis (95% CI: 
10.2-20.5), 1.0% for N. gonorrhoeae (95% CI: 0.1-3.5), 7.4% for T. vaginalis (95% CI: 
4.2-12.0), 19.3% for BV (95% CI: 14.1-25.4) and 2.5% for genital ulcers (95% CI: 0.8-5.7) 
[1]. Curable STIs have been associated with a number of adverse pregnancy outcomes, 
including spontaneous abortion, stillbirth, prematurity, low birth weight, postpartum sepsis 
and endometritis, and several sequelae in surviving neonates [2]. Preterm birth and low 
birth weight are major determinants of infant morbidity and mortality, especially in 
developing countries such as Kenya, where neonatal intensive care facilities are rarely 
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available. Mati et al. [3] reported a high incidence of 7.5% for low birth weight (< 2500 g), 
and a perinatal mortality of 2.2% in Nairobi, Kenya.  
Future perspectives: Investigating the influence of STIs on pregnancy outcome is 
complicated. For ethical reasons, it is not possible to prospectively investigate the 
influence of an untreated STI upon diagnosis. Therefore, most studies are retrospective, 
whereby data on STIs and birth outcomes have been collected at or after delivery, and 
whereby it may be difficult to take into account confounding factors, such as nutrition, 
malaria, gestational diabetes and/or genetic disorders that may have an effect on the 
pregnancy outcome [2]. 
In resource-constrained settings, as is the case in many developing countries, laboratory 
diagnosis to confirm the etiology of an STI is currently not an achievable option. In Kenya, 
syndromic management continues to be employed as the general approach in the 
management of the bulk of STIs, despite evidence showing that this approach lacks  both 
sensitivity and specificity [4, 5], also because STIs may be asymptomatic [6] or may 
present with non-specific clinical signs and symptoms. Simple and affordable techniques 
need to be considered for the diagnosis of some STIs. The diagnosis of T. vaginalis can 
be done using wet mount microscopy, whereby the main equipment required is a 
microscope, which is available in most hospitals across the country. Despite the low 
sensitivity of wet mount microscopy, this approach has high specificity of up to 100%, 
depending on the reader [7]. Wet mount microscopy remains one of the best options for 
clinicians in resource-constrained countries to quickly and specifically diagnose T. 
vaginalis in clinical practice.  
It is clear that a policy for testing for T. vaginalis in all women attending ANC could reduce 
the burden of T. vaginalis infections, especially in areas with a high prevalence of T. 
vaginalis. STI screening programs should be subject to a formal cost-effectiveness 
analysis to avoid the ineffective use of resources. The greatest argument against the 
general screening of T. vaginalis is that there is little evidence to indicate that treatment 
of asymptomatic T. vaginalis–positive individuals prevents any adverse health outcome. 
In particular, a randomized controlled trial treatment of T. vaginalis in pregnant women in 
sub-Saharan Africa failed to show benefit in relation to preterm births and moreover, no 
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difference was observed between the mean birth weight of children from mothers treated 
for T. vaginalis and mothers positive but not treated [8]. Results of this study are 
inconclusive, as this study was conducted in four resource-limited settings where an 
ultrasound was not generally available to determine the estimated due date. Women with 
trichomoniasis who did not receive treatment were more likely to deliver a preterm infant 
when the symphysis-fundal height was used to estimate gestational age (36% v. 
23%; p=0.03), but not when the Ballard score was used (16% v. 21%; p=0.41) [8].  
Factors associated with curable STIs including the ones identified in our study (BV, genital 
ulcer, early sexual debut, water for cleaning after visiting the toilet) may be used as a first 
level of screening to determine individuals who should undergo laboratory testing.  Finally, 
it has been hypothesized that widespread treatment of T. vaginalis has the potential to 
increase metronidazole resistance for a pathogen against which no other class of 
antibiotic is effective [9].  
In the current climate of sustainable development goals (SDGs) era, as promoted by the 
United Nations, there is a unique opportunity to reconsider approaches to health, 
including to endemic, long-standing infectious diseases. Sustainable development goal 
number 3 (SDG3) is primarily on health: “Ensure healthy lives and promote well-being for 
all at all ages”. One of the specific targets set out under SDG3 is: “By 2030, ensure 
universal access to sexual and reproductive health-care services, including for family 
planning, information and education, and the integration of reproductive health into 
national strategies and programmes” [10]. 
If Kenya is to achieve the ambitious targets as set out under the SDG3, a multidisciplinary 
approach has to be in place, as health is determined by multiple factors that often are not 
addressed within the health sector alone and require necessarily collaboration and 
partnership with different sectors. Within the Kenyan context, setting up and maintenance 
of antimicrobial resistance monitoring for STIs such as N. gonorrhoeae which is evolving 
into a superbug due to resistance to multiple antibiotics [11] should be set up. Moreover, 
a general national surveillance of all STIs ought to be organized in a well-thought-out 
manner by the government, as is the case for HIV [12]. The Kenyan government should 
consider screening and treatment of pregnant women co-infected with T. vaginalis and 
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HIV as this would go a long way in reducing mother-to-child HIV transmission.  At present, 
the HIV mother-to-child HIV transmission rate in Kilifi is 10% and the target is to reduce 
this rate to less than 5% by 2019 [13]. 
 
The second objective of this doctoral dissertation was to assess the urogenital pathogen 
correlates of T. vaginalis among pregnant women in Kilifi, Kenya.  
Since conventional screening of STIs is frequently only aiming at the diagnosis of 
chlamydia, gonorrhea, syphilis and trichomoniasis, while pathogens which demonstrate 
similar urogenital syndromes, such as Mycoplasma genitalium, remain undiagnosed 
and/or untreated. This objective is addressed in Chapter 4 of this PhD dissertation. By 
means of a nested case-control approach, vaginal swabs from 79 pregnant women, i.e., 
28 T. vaginalis-positive (cases) and 51 T. vaginalis-negative (controls), were screened by 
quantitative PCR for Adenovirus 1 and 2, Cytomegalovirus, Herpes Simplex Virus 1 and 
2, C. trachomatis, Escherichia coli, Haemophilus ducreyi, Mycoplasma genitalium, M. 
hominis, candidatus M. girerdii, N. gonorrhoeae, Streptococcus agalactiae, Treponema 
pallidum, Ureaplasma parvum, U. urealyticum, and Candida albicans. Additionally, we 
determined whether women with pathogens highly associated with T. vaginalis had 
distinct clinical signs and symptoms compared to women with T. vaginalis mono-infection. 
We could demonstrate that women infected with T. vaginalis were significantly co-infected 
with M. hominis (adjusted odds ratio = 6.8, 95% CI: 2.3–19.8). Moreover, M. genitalium 
and Ca M. girerdii were exclusively detected in women with T. vaginalis (P = 0.002 and P 
= 0.001), respectively.  
Future perspectives: Our results suggest that although most focus goes to the four most 
common prevalent curable STI pathogens, i.e., C. trachomatis, N. gonorrhoeae, T. 
pallidum and T. vaginalis, there are co-infections with pathogens that are not routinely 
screened for. These co-occurrences may have an impact on the management of the 
primary infection. Future studies ought to investigate the co-infections with these less 
well-known STIs and assess whether they play a synergistic role in the pathology.  
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The third objective was to assess the genetic diversity of T. vaginalis isolates among 
pregnant women in Kilifi, Kenya. This objective is addressed in Chapter 5 of this 
dissertation. In summary, genotyping was performed on 22 clinical isolates of T. vaginalis, 
collected from women attending the antenatal care clinic at Kilifi County Hospital, Kenya, 
in 2015. Genotyping followed a previously proposed restriction fragment length 
polymorphism (RFLP) scheme [14], which involved in silico cleavage of the actin gene by 
HindII, MseI and RsaI restriction enzymes. Phylogenetic analysis of all the sequences 
was performed to confirm the results obtained by RFLP-analysis and to assess the 
diversity within the RFLP genotypes. Additionally, we determined carriage of the four 
different types of TVVs by reverse transcription polymerase chain reaction. 
In silico RFLP-analysis revealed five T. vaginalis actin genotypes among women 
attending ANC who participated in our cross-sectional study; 50.0% of the isolates were 
of actin genotype E, 27.3% of actin genotype N, 13.6% of actin genotype G and 4.5% of 
actin genotypes I and P. The prevalence of TVVs was 43.5% (95% confidence interval, 
CI: 23.2–65.5). TVV1 was the most prevalent, present in 39.1% of the strains and 90% of 
the T. vaginalis isolates which harbored TVVs had more than one type of TVV. None of 
the isolates of actin genotype E harbored any TVV.  
For the first time, we now know the actin genotypes of T. vaginalis that are in circulation 
in Kilifi, Kenya. We can now make comparisons with T. vaginalis genotype that are in 
circulation in other places within the country and in other countries. For instance, the most 
common actin genotype in our study was genotype E, similar to what was observed in 
Congo [14]. In Zambia however, most common actin genotype was genotype G [14]. 
Mapping the global distribution of the genotypes will lead to better understanding of the 
epidemiology of T. vaginalis. 
This sequence based genotyping technique is able to produce portable and unambiguous 
results when compared to for gel based techniques where interpretation of band patters 
is very subjective. Using this sequence based techniques equally have good 
reproducibility as different laboratories following the same protocol would almost always 
have the same results.  
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The target gene (Actin) is a ubiquitous well conserved structural protein in all eukaryotic 
cells and has been used to clarify the molecular phylogeny of protists, plants, animals 
and fungi. 
The choice of doing direct sequencing of PCR products allows immediate and detailed 
analysis of the fragments without the extra steps associated with cloning. With the current 
availability of the thermostable polymerases and cycle sequencing, doublestranded 
sequencing of PCR products is very efficient. In our case we sequenced bidirectional 
which enabled assembling of a consensus sequence which was used for genotyping. 
Future perspectives: Our work on genotyping T. vaginalis also lays foundation for future 
studies that may examine aspects such as genotype replacement or that can identify new 
genotypes that may be imported from elsewhere or may be prevalent in a different 
population than the one we got our isolates from. Future studies that include both genders 
may test the hypothesis that there is no preferential gender infection with particular 
genotypes and further on examine whether lack of TVVs among genotype E still persists. 
Also, In vitro studies have demonstrated that TVVs can be sensed by the human epithelial 
cells via Toll-like receptor 3, upregulating Interferon Regulating Factor-3, interferon type 
I and proinflammatory cascades [15]. TVVs are also associated with upregulated levels 
of T. vaginalis immunogenic protein P270 [16] and differential qualitative and quantitative 
expression of cysteine proteinases [17]. Thus, since TVVs induce various phenotypic 
changes that may impact T. vaginalis virulence [17], future studies to better understand 
of the role of TVVs in the pathology of T. vaginalis are warranted. These studies may also 
determine whether there is an inflammation flare-up upon antibiotic treatment 
(metronidazole) which commonly kills the protozoan pathogen but at the same time 
releases the TVVs from the killed T. vaginalis cells. This may have an implication of 
clinical management especially that of pregnant women as the released TVVs may be 
responsible for initiation of the inflammation cascade. 
Finally, previous studies have shown that TVVs were associated with significantly higher 
minimum lethal concentration of metronidazole. From our study none of the isolates of 
actin genotype E harbored any TVVs. Future studies will determine if this actin genotype 
has the potential of to predict sensitivity to metronidazole.   
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The fourth objective was to describe the vaginal microbiome of pregnant women in 
relation to infection with either T. vaginalis or C. trachomatis. This objective is addressed 
in Chapter 6.  In summary, the vaginal bacterial composition of women with T. vaginalis ( 
N = 18) was compared to that of women with C. trachomatis (N = 14), and controls (N = 
21) (women negative for both T. vaginalis and C. trachomatis). The vaginal bacterial 
composition was determined using high throughput sequencing with the Ion 16S 
metagenomics kit, of the variable regions 2, 4 and 8 of the bacterial 16S ribosomal RNA 
gene from the vaginal swab DNA extract of the women. QIIME and R package “Phyloseq” 
were used to assess the α- and β-diversity and absolute abundance of the 16S rRNA 
gene per sample in the three groups. Differences in taxa at various levels were 
determined using the independent t-test. 
We demonstrated bacterial α-diversity by both Simpson’s, and Shannon indices was 
significantly higher (p = 0.056) and (p = 0.001) respectively, among women with either T. 
vaginalis or C. trachomatis than among controls, with mean α-diversity (T. vaginalis-
infected) > mean α-diversity (C. trachomatis-infected) > mean α-diversity (Controls). At 
the genus level, women infected with T. vaginalis had significantly (p < 0.01) higher 
abundance of Parvimonas and Prevotella compared to both controls and CT-infected 
women, whereas women infected with C. trachomatis had significantly (p < 0.05) higher 
abundance of Anaerococcus, Collinsella, Corynebacterium, and Dialister.   
Future perspectives: Future studies should determine whether the altered microbiomes 
are markers of disease, or whether they actively contribute to the pathology of the two 
genital infections. Future longitudinal studies of vaginal microbiome and STIs should 
determine temporality and causality of our observations. It will be also important to 
determine if clinical presentation i.e. asymptomatic vs symptomatic is associated with a 
particular microbiome. 
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The fifth and final objective was to better understand interactions between T. vaginalis 
and HIV, with particular interest to HIV acquisition. This objective was achieved through 
a systematic review and meta-analysis which is addressed in Chapter 7. In brief, we 
followed a review protocol we had developed and registered on the International 
Prospective Register of Systematic Reviews (PROSPERO) under registration number 
CRD42018082702. We searched databases to identify articles reporting on T. 
vaginalis and HIV acquisition, which we included in the systematic review and meta-
analysis. 
We identified 18 peer-reviewed articles and one conference abstract that were eligible for 
inclusion. Upon qualitative synthesis and meta-analysis, we found that infection with T. 
vaginalis enhanced the risk of HIV acquisition by a hazard ratio of 1.47 (95% CI, 1.25–
1.72; p < 0.001).  T. vaginalis is an important factor in HIV acquisition, especially 
in sSA where the prevalence of T. vaginalis is high. Diagnosis and treatment of T. 
vaginalis infection in both high-risk and low-risk populations may be a potential tool to 
reduce new HIV infections. 
 
Future perspectives: Currently, new tools are being introduced to reduce the number of 
new HIV infections, the main one being Pre-Exposure Prophylaxis (PREP) medication for 
high-risk individuals [18]. Future studies among individuals on PREP may shed light on 
whether infection with T. vaginalis will continue to be a factor associated with increased 
likelihood of HIV acquisition. Screening for T. vaginalis may provide a means for 
screening high-risk behavior among individuals on PREP. Another emerging field of 
interest for future studies will be on whether PREP influences selection of HIV resistant 
strains and on the role of diagnosis and treatment of T. vaginalis as a means to reduce 
acquisition of these resistant HIV-strains.  Also, among individuals infected with HIV, 
there have been changes in the treatment. The World Health Organization currently 
recommends the ‘test and treat’ approach, which is designed to place anyone who has 
been diagnosed with HIV on treatment immediately following diagnosis, targeting to 
suppress the HIV viral load as such reducing the probability of infected individuals to 
transmit HIV [18].  
171 
Chapter Eight
In this new context of most individuals with HIV being on treatment, future studies may 
explore genital viral shedding of HIV among individuals co-infected with T. vaginalis. Last 
but not least, future studies may also evaluate whether there will be a need for special 
dosage for treatment of T. vaginalis among individuals put early on HIV treatment as 
currently there is a suggestion that 2 g single oral dose of metronidazole is not as effective 
as 500 mg of metronidazole twice daily for 7 days among HIV-infected women [19], and 
this is possibly influenced by the time at which individuals were put on HIV treatment. 
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 De eerste doelstelling van dit doctoraal proefschrift betrof het beoordelen van de 
prevalentie en risicofactoren die verband houden met geneesbare seksueel 
overdraagbare aandoeningen (SOAs) bij zwangere vrouwen die op visite kwamen voor 
antenatale zorg in een landelijk provinciaal ziekenhuis in Kilifi, Kenia, in verband met 
routinematige screening voor HIV en syfilis. Meer details met betrekking tot de 
beoordeling van de prevalentie en risicofactoren worden gedetailleerd beschreven in 
Hoofdstuk 3. Samengevat werd, van juli tot september 2015, een cross-sectioneel 
onderzoek uitgevoerd, waarbij van de vrouwen een urinemonster werd getest op 
Chlamydia trachomatis / Neisseria gonorrhoeae (door middel van GeneXpert®) en een 
vaginale swab werd getest voor Trichomonas vaginalis (door middel van kweek en 
microscopie).  
Bacteriële vaginose (BV) werd gedefinieerd als een Nugent-score van 7-10 van de Gram-
kleuring van een vaginaal uitstrijkje in combinatie met zelfgerapporteerde vaginale 
afscheiding. Tijdens het verzamelen van vaginale uitstrijkjes werd nagegaan of er genitale 
ulcers aanwezig waren. Alle vrouwen beantwoordden vragen over socio-demografie en 
seksuele gezondheid en klinische symptomen van SOAs. Prognostische merkers voor 
geneesbare SOAs werden beoordeeld door middel van  multivariabele logistische 
regressie.  
De belangrijkste redenen waarom Trichomonas vaginalis door middel van kweek (cultuur 
via de Tv Inpouch kit) werd gedetecteerd, waren de kosten en beschikbaarheid van de 
kweektechniek. Daarenboven liet kweek toe om op dezelfde dag resultaten via directe 
microscopie te bekomen, omdat deze techniek kon worden toegepast op dezelfde testkit. 
Bovendien werd de financiering voor de moleculaire detectie van C. trachomatis en N. 
gonorrhoeae later afzonderlijk verkregen. Bovendien voorziet cultuur in stammen (d.w.z. 
volledige genomen) van T. vaginalis waaruit nucleïnezuren kunnen worden geëxtraheerd 
voor verdere studies zoals de bepaling van het actine gentype of de aanwezigheid van 
T. vaginalis virussen (TVVs). 
Van de 202 vrouwen die deelnamen aan de studie, had een totaal van 20.8% (95% 
confidentie-interval (CI): 15.4-27.0), d.w.z. één op de vijf, een geneesbare SOA. De 
prevalentie was 14.9% voor C. trachomatis (95% CI: 10.2-20.5), 1.0% voor N. 
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gonorrhoeae (95% CI: 0.1-3.5), 7.4% voor T. vaginalis (95% CI: 4.2-12.0) 19.3% voor BV 
(95% CI: 14.1-25.4) en 2.5% voor genitale ulcera (95% CI: 0.8-5.7) [1]. Geneesbare 
SOAs zijn in verband gebracht met een aantal ongunstige zwangerschapsuitkomsten, 
waaronder spontane abortus, doodgeboorte, prematuriteit, laag geboortegewicht, 
postpartum sepsis en endometritis en met verschillende sequellen voor de overlevende 
neonaten [2]. Vroeggeboorte en laag geboortegewicht zijn belangrijke bepalende 
factoren voor kindermorbiditeit en -mortaliteit, vooral in ontwikkelingslanden zoals Kenia, 
waar neonatale intensive care-faciliteiten zelden beschikbaar zijn. Mati et al. [3] meldden 
een hoge incidentie van 7.5% voor een laag geboortegewicht (< 2500 g) en een perinatale 
mortaliteit van 2.2% in Nairobi, Kenia.  
 
Toekomstperspectieven: Het bepalen van de invloed van SOAs op de uitkomst van de 
zwangerschap is niet eenvoudig. Om ethische redenen is het niet mogelijk om prospectief 
de invloed van een onbehandelde SOA te onderzoeken bij het stellen van de diagnose 
van SOA. Daarom zijn de meeste studies retrospectief, waarbij gegevens over SOAs en 
geboorte-uitkomsten bij of na de bevalling zijn verzameld en waardoor het moeilijk is om 
rekening te houden met andere verstorende factoren, zoals voeding, malaria, 
zwangerschapsdiabetes en/of genetische afwijkingen, die mogelijk een effect hebben op 
de zwangerschapsuitkomst [2]. 
In een omgeving met beperkte middelen, zoals in veel ontwikkelingslanden, is een 
laboratoriumdiagnose om de etiologie van een SOA te bevestigen momenteel geen 
haalbare optie. In Kenia blijft syndromisch management de algemene benadering bij het 
beheer van de meeste SOAs, ondanks het feit dat er aanwijzingen zijn dat deze aanpak 
tekortschiet zowel wat betreft gevoeligheid als specificiteit [4, 5], ook omdat SOAs 
asymptomatisch kunnen zijn [6] of kunnen voorkomen met aspecifieke klinische 
symptomen. Eenvoudige en betaalbare technieken moeten worden overwogen voor de 
diagnose van sommige SOAs. De diagnose van T. vaginalis kan bijvoorbeeld worden 
gedaan met behulp van microscopie op verse uitstrijkjes (‘wet mount’), waarbij de vereiste 
uitrusting beperkt is tot een microscoop, die beschikbaar is in de meeste ziekenhuizen in 
het hele land. Ondanks de lage gevoeligheid van wet mount microscopie, heeft deze 
techniek een hoge specificiteit, tot 100%, afhankelijk van de waarnemer [7]. Wet mount 
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microscopie blijft één van de beste opties voor clinici in landen met beperkte middelen 
om T. vaginalis snel en specifiek te diagnosticeren in hun klinische praktijk. 
Het is duidelijk dat een beleid, waarbij systematisch getest wordt voor T. vaginalis bij alle 
vrouwen die antenatale zorg zoeken, de prevalentie van deze infectie sterk kan 
reduceren, zeker in gebieden met een hoge prevalentie van T. vaginalis. SOA-
screeningsprogramma's moeten worden onderworpen aan een formele kosten-
batenanalyse om het niet-effectieve gebruik van middelen te voorkomen. Het grootste 
argument tegen de algemene screening van T. vaginalis is dat er weinig aanwijzingen 
zijn dat de behandeling van asymptomatische T. vaginalis-positieve personen nadelige 
gevolgen voor de gezondheid voorkomt. Zo was er bij een gerandomiseerde 
gecontroleerde klinische trial over behandeling van T. vaginalis bij zwangere vrouwen in 
sub-Sahara Afrika geen voordeel te zien met betrekking tot premature geboorten, en werd 
evenmin een verschil waargenomen in het gemiddelde geboortegewicht bij kinderen van 
vrouwen die werden behandeld voor T. vaginalis en van vrouwen die positief waren, maar 
niet behandeld [8]. De resultaten van deze studie zijn echter niet doorslaggevend, omdat 
deze studie werd uitgevoerd in vier sites met beperkte middelen waar een echografie niet 
algemeen beschikbaar was om de geschatte bevallingsdatum te bepalen. Vrouwen met 
trichomoniasis die geen behandeling kregen, hadden een grotere kans op vroeggeboorte 
wanneer de symfysis-fundal-hoogte werd gebruikt om de zwangerschapsduur te schatten 
(36% versus 23%; p = 0,03), maar niet toen de Ballard-score werd gebruikt (16% versus 
21%, p = 0,41) [8]. 
Factoren die samenhangen met geneesbare SOA's, inclusief de in onze studie 
geïdentificeerde genen (BV, genitale ulceratie, vroeg seksueel debuut, water voor 
reiniging na een bezoek aan het toilet), kunnen worden gebruikt als eerste niveau van 
screening om personen te bepalen die een laboratoriumtest moeten ondergaan. 
Daarnaast bestaat de bezorgdheid dat een wijdverspreide behandeling van T. vaginalis 
kan leiden tot toegenomen metronidazole-resistentie bij een pathogeen waarvoor geen 
enkele andere klasse van antibiotica effectief is [9].  
Kaderend in het huidige klimaat van duurzame ontwikkeling (sustainable development 
goals: SDGs), zoals gepromoot door de Verenigde Naties, doet zich een unieke 
gelegenheid voor om de aanpak van de volksgezondheid te heroverwegen, inclusief de 
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aanpak van endemische, langbestaande besmettelijke ziekten. Duurzame ontwikkeling 
doel nummer 3 (SDG3) is vooral gericht op gezondheid: "Zorg voor een gezond leven en 
bevorder het welzijn voor iedereen op alle leeftijden". Eén van de concrete doelstellingen 
van SDG3 bestaat erin: "Tegen 2030 zorgen voor universele toegang tot diensten op het 
gebied van seksuele en reproductieve gezondheidszorg, inclusief voor gezinsplanning, 
informatie en onderwijs, en de integratie van reproductieve gezondheid in nationale 
strategieën en programma's" [10].  
Als Kenia de ambitieuze doelen wil bereiken die zijn vastgelegd in SDG3, dan zal dit via 
een multidisciplinaire aanpak dienen te gebeuren, omdat gezondheid wordt bepaald door 
meerdere factoren die vaak niet alleen binnen de gezondheidssector worden aangepakt 
en die noodzakelijkerwijs samenwerking tussen en partnerschap met verschillende 
sectoren vereisen. Eén van de andere doelstellingen binnen de Keniaanse context zou 
het opzetten en onderhouden van antimicrobiële resistentiemonitoring voor SOAs 
moeten zijn, vooral in verband met N. gonorrhoeae, die evolueert tot een superbacterie 
als gevolg van resistentie tegen meerdere antibiotica [11]. Bovendien zou een algemene 
nationale surveillance van alle SOAs goed doordacht moeten worden opgezet door de 
overheid, zoals het geval is voor HIV [12]. De Keniaanse overheid zou screening en 
behandeling van zwangere vrouwen met gelijktijdige infectie met T. vaginalis en HIV 
moeten overwegen, omdat dit een belangrijke impact zou kunnen hebben op het 
verminderen van HIV-overdracht van moeder op kind. Op dit moment is de HIV-
overdracht van moeder op kind in Kilifi 10% en het doel is om dit percentage in 2019 terug 
te brengen tot minder dan 5% [13]. 
 
De tweede doelstelling van dit proefschrift bestond erin te bepalen welke urogenitale 
pathogenen gecorreleerd zijn met het voorkomen van T. vaginalis bij zwangere vrouwen 
in Kilifi, Kenia, omdat conventionele screening van SOAs vaak alleen gericht is op de 
diagnose van chlamydia, gonorroe, syfilis en trichomoniasis, terwijl pathogenen die 
vergelijkbare urogenitale syndromen vertonen, zoals bijvoorbeeld Mycoplasma 
genitalium, niet gediagnosticeerd worden en/of onbehandeld blijven. Deze doelstelling 
wordt behandeld in Hoofdstuk 4 van dit proefschrift. Door middel van een geneste case-
control benadering werden vaginale swabs van 79 zwangere vrouwen, d.w.z. 28 T. 
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vaginalis-positieven (cases/gevallen) en 51 T. vaginalis-negatieven (controles), 
gescreend met kwantitatieve PCR voor Adenovirus 1 en 2, Cytomegalovirus, Herpes 
Simplex Virus 1 en 2, C. trachomatis, Escherichia coli, Haemophilus ducreyi, M. 
genitalium, M. hominis, candidatus M. girerdii, N. gonorrhoeae, Streptococcus agalactiae, 
Treponema pallidum, Ureaplasma parvum, U. urealyticum, en Candida albicans. 
Daarnaast gingen we na of vrouwen met pathogenen die sterk geassocieerd zijn met T. 
vaginalis duidelijk verschillende klinische symptomen hadden in vergelijking met vrouwen 
met T. vaginalis mono-infectie. 
We konden aantonen dat vrouwen die geïnfecteerd waren met T. vaginalis significant 
geassocieerd waren met M. hominis (aangepaste odds ratio (AOR) = 6.8, 95% CI: 2.3-
19.8). Bovendien werden M. genitalium en Ca M. girerdii uitsluitend gedetecteerd bij 
vrouwen met T. vaginalis (respectieveljk P = 0.002 en P = 0.001). 
 
Toekomstperspectieven: Onze resultaten suggereren dat, hoewel er veel aandacht is 
voor de vier meest voorkomende overwegend geneesbare STI-pathogenen, d.w.z. C. 
trachomatis, N. gonorrhoeae, T. pallidum en T. vaginalis, er co-infecties zijn met 
pathogenen waarvoor niet routinematig wordt gescreend. Deze co-infecties kunnen van 
invloed zijn op het beheer van de primaire infectie. Toekomstige studies zouden de co-
infecties met deze minder gekende SOAs moeten onderzoeken, en ook bepalen of ze 
een synergetische rol spelen in de pathologie.  
 
De derde doelstelling betrof het in kaart brengen van de genetische diversiteit van T. 
vaginalis isolaten bij zwangere vrouwen in Kilifi, Kenia. Deze doelstelling wordt behandeld 
in Hoofdstuk 5 van dit proefschrift. Genotypering werd uitgevoerd op 22 klinische isolaten 
van T. vaginalis, die waren verzameld bij vrouwen die op consultatie kwamen in de kliniek 
voor prenatale zorg in Kilifi County Hospital, Kenia, in 2015. Hiertoe werd een eerder 
voorgesteld schema gevolgd voor bepaling van restrictiefragmentlengte-polymorfisme 
(RFLP) [14], waarbij we ons baseerden op in silico-analyse van restrictie van het actine-
gen d.m.v. HindII, MseI en RsaI-restrictie-enzymen.  
Fylogenetische analyse van alle sequenties werd uitgevoerd om de resultaten verkregen 
door RFLP-analyse te bevestigen en om de diversiteit binnen de RFLP-genotypen te 
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beoordelen. Daarnaast bepaalden we de overdracht van de vier verschillende soorten 
TVVs d.m.v. reverse transciptie-PCR (polymerasekettingreactie). 
In silico RFLP-analyse toonde vijf T. vaginalis actine-genotypes aan onder vrouwen die 
de antenatale gezondheidszorg consulteerden en deelnamen aan onze cross-sectionele 
studie: 50.0% van de isolaten was van actine genotype E, 27.3% van actine genotype N, 
13.6% van actine genotype G en 4.5% van actine genotypes I en P. De prevalentie van 
TVVs was 43.5% (95% CI: 23.2-65.5). TVV1 was de meest voorkomende, aanwezig in 
39.1% van de stammen, en 90% van de T. vaginalis-isolaten die TVVs herbergen hadden 
meer dan één type TVV. Geen van de isolaten van actine-genotype E was met TVV 
geïnfecteerd. 
Voor het eerst kennen we nu de actine-genotypes van T. vaginalis die in Kilifi, Kenia, in 
omloop zijn. We kunnen nu vergelijkingen maken met de T. vaginalis-genotypes die in 
andere delen van het land en in andere landen in omloop zijn. Het meest voorkomende 
actine-genotype was bijvoorbeeld genotype E in onze studie, vergelijkbaar met wat werd 
waargenomen in Congo [14], maar in Zambia was genotype G het meest voorkomend 
[14]. Het in kaart brengen van de wereldwijde verspreiding van de genotypen zal leiden 
tot een beter begrip van de epidemiologie van T. vaginalis. 
De op sequentie gebaseerde genotyperingstechnieken zijn in staat om draagbare en 
ondubbelzinnige resultaten te produceren in vergelijking met op gel gebaseerde 
technieken waarbij de interpretatie van bandpatronen zeer subjectief is. Het gebruik van 
op sequenties gebaseerde technieken heeft eveneens een goede reproduceerbaarheid 
omdat verschillende laboratoria die hetzelfde protocol volgen vrijwel altijd dezelfde 
resultaten zullen hebben. 
Het doelwitgen (Actine) is een alomtegenwoordig goed geconserveerd structureel eiwit 
in alle eukaryote cellen en is gebruikt om de moleculaire fylogenie van protisten, planten, 
dieren en schimmels te verduidelijken.  
De keuze om directe PCR-producten te sequeneren, maakt directe en gedetailleerde 
analyse van de fragmenten mogelijk zonder de extra stappen die met klonen zijn 
geassocieerd. Met de huidige beschikbaarheid van de thermostabiele polymerasen en 
cycle-sequentiebepaling is dubbelstrengs sequencing van PCR-producten zeer efficiënt. 
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In ons geval sequeneerden we bidirectioneel, wat de assemblage van een 
consensussequentie mogelijk maakte die werd gebruikt voor genotypering. 
 
Toekomstperspectieven: Ons werk rond genotypering van T. vaginalis legt ook de 
grondslag voor toekomstige studies die aspecten zoals genotype-vervanging kunnen 
onderzoeken of nieuwe genotypen kunnen identificeren die mogelijk van elders 
geïmporteerd worden of die voorkomen in een andere populatie dan die waar we onze 
isolaten vandaan hebben. Toekomstige studies die beide geslachten omvatten, kunnen 
de hypothese testen dat er geen preferentiële geslachtsinfectie is met bepaalde 
genotypen en verder onderzoeken of de bevinding dat TVVs ontbreken bij genotype E 
geldig blijft. 
In vitro-onderzoek heeft aangetoond dat TVVs kunnen worden waargenomen door de 
menselijke epitheelcellen via Toll-like receptor 3, opregulerende interferon regulerende 
factor (IRF)-3, interferon type I en pro-inflammatoire cascades [15]. TVVs zijn ook 
geassocieerd geworden met T. vaginalis immunogeen proteïne P270 [16] met 
differentiële kwantitatieve en kwantitatieve expressie van cysteïne-proteïnasen [17].  
Aangezien TVVs verschillende fenotypische veranderingen kunnen induceren die de 
virulentie van T. vaginalis kunnen beïnvloeden [17], lijken meer gedetailleerde studies 
over de rol van TVVs in de pathologie van T. vaginalis aangewezen. Bovendien kunnen 
toekomstige studies ook bepalen of er ontsteking optreedt na behandeling met antibiotica 
- zoals metronidazole - die het pathogeen doden, maar waarbij de TVVs uit de T. 
vaginalis-cellen worden vrijgesteld. 
Tenslotte hebben eerdere studies aangetoond dat TVVs geassocieerd waren met een 
significant verhoogde minimum lethale concentratie van metronidazol. In onze studie 
bevatte geen van de isolaten van actine genotype E TVV's. Toekomstige studies kunnen 
aantonen of dit actine-genotype een betere gevoeligheid voor metronidazole heeft. 
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De vierde doelstelling betrof de karakterisatie van het vaginale microbioom van 
zwangere vrouwen in relatie tot infectie met T. vaginalis, respectievelijk C. trachomatis. 
Deze doelstelling wordt behandeld in Hoofdstuk 6. Samengevat werd het vaginale 
microbioom van vrouwen met T. vaginalis (n = 18) vergeleken met dat van vrouwen met 
C. trachomatis (n = 14) en van controles, d.w.z. vrouwen negatief voor zowel T. vaginalis 
als C. trachomatis (n = 21). De samenstelling van het vaginale microbioom werd bepaald 
op basis van het DNA-extract van het vaginale uitstrijkje van de vrouwen, met behulp van 
high throughput sequencing, met de Ion 16S metagenomics kit, van de variabele regio's 
2, 4 en 8 van het bacteriële 16S ribosomale RNA-gen. QIIME en R-pakket "Phyloseq" 
werden gebruikt om de α- en β-diversiteit en de absolute abundantie van het 16S-rRNA-
gen per monster in de drie groepen te bepalen. Verschillen in taxa op verschillende 
niveaus werden bepaald met behulp van de onafhankelijke T-test. We konden aantonen 
dat bacteriële α-diversiteit zowel op basis van Simpson's en Shannon-indices significant 
hoger waren (p = 0.056, respectievelijk p = 0.001) bij vrouwen met T. vaginalis, 
respectievelijk C. trachomatis in vergelijking met de controles, met gemiddelde  α-
diversiteit (T. vaginalis-geïnfecteerd) > gemiddelde  α-diversiteit (C. trachomatis 
geïnfecteerd) > gemiddelde  α-diversiteit (Controles)). Op genusniveau hadden vrouwen 
die geïnfecteerd waren met T. vaginalis significant (p < 0.01) een hogere abundantie van 
Parvimonas en Prevotella dan zowel controles als met C. trachomatis-geïnfecteerde 
vrouwen, terwijl vrouwen die met C. trachomatis waren geïnfecteerd een significant (p < 
0.05) hogere abundantie hadden van Anaerococcus, Collinsella, Corynebacterium en 
Dialister.  
 
Toekomstperspectieven: Verdere studies moeten uitwijzen of de gewijzigde 
microbiomen alleen maar merkers van de infecties zijn dan wel bijdragen aan de 
pathologie van de twee genitale infecties. Toekomstige longitudinale onderzoeken van 
vaginaal microbioom en SOAs zijn hiervoor aangewezen. Het is ook belangrijk om te 
bepalen of de klinische presentatie van deze genitale infecties, asymptomatisch vs. 
symptomatisch, geassocieerd is met een bepaald microbioom. 
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De vijfde doelstelling beoogde de interacties tussen T. vaginalis en HIV beter te 
begrijpen, met bijzondere aandacht voor HIV-verwerving. Deze doelstelling werd bereikt 
door het uitvoeren van een systematische review en meta-analyse die in Hoofdstuk 7 
wordt behandeld. Kort samengevat hebben we een reviewprotocol gevolgd dat we 
hadden ontwikkeld en geregistreerd op het International Prospective Register of 
Systematic Reviews (PROSPERO) onder registratienummer CRD42018082702. We 
hebben databases doorzocht om artikelen te identificeren die rapporteren over T. 
vaginalis en HIV-infectie, die we hebben opgenomen in de systematische review en meta-
analyse. 
We identificeerden 18 peer-reviewed publicaties en één conferentie-abstract die in 
aanmerking kwamen voor opname. Bij kwalitatieve synthese en meta-analyse vonden we 
dat infectie met T. vaginalis de kans op HIV-infectie verhoogde met een hazard ratio van 
1.47 (95% CI, 1.25-1.72; p < 0.001). T. vaginalis is een belangrijke factor bij de verwerving 
van HIV, vooral in sub-Sahara Afrika, waar de prevalentie van T. vaginalis hoog is. 
Diagnose en behandeling van T. vaginalis-infecties bij zowel hoog-risico en laag-risico 
populaties kunnen een mogelijk hulpmiddel zijn om het aantal nieuwe HIV-infecties te 
verminderen. 
 
Toekomstperspectieven: Momenteel worden er nieuwe hulpmiddelen geïntroduceerd 
om nieuwe HIV-infecties te verminderen, waarvan de belangrijkste bestaat uit Pre-
Exposure Profylaxe (PREP)-medicatie bij personen met een hoog risico [18]. 
Toekomstige studies, voornamelijk onder individuen op PREP-medicatie, kunnen licht 
werpen op de vraag of infectie met T. vaginalis een factor blijft die geassocieerd is met 
een verhoogde kans op HIV-verwerving. Een ander opkomend interessegebied voor 
toekomstige studies is de mogelijke invloed van PREP op de selectie van resistente HIV-
stammen en de rol van diagnose en behandeling van T. vaginalis als middel om de 
verwerving van deze resistente HIV-stammen te verminderen. Ook zijn er voor individuen 
die met HIV zijn geïnfecteerd, veranderingen in de behandeling. De 
Wereldgezondheidsorganisatie beveelt momenteel de ‘test- en behandel’ aanpak aan, 
die erin bestaat om iedereen die gediagnosticeerd is met HIV onmiddellijk na de diagnose 
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te behandelen, en die gericht is op het onderdrukken van de virale lading van het HIV-
virus, waardoor de kans kleiner wordt dat geïnfecteerde personen HIV doorgeven [18] .  
In een nieuwe context waarbij de meeste mensen met HIV onder behandeling staan, 
kunnen toekomstige studies de genitale virale shedding van HIV onderzoeken bij 
individuen die tegelijkertijd geïnfecteerd zijn met T. vaginalis en die al vroeg HIV-
behandeling krijgen.  
Tenslotte, maar niet in het minst, kunnen toekomstige studies ook evalueren of er 
behoefte is aan een speciale dosering voor de behandeling van T. vaginalis bij individuen 
die vroeg op HIV-behandeling worden gezet, aangezien er momenteel een suggestie is 
dat 2 g enkelvoudige orale dosis metronidazole niet zo effectief is als 500 mg 
metronidazol tweemaal daags gedurende 7 dagen bij met HIV-geïnfecteerde vrouwen 
[19], iets wat mogelijk wordt beïnvloed door het tijdstip waarop personen met een HIV-
behandeling starten. 
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